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8Paraneoplastic neurological syndromes (PNS) are remote effects of cancer. These are 
not caused by invasion of the tumor or its metastasis nor by other direct effects of the 
tumor or its treatment, such as infection, ischemia, metabolic and nutritional deficits, 
drug neurotoxicity or surgery.1 
PNS are rare, affecting less than 0.1% of all cancer patients.2 PNS generally have a 
subacute course, leaving the patient severely disabled in weeks to months. Often the 
patient is not yet known to suffer from cancer and the rapid neurological deterioration 
can present a diagnostic challenge.1 The discovery of paraneoplastic antineuronal 
antibodies not only facilitated the diagnosis of PNS but also resulted in the general 
belief that these disorders are triggered by the often aberrant expression of neuronal 
antigens in the associated tumor.3
Several classification systems for antineuronal antibodies have been deployed. In 
chapter 2 we classify antibodies by their level of characterization.4 In this classification, 
‘well characterized onconeural antibodies’ are defined by (a) recognizable patterns on 
routine rat brain immunohistochemistry and positive immunoblotting on recombinant 
antigen proteins; (b) the number of cases antibody-positive reported associated with 
tumors; (c) the description of well characterized neurological syndromes associated 
with the antibodies; (d) the unambiguous identification of the Abs among different 
studies, and (e) the frequency of these Abs in patients without cancer.4 These ‘well-
characterized’ onconeural antibodies are by definition almost exclusively found in 
patients with cancer and include anti-Hu, Yo, CV2, Ri, Ma2 and amphiphysin.4 Most 
of the ‘well-characterized’ onconeural antibodies are directed against intracellular 
antigen. Studies of patients’ brain tissues obtained at autopsy, cancer, CSF and blood 
suggest that these disorders are mediated by a cytotoxic T cell response, explaining the 
generally poor response to treatment and poor prognosis. The ‘onconeural’ antibodies 
are probably not pathogenic and markers of neoplasia. The other antibody categories 
included the ‘partially characterized paraneoplastic antibodies’ and ‘antibodies that 
occur with and without cancer’.4
More recently a still growing number of autoantibodies directed against synaptic 
or neuronal cell-surface antigens has been identified, such as the metabotropic 
glutamate receptors 1 and 5 (mGluR1,5), N-methyl-D-aspartate receptors (NMDAR), 
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPAR) or 
gamma-aminobutyric acid receptors (GABAR) (Table 1).5-8 These autoantibodies have 
direct access to their target antigen and are potentially pathogenic.5,9 The associated 
clinical syndromes may be paraneoplastic (with underlying tumor) or may represent 
an autoimmune encephalitis (without underlying tumor). In general, patients harboring 
autoantibodies directed against synaptic or neuronal cell-surface antigens respond 
favorably to immunotherapy with a good outcome in up to 80%.7,10 
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1Table 1. Autoantibodies associated with paraneoplastic neurological syndromes and 
autoimmune encephalitis
Intracellular antigens
Antigen Main clinical syndrome Tumor 
Hu (ANNA-1) Encephalomyelitis, sensory neuronopathy, limibic 
encephalitis, subacute cerebellar degeneration, 
autonomic neuropathy
SCLC, neuroblastoma, 
prostate carcinoma14-17
Yo (PCA-1) Subacute cerebellar ataxia Ovary, breast, fallopian tube, 
endometrium carcinoma16,18,19
CV2 (CRMP-5) Encephalomyelitis, limbic encephalitis, chorea, optic 
neuritis, sensory and sensorimotor neuropathy, 
subacute cerebellar degeneration
SCLC, thymoma, renal 
cel land tyroid gland 
carcinoma16,20
Ri (ANNA-2) Opsoclonus-myoclonus, brainstem encephalitis Breast carcinoma, SCLC16,21
Ma2 (Ta) Limbic/diencephalic/brainstem encephalitis, subacute 
cerebellar ataxia
Testis (men), ovary, breast, 
lung carcinoma16,22-24
Intracellular synaptic antigens
GAD65 Subacute cerebellar ataxia, limbic encephalitis Rarely lung, colon, pancreas, 
breast, thyroid, renal cell 
carcinoma, thymoma25
Amphiphysin Stiff-person syndrome, encephalomyelitis, subacute 
sensory neuronopathy, sensorimotor neuropathy
Breast carcinoma, SCLC, 
melanoma16,26 
Synaptic or cell-surface antigens
NMDAR Anti-NMDAR encephalitis (complex neuropsychiatric 
syndrome)
Ovarian teratoma27,28 
(Age related)
AMPAR Limbic encephalitis, psychosis Lung, breast carcinoma, 
thymoma29
GABABR Limbic encephalitis with prominent seizures SCLC
30
GABAAR Status epilepticus, refractory seizures Rarely thymoma
31
LGI1 Limbic encephalitis, faciobrachial dystonic seizures, 
hyponatremia
<10% thymoma32,33 
Caspr2 Neuromyotonia, Morvan’s syndrome Rarely thymoma34,35
DNER/Tr Subacute cerebellar ataxia Hodgkin lymphoma13,36
VGCC Subacute cerebellar ataxia, Lambert-Eaton myasthenic 
syndrome
SCLC37-40
GlyR Stiff-person syndrome, hyperekplexia, PERM Rarely Hodgkin lymphoma, 
breast, lung carcinoma41-43
mGluR1 Subacute cerebellar degeneration Hodgkin lymphoma44
mGluR5 Limbic encephalitis (Ophelia syndrome) Hodgkin lymphoma45
Dopamine-2R Basal ganglia encephalitis, Sydenham’s chorea No tumors reported46,47
DPPX Hallucinations, agitation, myoclonus, tremor, seizures, 
diarrhea
No tumors reported48
IgLON5 NREM/REM parasomnia, sleep breathing disorder No tumors reported49
10
At present, antibody associated disorders of the central nervous system are divided 
broadly into three groups based on the location of the target antigens (Table 1).11 
The first and second groups of disorders are characterized by autoantibodies against 
intracellular and synaptic or cell-surface antigens respectively. In the third group of 
disorders antibodies target intracellular synaptic proteins (e.g. 65kDa glutamic acid 
decarboxylase [GAD65] and amphiphysin) that might be vulnerable to antibody-
mediated disruption during synaptic vesicle fusion and reuptake. However, at present it 
is still unclear whether antibodies or T cell mechanisms mediate the neuronal damage.12
This thesis focuses on paraneoplastic antineuronal antibodies and includes studies 
on new methods of autoantibody detection, identification of novel paraneoplastic 
antigen(s) and the description of clinical syndromes associated with newly detected 
paraneoplastic antibodies. In chapter 2, the epidemiology, pathogenesis, diagnosis and 
treatment and prognosis of paraneoplastic neurological syndromes are reviewed. The 
‘well characterized’ onconeural antibodies and classical paraneoplastic syndromes are 
described in detail. 
In chapter 3, advanced mass spectrometry is used to detect specific petide sequences 
in the antigen binding site of IgG that are shared between patients harboring anti-
HuD onconeural antibodies. The ultimate aim of this approach is to identify specific 
IgG molecules by their peptide sequences rather than by the antigen that they bind. 
Chapter 4 focuses on the development of a ‘multiplex’ assay for the simultaneous and 
quantitative detection of onconeural antibodies using color-coded polystyrene beads. 
Subsequently we compare this technology with the ‘gold standard’ (i.e. combined 
immunohistochemistry and Western blotting). In chapter 5 mass spectrometry is used to 
identify the long sought target antigen recognized by anti-Tr antibodies, that are marker 
of paraneoplastic cerebellar degeneration and Hodgkin’s disease.13 Mass spectrometry 
analysis of immunopurified rat brain extract using 4 different anti-Tr positive sera led to 
the identification of Delta/notch-like epidermal growth factor-related receptor (DNER) 
as the Tr antigen. Chapter 6 describes the presenting symptoms in the first 15 Dutch 
patients with NMDAR encephalitis, with special focus on the psychiatric phenomena. 
In chapter 7, we describe the clinical features and presence in CSF of antineuronal 
antibodies in 21 patients with pathologically proven autoimmune encephalitis. The study 
was performed in collaboration with The Dutch Surveillance Centre for Prion Diseases 
(DSCPD) and the 21 patients with pathologically proven autoimmune encephalitis were 
identified from 384 autopsies performed on patients with suspected CJD over a 14-year 
period (1998 – 2011). The main findings are summarized and discussed in chapter 8.
11
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AbsTRACT 
Paraneoplastic neurologic syndromes (PNS) are remote effects of cancer. Immunological 
factors appear important in the pathogenesis of PNS since the detection of antineuronal 
autoantibodies. Detection of paraneoplastic antibodies is very helpful in diagnosing 
an unexplained neurological syndrome as paraneoplastic and in directing the search 
towards the underlying neoplasm. There are seven well-characterized paraneoplastic 
antibodies reactive with the onconeural Hu, Yo, Ri, Ma2, CV2, amphiphysin and recoverin 
antigens. Recently, anti-VGKC and anti-NMDA receptor antibodies were identified in 
patients with limbic encephalitis (LE). 30% of patients with anti-VGKC and LE have an 
underlying tumor while most patients with anti-NMDAR and LE are young women with 
an ovarian teratoma. Both VGKC and NMDAR related LE respond well to immunotherapy. 
In contrast, the effect of immunotherapy in patients with PNS associated with antibodies 
against the intracellular onconeural antigens is disappointing. These patients benefit 
most from early detection and treatment of the underlying tumor.
17
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InTROduCTIOn
Paraneoplastic neurologic syndromes (PNS) are syndromes that result from dysfunction 
of the nervous system, caused by a benign or malignant tumor via mechanisms other 
than direct tumor cell infiltration, metastasis, coagulopathy, infection or any treatment 
side effects.1 All parts of the central and peripheral nervous system may be affected 
by PNS and, as a result, signs and symptoms are diverse. Most PNS of the central 
nervous system have in common a subacute course leaving the patients severely 
disabled in weeks to months and inflammatory changes in the CSF, including moderate 
lymphocytic pleocytosis, increased protein levels and IgG index and presence of CSF-
specific oligoclonal bands.2 Early recognition may be difficult because PNS is the first 
manifestation of the tumor in approximately 70% of patients. 
In 1919 Brouwer described a first case of paraneoplastic cerebellar degeneration3 and 
with Biemond he postulated a “toxicosis” generated by the presence of a tumor as the 
cause in 1938.4 The term ‘paraneoplastic’ was first used by Guichard and Vignon in 
1949 in a case of metastatic neuropathies.2 Later on the term was used for a scala of 
syndromes that were related to the presence of a neoplasm, but of unclear origin. In 
1965, Wilkinson and Zeromski first described the presence of antineuronal antibodies 
in patients with lung cancer and paraneoplastic sensory neuropathy.5 Since then, 
an ever growing number of well characterized paraneoplastic antibodies has been 
defined and detection of these highly specific antibodies in about 60% of PNS patients 
nowadays facilitates early diagnosis and helps direct the search to an underlying 
tumor.1 Notwithstanding the presumed autoimmune mechanisms of PNS, the results 
of immunosuppressive and immunomodulating treatments have been disappointing in 
most cases. Detection and subsequent treatment of the underlying tumor offers best 
chance of preventing further neurological deterioration.1 
ePIdeMIOlOgy
Paraneoplastic syndromes are rare, affecting less than 0.1% of all patients with cancer.2 
However, the incidence of PNS varies with the neurological syndrome and with the 
tumor. Approximately 10% of patients with tumors derived from cells that produce 
immunoglobulins (plasma cell disorders, B-cell lymphoma) are affected by a paraneoplastic 
peripheral neuropathy. Over half of the patients with the rare osteosclerotic form of myeloma 
develop a severe predominantly motor paraneoplastic peripheral neuropathy. In other 
hematological malignancies, the incidence of PNS is very low with the exception of Hodgkin’s 
disease. However, the incidence of PNS is even in Hodgkin’s disease well below 1%. Tumors 
commonly involved in PNS of the central nervous system express neuroendocrine proteins 
(small cell lung cancer (SCLC) and neuroblastoma), affect organs with immunoregulatory 
properties (thymoma) or contain mature or immature neuronal tissue (teratomas). As a 
result, in SCLC the frequency of Lambert-Eaton myasthenic syndrome (LEMS) is 3%6 and 
myasthenia gravis (MG) occurs in 15% of patients harboring thymomas.
18
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The discovery of paraneoplastic antineuronal autoantibodies resulted in the general 
belief that most or all PNS are immune-mediated disorders triggered by the aberrant 
expression of so-called onconeural antigens in the tumor (Figure 1). Normally, the 
onconeural antigens are expressed only in immunologically privileged sites, such as 
brain and testis(, which may explain that the immune system identifies these antigens 
as foreign following expression by the systemic tumor. Tumors in patients with PNS 
are often heavily infiltrated with inflammatory cells (in contrast to histologic features 
of tumors in non-PNS patients).The immune hypothesis of PNS is further supported 
by the following facts: The target onconeural antigens are expressed both in the tumor 
and in the affected parts of the nervous system; examination of the CSF frequently 
shows moderate lymphocytic pleocytosis, intrathecal synthesis of IgG and CSF-specific 
oligoclonal bands; pathological examination of the nervous system shows loss of 
neurons in affected areas with inflammatory infiltration by CD4+ T cells and B cells in 
the perivacular spaces and by CD8+ T cells in the interstitial spaces; control of tumor 
growth by the immune response is suggested by well documented regression or even 
obliteration of the underlying tumor (usually SCLC) at the time when PNS developed.7 
Finally, SCLC patients with low titers of anti-Hu antibodies (no PNS) a have more limited 
disease distribution and better oncologic outcome than patients who do not have the 
antibodies.8 A pathogenic role for humoral immunological mechanisms could only be 
proven for those antibodies directed against easily accessible antigens located at or 
near the cell surface, such as voltage-gated ion channels (VGCC, VGKC) and membrane-
associated receptors (mGluR1, NMDA, GAD).2,9 However, most onconeural antigens 
are localized in the cell nucleus (Hu, Ri, Ma) or cytoplasm (Yo, CV2, Tr) (table 1) and a 
pathogenic role for these paraneoplastic antibodies could never be proven.10 Instead, 
indirect lines of evidence support a role of the cellular immunity in these disorders.11 The 
relative roles of humoral immunity and cellular immunity however are still incompletely 
resolved.12,13 
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figure 1. The hypothesized pathogenesis of antibody-associated PNS. 
Onconeural antigen expressing tumour cells are phagocytozed by antigen-presenting 
cells (APC) that migrate to lymph nodes, where they present antigenic peptides to specific 
CD8+ and CD4+ T cells via HLA-class I and HLA-class II molecules, respectively. Tumour cells 
themselves present onconeural antigens to CD8+ T cells via HLA-class I molecules. The CD4+ 
T cells support CD8+ T-cell activation and proliferation by cytokines such as IFN-g and IL-2. 
CD4+ T cells stimulate B cells through cytokines including interleukin (IL)-4 and IL-5. B cells 
recognize soluble onconeural antigens throughtheir B-cell receptor. After activation, B cells 
differentiate into plasma cells,which secrete specific antibodies.Upon engagement of their 
TCR and accessorymolecules,CD8+ T cells can destroy tumour cells by secreting granzymes, 
perforins and cytokines such asTNF-a, or by upregulation ofCD95 (Fasligand) on tumour cells. 
The remnants of destroyed tumour cells can be taken up by APC, processed and presented 
to T cells. In addition, they can be specifically recognized by antibodies and eliminated via 
Fc receptor-expressing phagocytes. Cytotoxic specific CD8+ T cells not only slow the tumour 
growth, but they also cross the blood brain barrier and similarly attack neurons expressing 
the onconeural antigen, causing severe neurological damage in these patients. Reprinted 
with permission of J.W.K. de Beukelaar14
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Table 1. Antibodies, antigen location, neurological syndrome and associated tumors
Antibody Antigenic location neurological syndromes Associated tumors
Well characterized paraneoplastic antibodies
Anti-Hu (ANNA-1) Nucleus more than cytoplasm
(all neurons)
Encephalomyelitis
limbic encephalitis
sensory neuronopathy
subacute cerebellar degeneration 
autonomic neuropathy 
SCLC, 
neuroblastoma, 
prostate 
Anti-Yo (PCA-1) Cytoplasm, Purkinje cells Subacute cerebellar degeneration Ovary, breast 
Anti-CV2 (CRMP5) Cytoplasm, oligodendrocytes, 
neurons
Encephalomyelitis 
limbic encephalitis
chorea
sensory neuronopathy
sensorimotor neuropathy
optic neuritis
subacute cerebellar degeneration
autonomic neuropathy 
SCLC Thymoma 
Anti-Ri (ANNA-2) Nucleus more than cytoplasm
(central nervous system 
neurons)
Opsoclonus-myoclonus
brainstem encephalitis 
Breast, SCLC 
Anti-Ma2 (Ta)* Neurons (subnucleus) Limbic/diencephalic/brainstem 
encephalitis,
subacute cerebellar degeneration 
Testis, lung 
Anti-amphiphysin Presynaptic nerve
terminals
Stiff-person syndrome
Encephalomyelitis
subacute sensory neuronopathy
sensorimotor neuropathy 
Breast, SCLC 
Anti-recoverin Photoreceptors, ganglion cells Cancer associated retinopathy  SCLC 
Partially characterized paraneoplastic antibodies 
Anti-Tr (PCA-Tr) Cytoplasm, Purkinje cells Subacute cerebellar degeneration Hodgkin’s 
disease 
ANNA-3 Nuclei, Purkinje cells Encephalomyelitis
subacute sensory neuronopathy 
SCLC 
PCA-2 Cytoplasm, Purkinje cells and 
other neurons
Encephalomyelitis
subacute cerebellar degeneration 
SCLC 
Anti-Zic4 Subacute cerebellar degeneration SCLC 
Anti-NMDAR Axonal membrane Limbic encephalitis Ovarian 
teratoma
Anti-mGluR1 Purkinje cells, olfactory 
neurons, hippocampus
Subacute cerebellar degeneration Hodgkin’s 
disease 
Antibodies that occur with and without cancer 
Anti-VGCC Presynaptic neuromuscular
junction
Lambert-Eaton myasthenic 
syndrome
subacute cerebellar degeneration 
SCLC 
Anti-AchR Neuromuscular junction Myasthenia gravis Thymoma 
Anti-VGKC Peripheral nerve Limbic encephalitis
neuromyotonia 
Thymoma, SCLC 
*Patients with brainstem encephalitis or subacute cerebellar degeneration usually associate with tumors other 
than testicular cancer and their sera also react with Ma1 protein. ANNA = antineuronal nuclear antibody; SCLC 
= Small Cell Lung Carcinoma; VGCC = voltage gated calcium channels; PCA = Purkinje cytoplasmic antibody;
mGluR1 = metabotropic glutamate receptor type 1; VGKC = voltage gated potassium channel 
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dIAgnOsIs And MAnAgeMenT
Clinical syndromes are never pathognomonic for a paraneoplastic aetiology and a 
high index of clinical suspicion is important. Symptoms can be atypical, psychiatric or 
even fluctuating and PNS should often be in the differential diagnosis of otherwise 
unexplained severe neurological syndromes. Radiologic findings are especially important 
to rule out other possible causes; in case of PNS they often render aspecific findings. 
As an exception, CT and MRI reveal temporal lobe abnormalities in 65-80% of patients 
with limbic encephalitis (LE)2 and often some degree of cerebellar atrophy is seen in 
the chronic stage of predominantly cerebellar syndromes. In patients suffering from 
paraneoplastic cerebellar degeneration (PCD), early MRI may show cerebellar contrast 
enhancement.2 CSF examination reveals a mild pleocytosis (typically 30-40 white cells 
per cubic millimeter), a slightly elevated protein (50-100 mg/dl) and an elevated IgG 
level, with or without oligoclonal bands. 
Testing for paraneoplastic antibodies in serum of patients with unresolved severe 
neurologic syndromes is clinically important, because it proves a paraneoplastic origin 
and directs the search to an underlying malignancy. Rapid detection of antibodies and 
early detection followed by treatment of the underlying tumor appears to offer the best 
chance of stabilizing the patient and preventing further neurologic deterioration.1 
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Table 2. Classical and non-classical PNS
Central nervous system 
Encephalomyelitis 
Limbic encephalitis 
Brainstem encephalitis 
Subacute cerebellar degeneration 
Opsoclonus – myoclonus
Stiff-person syndrome
Paraneoplastic visual syndromes 
   Cancer-associated retinopathy 
   Melanoma-associated retinopathy 
   Paraneoplastic optic neuropathy 
Motor neuron syndromes 
   Subacute motor neuronopathy 
   Other motor neuron syndromes 
Peripheral nervous system 
Subacute sensory neuronopathy 
Acute sensorimotor neuropathy
Chronic sensorimotor neuropathy 
   Association with M-proteins 
Subacute autonomic neuropathy 
Paraneoplastic peripheral nerve vasculitis 
neuromuscular Junction and Muscle
Lambert-Eaton myasthenic syndrome
Myasthenia gravis
Neuromyotonia
Dermatomyositis
Acute necrotizing myopathy
Cachectic myopathy
Classical paraneoplastic syndromes are in italics.
Some neurological syndromes such as LE and subacute cerebellar degeneration associate 
relatively often with cancer. These are called “classical” and described separately below.15 
Other syndromes, like peripheral sensorimotor neuropathies are more prevalent, have a 
broad differential diagnosis and are less often related to a malignancy.15 
Paraneoplastic antibodies are generally divided into three categories (Table 1). Well-
characterized paraneoplastic antibodies (Figure 2) are reactive with molecularly defined 
onconeuronal antigens and strongly associated with cancer. They have been detected 
unambiguously by several laboratories in a reasonable number of patients with well 
defined neurologic syndromes.15 
Partially characterized paraneoplastic antibodies are those with an unidentified target 
antigen and those that have either been described by a single group of investigators or 
have been reported in only a few patients. 
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The third group consists of antibodies that are associated with specific disorders but 
do not differentiate between paraneoplastic and non-paraneoplastic cases. Because 
of overlapping syndromes in separate antibodies, paraneoplastic antibodies should be 
searched for by screening rather than by focusing on a specific antibody. Unfortunately, 
not all patients with paraneoplastic syndromes have identifiable antibodies in their 
serum.
Once a paraneoplastic etiology is strongly suspected, a careful search for the underlying 
neoplasm is mandatory. If detailed history taking, thorough physical examination and 
high resolution computed tomography (CT) of chest, abdomen and pelvis do not show 
a primary tumor, whole body positron-emission tomography (PET) or PET/CT may be 
the best screening method for locating the occult cancer.16 Besides, the type of antibody 
and paraneoplastic syndrome may suggest a specific underlying tumor and indicate 
more directed diagnostic tests, such as mammography (or MRI) when breast cancer 
is suspected. With positive antibody screening and strong suspicion of paraneoplastic 
disease, negative tumor search should be repeated at 3-6 months intervals for 2-3 years. 
Table 3. Diagnostic criteria for definite and possible PNS
Definite
1. A classical syndrome (i.e. encephalomyelitis, limbic encephalitis, subacute cerebellar degeneration, 
opsoclonus-myoclonus, subacute sensory neuronopathy, chronic gastrointestinal pseudo-obstruction, 
LEMS or dermatomyositis) and cancer that develops within 5 years of the diagnosis of the neurological 
disorder, regardless of the presence of paraneoplastic antibodies
2. A non-classical syndrome that objectively improves or resolves after cancer treatment, provided that 
the syndrome is not susceptible to spontaneous remission.
3. A non-classical syndrome with paraneoplastic antibodies (well characterized or not) and cancer that 
develops within 5 years of the diagnosis of the neurological disorder.
4. A neurological syndrome (classical or not) with well characterized paraneoplastic antibodies (i.e. Hu, Yo, 
Ri, amphiphysin, CV2 or Ma2).
Possible
1. A classical syndrome without paraneoplastic antibodies and no cancer but at high risk to have an 
underlying tumor (e.g. smoking habit).
2. A neurological syndrome (classical or not) without cancer but with partially characterized 
paraneoplastic antibodies.
3. A non-classical neurological syndrome, no paraneoplastic antibodies and cancer that presents within 
two years of the neurological syndrome.
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PNS are rare disorders and even neurologists interested in the field personally examine 
only a few patients per year. Because of the difficulties in diagnosing a neurologic 
syndrome as paraneoplastic, an international panel of neurologists has established 
diagnostic criteria that divide patients with a suspected paraneoplastic syndrome into 
‘definite’and ‘probable’ categories (Table 3). These criteria are based on the type of 
clinical syndrome, the presence of ‘well characterized’ antibodies and on the presence or 
absence of cancer.15 However, the detection of additional antibodies (e.g. anti-NMDAR 
and anti-VGKC) and their clinical associations suggests that these criteria already need 
revision.17-19  
figure 2. Antineuronal antibodies in paraneoplastic cerebellar degeneration.
Staining of rat cerebellum (a–e) or cortex (f) using patients’ sera as primary antibody and 
peroxidase labelled secondary anti-IgG antibodies show nuclear more than cytoplasmic 
staining of granular and molecular layer neurons and Purkinje cells using anti-Hu (a) antibody 
positive serum; characteristic cytoplasmic staining of Purkinje cells by anti-Yo positive 
serum(b); cytoplasmic staining of Purkinje cells with staining of fine dots in the molecular 
layer by anti-Tr positive serum (c); strong staining of the molecular layer by anti-mGluR1 
positive serum (d); synaptic interstitial staining of the molecular and granular layer by CV2 
positive serum (e) and sub-nuclear staining of cortical neurons using anti-Ma2 positive serum 
(f). ML, molecular layer; PC, Purkinje cell; GL, granular layer; N, (cortical) neuron.
TheRAPy And PROgnOsIs
Because PNS are considered to be immune-mediated, two treatment approaches look 
obvious: removal of the source of antigen by tumor treatment, and immunosuppressive 
treatment. For most PNS the effect of immunotherapy is disappointing, underlining the 
importance of tumor search and tumor treatment.
Immunotherapy is most effective in PNS associated with antibodies that are directed 
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against antigens located at the cell-surface and therefore accessible to circulating 
antibodies. These include syndromes of the peripheral (neuromyotonia, LEMS and 
MG) and central nervous system (anti-mGluR1 associated PCD9 , anti-amphipysin 
associated stiff-person syndrome20 and anti-VGKC and anti-NMDAR associated LE.21 ). 
Recommended modalities include plasma exchange, immunoadsorption (serum IgG 
extraction over a protein A column), steroids and intravenous immune globulins (IVIG). 
In PNS where the antigen is either nuclear or cytoplasmic, the dysfunction is probably 
the result of cellular immune mechanisms. Hence removal of antibodies is not expected 
to be beneficial. Therapies that modulate the activation and function of effector T cells 
could be more promising, but until now only limited evidence for the effectiveness of 
steroids, cyclophosphamide, IVIG or other immunosuppressive therapies exists.22 B 
cell depletion by monoclonal anti-CD20-antibodies (rituximab) has been encouraging 
in opsoclonus-myoclonus syndrome (OMS) in children23 , although results in adults 
were less convincing.24 These effects probably result from influencing the cell signaling 
between B-cells and T-cells and macrophages.
Anti-tumor therapy offers the best chance to stop the paraneoplastic neurological 
deterioration and leaves the patients, on average, in a better condition.25,26 In severely 
debilitated patients, e.g. the elderly and bedridden, an underlying tumor is often not 
treated because chances of clinically relevant improvement are small. 
ClAssICAl syndROMes
Encephalomyelitis 
Paraneoplastic encephalomyelitis (PEM) is characterized by involvement of several 
areas of the nervous system, including temporal lobes and limbic system (LE), 
brainstem (brainstem encephalitis), cerebellum (PCD), spinal cord (myelitis), dorsal root 
ganglia (SSN) and autonomous nervous system (autonomic neuropathy).27 Patients with 
predominant involvement of one area but clinical evidence of only mild involvements of 
other areas are usually classified according to the predominant syndrome. Symptoms 
can include diplopia, dysarthria, dysphagia, gaze abnormalities (nuclear, internuclear 
or supranuclear), facial numbness and subacute hearing loss. More rarely, patients 
present with hypoventilation28 , epilepsia partialis continua29 or nonconvulsive status 
epilepticus.30 
Most patients have an underlying SCLC and harbor anti-Hu antibodies (ANNA-1) in 
serum and CSF. Other associated antibodies are anti-CV2(CRMP5)2 , anti-amphihysin31 
, anti-Ri (ANNA-2)32 and the less well characterized ANNA-333 and PCA-234 antibodies. 
Approximately 5% of patients with anti-Hu antibodies develop no cancer despite 
longterm follow-up.35 The absence of distinguishing clinical features between anti-Hu 
positive patients without cancer and those who develop cancer supports the possibility 
that these patients developed an effective Hu—probably a T cell-mediated—immune 
response that eliminated the tumour at an early stage of its development. Tumor 
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treatment offers the best chance of stabilizing the patient’s neurological condition 
while immunomodulating therapies do not appear to modify the outcome of PEM.27 
In spite of descriptions of spontaneous improvement and incidental good response to 
immunosuppressive treatment, overall functional outcome is bad and more than 50% 
of patients are confined to bed or chair in the chronic phase of disease.27 
Limbic encephalitis and variants
LE is characterized by a subacute onset (days to a few months) of short memory loss, 
seizures, confusion and psychiatric symptoms suggesting involvement of the limbic 
system. In patients primarily presenting with confusion or multiple seizures, the 
memory loss may not be evident. Approximately 80% of patients have MRI T2 and 
FLAIR hyperintensities involving one or both medial temporal lobes.36 FDG-PET may 
show hypermetabolism in one or both temporal lobes, which could (when seizures 
are excluded) be a hallmark of the inflammatory or immune-mediated process.2 
More than half of the patients presenting with limbic encephalitis have an underlying 
neoplasm.17,37 Associated tumors include SCLC, testicular germ-cell tumors, thymoma, 
breast cancer, Hodgkin’s disease and teratoma.38 More than 80% of patients with LE 
harbour antineuronal antibodies and recent studies emphasize the importance of 
classifying antibody-positive LE according to the location of the target antigens.2,17 
LE with antibodies to intraneuronal antigens
The main intracellular antigens related to LE are Hu, Ma1/2, and less frequently 
CV2(CRMP-5) and amphiphysin. Most patients with LE and anti-hu antibodies have 
symptoms suggesting dysfunction of areas of the nervous system distant from the 
limbic system, such as brainstem, cerebellum, dorsal root ganglia, cerebral cortex, 
spinal cord or autonomic nervous system.38 The median age is around 62 years and 
in most patients an underlying tumor is identified, usually SCLC followed by prostate 
cancer.37 The neurological outcome is generally poor although some improvement may 
occur in up to 38% of the patients.37 
Anti-Ma antibodies react with Ma1 and Ma2 onconeural antigens while anti-Ta 
antibodies only react with Ma2.39 Patients with anti-Ma often present with limbic 
encephalitis and/or cerebellar symptoms. They are more often female with a median 
age of around 61 years. A wide range of tumors is associated, including lung and breast 
cancer, lymphoma and germ cell tumors. In most patients the neurological disease is 
progressive.39 
Patients with anti-Ta present with limbic symptoms often in combination with 
hypothalamic deficits and brainstem symptoms. The patients are predominantly male 
with a median age of 34-44 years.39 Anti-Ta is associated with testicular germ-cell tumors 
that are often nearly undetectable at presentation.39 Most of these patients benefit 
from orchidectomy and they may also respond to immunotherapy.39 A recent review 
of the literature extended the age range (21-81 years) and sex (8/36 female) of anti-Ta 
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positive patients.39 
In patients with anti-CV2 antibodies, the symptoms are rarely confined to the limbic 
system as they generally present with encephalomyelitis, sensory neuronopathy (SN), 
ataxia, chorea and optic neuritis. Development of myelitis and optical neuritis may 
initially resemble Devic’s syndrome. The anti-CV2 antibodies are mostly associated with 
SCLC, neuroendodrine tumors and thymomas.2  In PLE associated with intraneuronal 
antigens, spontaneous complete recovery has been described, although very rarely.1 
Immunotherapy is largely ineffective39 , but multiple cases benefiting from anti-tumor 
treatment have been reported.1 Therefore, all efforts should be directed at identifying 
and treating the underlying tumor.
LE with antibodies to neuronal cell-surface antigens
Up to 40% of patients with antibody associated LE harbour antibodies reactive with 
voltage-gated potassium channels (anti-VgKC).17,37 These patients either present with 
a typical limbic encephalitis or with a less focal encephalitis that is associated with 
psychiatric symptoms, peripheral nerve hyperexcitability (myokymia, neuromyotonia), 
hyperhydrosis and other symptoms of autonomic dysfunction occur (Morvan’s 
syndrome). REM sleep disturbances and hyponatremia are common in both groups 
About 30% of patients have tumors, most often SCLC or thymomas. Corticosteroid 
treatment, plasma-exchange and IVIG are beneficial in about 80% of patients.2 
Antibodies to the NR1/NR2 heteromer of the N-methyl-D-aspartate receptors (anti-
nMdAR) were first described in young women harbouring an ovarian teratoma.40 The 
patients presented with prodromal symptoms including headache, fever or a viral-like 
illness followed by severe psychiatric symptoms or memory loss, seizures, a decreased 
consciousness accompanied by dyskinesias, hypoventilation or autonomic instability.40 
When untreated, many patients require long term mechanical ventilation. Treatment 
of the tumor combined with immunosuppressive or immunomodulating therapy often 
results in complete recovery.2 More recently, anti-NMDAR antibodies have also been 
described in male patients with LE41 and in LE patients without a tumor or with an 
underlying SCLC.17 
Approximately 25% of patients presenting with LE harbour antibodies reactive with 
unidentified neuronal surface antigen (i.e. not anti-NMDAR or anti-VGKC).17 These 
patients usually have additional onconeural antibodies including antibodies against 
amphiphysin, Hu, CV2, SOX1 and GAD.17 These PLE patients generally have no clinical 
response to treatment. 
Paraneoplastic cerebellar degeneration (PCD) 
PCD is one of the most common and characteristic paraneoplastic syndromes. In 
series of patients with antibody-associated PNS, presentation with cerebellar signs 
occurred in 37%. Usually the syndrome starts acutely with nausea, vomiting, dizziness 
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and slight incoordination of walking, evolving rapidly over weeks to a few months with 
progressive ataxia of gait, limbs and trunk, dysarthria and often nystagmus associated 
with oscillopsia. The disease is progressive in months and then stabilizes. By that time 
most patients are severely disabled: walking without support, sitting unsupported and 
self-feeding becomes difficult while handwriting is often impossible. Signs are always 
bilateral but may be asymmetrical. Diplopia is common at presentation although ocular 
movement may seem normal at investigation. Symptoms and signs are mostly limited 
to the cerebellum and cerebellar pathways, but on careful examination other mild 
neurological abnormalities e.g. hearing loss, dysphagia, pyramidal and extrapyramidal 
tract involvement, mental status change and peripheral neuropathy may be found.1 
Approximately 50% of patients presenting with acute or subacute, non-familial ataxia 
are estimated to have an underlying malignancy. Associated malignancies include 
ovarian, breast and lung cancer (SCLC) and lymphomas (Hodgkin’s disease) Symptoms 
precede cancer diagnosis in 60-70% of patients. 
In the initial stages MRI of the brain is normal but may exceptionally show diffuse 
enlargement of the cerebellar hemispheres or contrast enhancement of the sulci.2 
Brain FDG-PET scan and SPECT may show cerebellar hypermetabolism and increased 
perfusion during the acute stages of PCD.42 In the chronic phase, CT and MRI often 
reveal cerebellar atrophy. In the search for antibodies and associated malignancy 
anti-Yo (PCA-1), anti-Tr (PCA-Tr) and anti-mGluR1 are associated with relatively ‘pure’ 
cerebellar syndromes. Anti-Yo antibodies point at breast, ovarian, endometrium and 
fallopian tube cancers. Rarely, anti-Yo associated PCD occurs in male patients, usually 
associated with a gastrointestinal adenocarcinoma, expressing the cdr2 antigen.43 
Anti-Tr antibodies appear specific for Hodgkin’s disease44 and anti-mGluR1 antibodies 
have been found in two patients with PCD and Hodgkin’s disease.9 About 50% of PCD 
patients with an underlying SCLC have high titers of anti-Hu antibodies while the 
remaining patients are likely to have anti-P/Q-type VGCC antibodies. These antibodies 
were present in all patients who also had Lambert-Eaton myasthenic syndrome (LEMS). 
In patients with anti-amphihysin or anti-CV2 antibodies, the cerebellar degeneration 
is often part of the PEM syndrome and more widespread neurological symptoms and 
signs are usually found. The less well characterized PCA-2, ANNA-3 and Zic4 antibodies 
are associated with lung cancer and various neurological syndromes including PCD. 
The outcome of PCD is usually poor and the best chance to at least stabilize the syndrome 
is to treat the underlying tumor. In patients with anti-Yo-associated PCD, the prognosis 
is better for patients with breast cancer than for those with gynecologic cancer. An also 
better prognosis is found in patients with Hodgkin’s disease and anti-Tr or anti-mGluR1 
antibodies. With successful treatment of the tumor and/or immunotherapy, symptoms 
may disappear and the antibodies vanish.9,44 
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Opsoclonus-Myoclonus syndrome (OMS) 
OMS – the ‘dancing eye and dancing feet syndrome’ – is a disorder of ocular motility that 
consists of involuntary, arrhythmic, high amplitude conjugate saccades in all directions. 
Opsoclonus may occur intermittently or constantly in more severe cases and it does 
not remit when the eyes are closed or in the darkness. There is often a diffuse or focal 
myoclonus and other cerebellar and brainstem signs. An excessive startle response 
reminiscent of hyperekplexia may also occur.45  MRI is usually normal but may show 
hyperintensities in the brainstem on T2 weighted images. Recent pathological and fMRI 
studies suggest that disinhibition of the fastigial nuclei of the cerebellum is involved, 
probably resulting from dysfuntion of Purkinje cells in the cerebellar vermis.46 
Approximately 20% of adult patients with OMS have a previously undiscovered 
malignancy, most commonly SCLC and breast and gynecologic cancers. In some 
patients, paraneoplastic OMS resembles PCD. The prominent opsoclonus and truncal 
rather than appendicular ataxia distinguish this syndrome from anti-Yo and anti-Hu 
associated PCD Adult patients with paraneoplastic OMS are older (median age 66 years) 
than patients with the idiopathic syndrome (median age 40 years). Non-malignant 
causes for opsoclonus include infections (West Nile virus, Lyme disease), celiac disease, 
metabolic or toxic influences and allogeneic hematopoietic stem cell transplantation.46 
In women, anti-Ri antibodies (ANNA-2) are frequently associated with breast and 
gynecologic tumors. In male patients anti-Ri has occasionally been found in bladder 
cancer and SCLC. Paraneoplastic OMS can also be associated with anti-Hu antibodies, 
usually as part of a more widespread PEM. 
In children with OMS, almost 50% have an underlying neuroblastoma. Conversely, 
approximately 2-3% of children with neuroblastoma have paraneoplastic OMS. Non-
paraneoplastic pediatric OMS occurs as a self-limiting illness and is probably the 
result of a viral infection of the brainstem. The search for an occult neuroblastoma 
should include imaging of chest and abdomen (CT scan or MRI), urine catecholamine 
measurements and metaiodobenzylguanidine scan.1 When negative, the evaluation 
should be repeated after several months. 
Sera of children (not of adults) with OMS have antibodies that react with the cell 
surfaces of cerebellar granule neurons and neuroblastoma cells.47 Incubation of 
neuroblastoma cell lines with these antibodies inhibits cell proliferation and induces 
apoptosis, indicating that humoral immune mechanisms have an important pathogenic 
role in pediatric OMS. 
In contrast to most of the other PNS, paraneoplastic OMS may remit either spontaneously, 
following treatment of the tumor, or in association with clonazepam or thiamine 
treatment. Most patients with idiopathic OMS make a good recovery that seems to be 
accelerated by immunosuppressive therapy. Paraneoplastic OMS has usually a more 
severe clinical course and treatment with steroids or IVIG appears ineffective. However, 
improvement following immunosuppressive or immunomodulating therapy. In 
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children, paraneoplastic OMS may improve following treatment with ACTH, prednisone, 
azathioprine or IVIG, but residual neurologic signs are frequent. 
Subacute sensory neuronopathy (SSN)
SSN is an uncommon disorder that is probably paraneoplastic in about 20% of 
patients.48 Starting symptoms are asymmetrical or multifocal pain and paraesthesiae 
in the extremities followed by clumsiness and an unsteady gait. Sensory loss may 
also affect the face or trunk. On neurological examination all sensory modalities are 
affected but the most striking abnormality is loss of deep sensation causing sensory 
ataxia with pseudoathetosis of the hands. Tendon reflexes are depressed or absent. 
In most patients, the disease progresses rapidly over weeks to months, leaving the 
patient severely affected. In a few patients the neuronopathy remains stable for 
months with mild neurological deficits.49 SSN occurs in approximately 75% of patients 
with PEM, is predominant in 50% and clinically pure in 25%.1 Autonomic neuropathy 
including gastrointestinal pseudo-obstruction is common. SSN is associated with lung 
cancer, usually SCLC, in 70-80% of patients.2 Other associated tumors include breast 
and ovarian cancer, sarcoma and Hodgkin’s disease. SSN usually precedes the diagnosis 
of cancer with a median delay of 3.5-4.5 months.27 
The hallmark in electromyography is the absence or marked reduction of sensory nerve 
action potentials. Motor conduction velocities may be mildly reduced. Sural nerve 
biopsy is rarely required for the diagnosis but can be considered to differentiate from 
vasculitic neuropathy. 
Anti-Hu is the most frequent paraneoplastic antibody in SSN.25 In this setting, anti-Hu 
antibody detection has a specificity of 99% and sensitivity of 82%.50 The absence of anti-
Hu antibodies does not rule out an underlying cancer. Anti-CV2 and anti-amphiphysin 
antibodies also occur with paraneoplastic peripheral neuropathies, usually in 
combination with other symptoms.
In most cases immunotherapy is ineffective. Early tumor detection and treatment 
offer the best chance of stabilizing the neurological syndrome. Despite negative tumor 
screening, antitumor treatment can be considered in patients with anti-Hu antibodies, 
age > 50 and a history of smoking. Symptomatic treatment is often needed for 
neuropathic pain and dysautonomic symptoms such as orthostatic hypotension.
Lambert-Eaton myasthenic syndrome (LEMS)
LEMS typically presents with proximal weakness of the lower extremities and 
fatigability. Bulbar symptoms may occur but are generally milder than in myasthenia 
gravis. Respiratory weakness can occur. Deep tendon reflexes, especially those in the 
legs, are diminished or absent but typically increase after exercise. 95% of patients 
ultimately develop autonomic features, especially dryness of the mouth, impotence 
and ptosis.6,51 The typical pattern of incremental response at high rates of repetitive 
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stimulation (50 Hz) or following 15-30 seconds of maximal voluntary contraction forms 
the electromyographic hallmark of LEMS. Most patients with LEMS have antibodies 
against P/Q type voltage-gated calcium channels (VGCC).
Approximately 50-60% of patients with LEMS have cancer, mostly SCLC.6 In some patients, 
LEMS may develop in association with other paraneoplastic syndromes, including 
paraneoplastic cerebellar degeneration and encephalomyelitis. Other tumors include 
small cell carcinomas of the prostate and cervix, lymphomas and adenocarcinomas. 
The prevalence of LEMS in SCLC is approximately 3%.6 
History of smoking, absence of the HLA-B8 genotype and presence of SOX1 antibodies 
strongly predict an underlying SCLC.18 Patients with SCLC and LEMS survive significantly 
longer than SCLC patients who do not have the paraneoplastic syndrome.6 
Treatment of LEMS must be tailored to the individual, based on severity of the 
symptoms, underlying disease, life expectancy and previous treatment response. 
Treatment of the tumor frequently leads to neurological improvement. Symptoms are 
treated with drugs that facilitate the release of acetylcholine from motor nerve terminals 
such as 3,4-diaminopyridine (3,4-DAP). Cholinesterase inhibitors (e.g. pyridostigmine) 
may improve dryness of mouth but rarely relieve weakness. If these treatments are 
not effective enough, immunosuppressive therapy must be considered. Removal of 
the pathogenic anti-VGCC antibodies by plasma exchange and IVIG can give quick but 
transient relief.
Dermatomyositis 
In dermatomyositis the characteristic heliotrope rash (purplish discoloration of the eyelids) 
often precedes the appearance of proximal muscle weakness. Other manifestations 
include arthralgia, myocarditis and congestive heart failure and interstitial lung disease. 
The standardized incidence rate for a malignant disease in dermatomyositis is 6.2 (95% 
confidence interval 3.9 – 10.0).52 Similar clinical, electromyographical, and pathological 
results are found compared to dermatomyositis without presence of malignancy.52 
Dermatomyositis is associated with cancer of the ovary, lung, pancreas, stomach, 
colorectal and breast and with non-Hodgkin lymphoma. Most patients have elevated 
serum creatine kinase levels and electromyographic evidence of myopathy. Muscle or 
skin biopsy is the definitive diagnostic procedure and shows inflammatory infiltrates. 
Muscle imaging (CT or MRI) may help in confirming the diagnosis and determining 
the type of an inflammatory myopathy and in selecting an appropriate biopsy site. 
Antibodies to the Mi-2 protein complex are specific for dermatomyositis and are 
present in high titers in about 35% of cases.53 Treatment of patients with paraneoplastic 
dermatomyositis does not differ from those without a tumor. Nearly all patients 
respond to corticosteroids. Refractory patients and patients requiring a lower dose of 
steroids can be treated with azathioprine. Methotrexate and cyclophosphamide may 
also be considered.
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AbsTRACT
Paraneoplastic neurological syndromes (PNS) are severe immune mediated effects of 
cancer. The presence of IgG autoantibodies against onconeural antigens in serum is 
a hallmark of the disease. Multiple paraneoplastic antibodies have been described, 
including antibodies against HuD, Yo, amphiphysin and CV2. In this study, we test the 
hypothesis that primary amino-acid structures of the antigen binding part of antibodies 
from various individuals share common sequences that are specific for each auto-
antigen.
We selected 60 patients with PNS, associated with antibodies against HuD, Yo, Amp or 
CV2.
Affinity purified IgG was separated using SDS-PAGE and IgG heavy chains were excised,
trypsinized and subjected to tandem mass spectrometry. We selected masses that 
uniquely identified a PNS autoantibody group, and used MS/MS fragmentation 
spectra to obtain information on peptide sequences. Out of 19,173 unique masses, 
28 immunoglobulin derived peptides were found exclusively in samples from a single 
autoantibody defined PNS group.
Our results confirm that specific peptide structures exist in the antigen binding site of 
IgG that are shared between individuals harboring autoantibodies against the same 
onconeural antigen. Thus, the immune response in these patients followed converging 
paths during the rearrangement, selection and maturation of immunoglobulin 
sequences. The identified peptides can be applied in the diagnosis of PNS, but these 
data also indicate that a similar approach in a variety of other diseases involving an 
immune response would have an appealing outlook. 
KeywORds
Paraneoplastic neurological syndrome; antibody; immunoglobulin; repertoire; 
proteomics
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InTROduCTIOn
Paraneoplastic neurological syndromes (PNS) are devastating, remote effects of cancer 
that are not caused by tumor growth, infiltration, metastasis or tumor treatment.1 In 
about 70% of cases, the neurological symptoms precede the cancer diagnosis. Clinical 
outcome depends mostly on an early diagnosis of PNS combined with rapid detection 
and treatment of the underlying tumor.1 Early diagnosis is aided by the detection of 
anti-neuronal antibodies that are present in the serum of approximately 50-70% of 
patients with PNS. These autoantibodies are directed against neuronal antigens that are 
ectopically expressed by the tumor (i.e. onconeural antigens). Autoantibodies against 
several onconeural antigens have been described including anti-HuD (HuD-Ab), anti-
Yo (Yo-Ab), anti-amphiphysin (Amp-Ab), and anti-CV2 (CV2-Ab) antibodies.1,2 Antibodies 
against onconeural antigens are now routinely tested in diagnostic assays that employ 
proteins produced by recombinant technology.
Immunoglobulin G (IgG) consists of 4 chains: two identical heterodimers of a heavy and 
a light chain held together covalently by disulfide bonds. Both heavy and light chains 
have a constant part and a variable antigen binding part. Within the antigen binding 
part, a set of 3 complementary determining regions (CDRs) embedded in framework 
regions form a groove that fits the epitope of an antigen. The CDRs and framework 
regions are selected from rearrangements of V-, D- and J-genes, and subsequent 
somatic hypermutation during affinity maturation.3 The CDR3 region of the heavy chain 
contributes the most to both the variability in immunoglobulin sequences, and also to 
their specificity to an antigen.3,4
Although rearrangement and junctional diversity in the heavy chain can yield more than 
107 different variable regions 3, many reports show an unexpected sequence overlap in 
different species.5-8 Based on the fact that a few major epitopes are present within an 
antigen molecule, including HuD and that selection pressures exist for the best binding 
variants during antibody development, we hypothesize that the diversity in the variable 
epitope binding regions of immunoglobulins will be significantly less than the total 
potential diversity.7-9 As a result, we expect that individuals harboring HuD-Ab in their 
serum may share some of the amino-acid sequences of the antigen binding regions of 
HuD-Ab with those of other individuals with HuD-Ab.
Previous work of our group showed that, after immunization of outbred rats with 
recombinant HuD protein, shared identical CDR-derived IgG peptides specific for HuD-
Ab could indeed be detected, and that sera could be distinguished in this manner 
from that of animals immunized with another antigen10, Therefore, it seems plausible 
that also in humans, antigen specific IgG derived peptides might be shared between 
individuals who have in their serum autoantibodies reactive with the same antigen.
Mass spectrometry (MS) is a reliable technique to quantify peptides, even in low 
nanomolar amounts.11 The instrument also provides peptide fragmentation spectra 
that can be used to obtain sequence information on the peptide of interest. Commonly, 
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a search algorithm screens a protein database in combination with the spectra to arrive 
at identification. This approach is not available for work on antigen binding regions, 
as these variable parts are hardly covered by protein databases. Recent advances in 
de novo sequencing of unidentified MS/MS spectra offer opportunities to construct an 
optimal sequence hypothesis for a peptide without the use of a database. First reports 
of IgG amino acid sequencing show that a proteomic approach is feasible.10,12 In the 
current work, the goal is to establish that the proteomic analysis of immunoglobulins 
can differentiate between immunoglobulin samples from human patients with a specific 
immune response. The clinical parameters of paraneoplastic disease are well-defined 
and the recombinant onconeural target antigens and sera specific for these antigens 
are well validated and available. Therefore, PNS serves as a suitable model to test the 
feasibility of detecting antigen-specific immunoglobulin peptides in affinity purified 
patient sera. While conventional diagnostic tests for the paraneoplastic antigens 
described here are currently adequate, this work sets the stage for diseases where 
diagnostics remain more challenging, such as paraneoplastic diseases that require 
cumbersome cell-based assays, radioactive assays, or conditions where the antigen 
remains unidentified.
MATeRIAls And MeThOds
Samples
We selected 20 HuD-Ab positive sera that were negative for antibodies against the 
onconeural antigens NOVA (Ri), CDR62 (Yo), amphiphysin, CV2 (CRMP-5), Ma2, recoverin 
and Tr.1 In addition, we selected 20 Yo-Ab positive sera, 10 Amp-Ab positive and 10 CV2-
Ab positive sera. All sera reacted with only one of the onconeural antigens mentioned 
above, and thus could also be used as controls for other antigen groups. IgG titers of 
the paraneoplastic antibodies were determined by endpoint titration on rat cerebellar 
sections using peroxidase immunohistochemistry as described before.13 From all 
patients clinical information was retrieved from the treating neurologist. Characteristics 
of patients and sera are depicted in Table 1. All patients had a ‘definite PNS’ according 
to published criteria and all sera had been stored at -800 C until use.14 The study was 
approved by the Erasmus MC institutional review board, and patients consented to the 
use of their samples for research.
Materials and Reagents
All chemicals were, unless otherwise noted, purchased from Sigma-Aldrich, Saint Louis, 
MO.
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Recombinant antigen production and purification 
cDNA’s encoding HuD9, Yo15, amphiphysin16 and CV217 were ligated into pET-
21b vectors (Novagen/Merck4Biosciences, Darmstadt, Germany) followed by 
transfection and induction of E.Coli strain BL21(DE3)pLysS (Novagen) as described 
before.13 After E.coli lysis, His-tag purification was performed on HisTrap columns 
(HisTrap FF, GE Healthcare, Diegem, Belgium) using a 20-500 mM imidazole gradient 
in a buffer containing 8 M urea, 0.1 M sodium phosphate and 0.3 M sodium chloride 
(pH 8.0). Elution fractions containing the recombinant proteins were analyzed for 
purity by SDS-PAGE by means of Colloidal Coomassie 
Table 1.Patient characteristics.
HuD-Ab Yo-Ab Amp-Ab CV2-Ab
Patients
 Male:female 10:10 20:0 8:2 7:3
 Age (y)(range) 65.5 (50–81) 60.9 (41–81) 66.2 (45–85) 66.2 (53–75)
PNS
 SCD 6 (30%) 20 (100%) 2 (20%) 3 (30%)
 SN 9 (30%) 1 (10%)
 LE 4 (20%) 1 (10%) 1 (10%)
 EM 4 (20%) 3 (30%)
 PNP 3 (30%)
 LEMS 1 (10%)
 SPS 1 (10%)
 Not available 1 (10%) 2 (20%)
Tumor
 Lung 18 (90%) 4 (40%) 6 (60%)
 Breast 6 (30%) 1 (10%)
 Ovary 7 (35%)
 Endometrium 2 (10%)
 Other 1 (5%) 2 (20%)
 No tumor found 2 (10%) 4 (20%) 2 (20%) 4 (40%)
Laboratory
 Titer (median) 
(range)
11,880 
(800–51,200)
84,365 
(400–409,600)
89,640 
(400–819,200)
21,360 
(800–102,400)
Age, age at diagnosis; PNS, paraneoplastic neurological syndrome; SCD, subacute cerebellar degeneration; SN, 
sensory neuronopathy; LE, limbic encephalitis; EM, encephalomyelitis; PNP, polyneuropathy; LEMS, Lambert-
Eaton myasthenic syndrome; SPS, stiff person syndrome.
Blue staining (Novex®, Invitrogen, Carlsbad, CA). Subsequently, Western blot detection 
with an anti-T7 monoclonal antibody (Novagen) was performed. Elution fractions 
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with the highest concentration of recombinant protein were subjected to further 
purification by ion exchange chromatography on HiTrapQ HP columns (GE Healthcare) 
using a buffered pH gradient of 12 to 2.5 in a buffer containing 8M urea, 0.01M sodium 
phosphate, 0.01M citric acid, 0.01M glycine, 0.01M tricine and 0.01M aminocaproic 
acid.18 Fractions containing the highest purity of recombinant proteins were pooled, 
the buffer was exchanged to 8M urea and 0.1M sodium phosphate (pH 8.0) using a 
desalting column (Hitrap Desalting, GE Healthcare), and the sample was concentrated 
to 1 mg onconeural antigen / ml by ultrafiltration (Ultra-4 30kDa NWCO, Millipore, 
Amsterdam, The Netherlands), analysed by SDSPAGE as mentioned above and aliquots 
were stored at -800C.
Affinity purification
IgG was purified from serum samples by Melon Gel purification (Melon Gel IgG 
Purification Kit, Pierce Biotechnology, Rockford, IL) according to the manufacturer’s 
protocol. Recombinant purified HuD, Yo, amphiphysin and CV2 proteins were each 
coupled to carboxylated magnetic beads (CMS-30-10, Spherotech, Lake Forest, Illinois, 
US). For each serum sample, 107 beads were used. After washing the beads with 
water, 20 μl 50 mg/ml N-hydroxysulfosuccinimide (Pierce Biotechnology), 20 μl 50 mg/
ml carbodiimide EDC (Pierce Biotechnology) and 160 μl 100 mM sodium phosphate 
buffer, pH 6.2 were added to the beads. After incubation for 20 minutes, the activated 
beads were washed with 2-(N-morpholino) ethanesulfonic acid, pH 5.0. Subsequently, 
200 pmoles of recombinant protein per 107 beads were added. After incubation, the 
coupled beads were blocked with PBS, 0.1% BSA, 0.02% tween-20, 0.05% NaN3 pH 7.4 
and stored at 400C until use.10 For use, the beads were washed twice using PBS-0.02% 
Tween-20 (PBS-T) and incubated for 1 hour at room temperature with 2.5 ml of purified 
IgG, 1:10 diluted in Melon purification buffer, followed by centrifugation (1000g) for 30 
seconds. Supernatant was removed while the tube was placed on a magnet to prevent 
loss of beads. For washing, we added 2.5 ml PBS-T followed by vigorous mixing for 10 
seconds, washing on roller bank for 5 minutes, followed again by mixing. This procedure 
was repeated twice. For elution of the bound antibodies, 225 μl 100 mM glycine-HCl 
pH 2.6 was added followed by mixing. After 5 minutes of incubation, the samples 
were centrifuged and the purified antibody-containing supernatant was collected on a 
magnetic sample holder. The pH was reconstituted to pH 8.0 using 1M Tris-HCl pH 9. As 
a control, a Yo-Ab positive serum was subjected to affinity purification on HuD coated 
beads (Supplementary Figure 4). 
Electrophoresis and digestion of proteins
SDS-PAGE was performed as previously described.9 Polyacrylamide gels (10%) of 0.75 
mm thickness were used. To 15 μL sample 5 μL sample buffer was added and samples 
were heated for 10 minutes at 90⁰ C. Proteins in the gel were stained with Colloidal 
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Coomassie Blue staining (Invitrogen) following the manufacturers instructions. The 
concentrations of the affinity purified IgG fractions were then calculated with serial 
dilutions of commercial human IgG (Nanogam®, Sanquin, Amsterdam, The Netherlands) 
as a reference. From the Colloidal Coomassie Blue stained gels, IgG heavy chain bands 
were excised. The gel plugs were reduced and alkylated with iodoacetamide and 
digested with trypsin in the presence of RapiGestSF (Waters Corporation, Milford, MA) 
as described previously.10
LTQ-Orbitrap
Based on the UV absorption of the peptides in a test chromatography run, an optimal 
injection volume of 15 μL was selected for nanoLC (nanoLC Ultimate 3000; Dionex, 
Sunnyvale, CA) separation, followed by Orbitrap MS (LTQ Orbitrap XL ETD, Thermo 
Scientific, Bremen, Germany), as described before.19 All samples were measured in a 
data dependent acquisition mode. MS spectra from the Orbitrap were acquired with a 
resolution of 30,000. Under dynamic exclusion rules, the five most intense masses in the 
mass spectrum were selected for collision-induced dissociation (CID) in the linear ion 
trap of the instrument. Before each run, a blank LC-MS run was performed to monitor 
system background and sample carry-over.
Data analyses
Raw mass spectrometry data files were loaded into Progenesis LCMS labelfree 
quantitation software (version 2.6; Nonlinear Dynamics Ltd, New Castle, UK). This 
software aligns the retention times of all samples, detects mass features in the data, 
defines a region of interest around these and integrates signal intensities in such regions 
for all samples. Also, available MS/MS spectra and peptide identifications are associated 
with the features. As our analysis has focus on the presence of peptide markers that 
are absent in control groups, the software output is limited by the fact that the reported 
abundances simply reflect the amount of signal within the region of interest, without 
verification of the presence of a proper isotopic pattern for a peptide of interest in each 
sample. To address this, we only consider feature abundance as valid for a given sample 
when we found a corresponding feature after analysis of just this sample in isolation. 
If that was not the case, an abundance of ‘0’ was assigned with a script written in R 
(R 2.12.2, www.r-project.org). Where possible, features were annotated in Progenesis 
with sequence information. First, Mascot (version 2.2.06; Matrix Science Inc., London, 
UK) was used to perform database searches against the human subset of the NCBI 
nonredundant database (version 20090311; Homo sapiens species restriction; 222,066 
sequences). For the database search the following settings were used: a maximum of 
two miss cleavages, oxidation as a variable modification of methionine, deamidation 
as a variable modification of asparagine or glutamine, carbamidomethylation as a 
fixed modification of cysteine, and trypsin as protease. A peptide mass tolerance of 
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10 ppm and a fragment mass tolerance of 0.5 Da were allowed. An ion score of 25 was 
used as a cut-off value. In addition, the MS/MS data were loaded into Peaks Studio 
5.2 (Bioinformatics Solutions Inc., Waterloo, Canada) and de novo sequencing was 
performed for all specific features. The parent peptide mass accuracy was set at 6 ppm 
and for the MS/MS fragments 0.5 Da tolerance was allowed. Oxidation was allowed as 
a variable modification of methionine, carbamidomethylation as a fixed modification of 
cysteine, and trypsin as protease.
From the feature abundance data, we selected as potential markers those that were 
present in many patients for an antigen while absent in all other antigens. Some of the 
features emerging from that step were identified as antigen-derived, and were excluded 
from the marker set at that point. We also excluded features that were associated with 
common environmental or serum contaminants (e.g. keratins, complement factors, 
plasminogen, transferrin). A permutation analysis was performed to determine the 
false discovery rate. We randomized the group assignments 30 times and determined 
the number of background features matching our selection criteria.
Sequence information of features that were identified as potential markers was manually 
curated after assessing homology of the sequence to known germline sequences (Spider 
search in Peaks), re-analysis with summed MS/MS spectra, and rejection of outlier MS/
MS spectra after pairwise comparison of their similarity with R. All final amino-acid 
sequences of antibody group specific features identified by Mascot database search 
or proposed by de novo sequencing were aligned to human immunoglobulin germline 
sequences using the IMGT (ImMunoGeneTics information system® http://www.imgt.
org; Montpellier, France) database as described before.19,20 The alignment with the most 
homologous germ allele was registered as provided by the IMGT tool where Smith-
Waterman homology scores exceeded 35. An additional homology search with the 
BLAST algorithm against the NCBI nonredundant database was used to exclude the 
presence of variants of serum contaminants in the dataset.21
ResulTs
Affinity purification
Sera were collected from a total of 60 PNS patients (Table 1). Antigen-specific 
immunoglobulins were affinity purified from the sera with beads covalently coupled 
to recombinant antigen. The concentration of affinity purified IgG, expressed as serum 
concentration, was for HuD-Ab 0.017 ± 0.013 mg/mL (mean ± SD), Yo-Ab 0.036 ± 0.027 
mg/mL, Amp-Ab 0.007 ± 0.010 mg/mL and CV2-Ab 0.020 ± 0.013 mg/mL as determined 
by densitometry of Coomassie stained SDS-PAGE gel bands. Two of the 60 affinity 
purified IgG bands (one HuD-Ab and one Yo-Ab) were absent on visual inspection of the 
Coomassie stained gels. These two samples were excluded from further analysis.
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Feature detection (Progenesis) and identification (Mascot)
The antigen-specific IgG heavy chain bands were excised from the gels, digested with 
trypsin, and analyzed by nano-LC and mass spectrometry (LC-MS). The Progenesis label-
free analysis software identified 19,173 peptide features in the MS dataset. A Mascot 
search of the data against the NCBI non-redundant protein database yielded amino acid 
sequences for 2904 peptides, of which 2,765 were unique. In addition, 10,705 peptides 
were associated with a de novo sequence hypothesis, and 5,564 peptides remained 
without sequence identification.
As we seek peptides that uniquely identify a patient group, it is important to give an 
accurate assessment on the presence or absence of a particular peptide in a sample. 
The common workflow for label-free analysis in proteomics enumerates the total signal 
in a region of interest (a ‘feature’) in all samples. This approach works relatively well when 
looking at concentration differences in abundant peptides, but is prone to report an 
erroneous abundance in absence of a peptide due to signals from noise or partial signals 
from other peptides present near in the region of interest (Supplementary Figure 1). As 
explained in the Materials and Methods section (2.7), we constructed a refinement of 
the workflow that is much more effective at judging the presence or absence of peptides 
in each individual sample. The inadvertent release of antigen from the affinity resin 
provides us with nice markers in the samples to test our analysis, as e.g. HuD-derived 
peptides cannot be present in the Yo samples that were enriched on a Yo affinity resin. 
This is indeed the outcome of our analysis, but not that of the initial data produced by the 
label-free Progenesis analysis software (Figure 1). This shows that our additional data-
analysis was both necessary and sufficient to produce reliable data for marker discovery. 
Figure 1.  Result of the additional processing of abundance data from label-free analysis. A) 
Shows the initial abundance data reported by the software for the peptide AINTLNGLR in all 
samples. The peptide comes from the HuD antigen which was released during the affinity 
purification, and cannot be present in samples from other groups. B) After processing (right 
panels), abundances are only accepted when a peptide feature could also be detected based 
on data of the just the single patient in isolation. Indeed, the peptide is now only detected 
in samples where its presence is plausible. A value of 1 was added to all data points to also 
allow the plotting of an abundance of 0 on the logarithmic axis.
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Selection of group-specific features
From the dataset we selected discriminating features that were present in more than 4 
samples from Amp and CV2, or more than 5 samples for HuD and Yo, while being absent 
in the other antigen groups. By these abundance criteria, 67 features were included. To 
get an impression of the false discovery rate, we performed a repeated (n=30) random 
permutation of the group assignments. In this way, it was found that our criteria yielded 
0.9±1.1 false positive markers from the dataset.
Some of the 67 features were rejected because of the sequence information associated 
with them. Among them, we found some peptides from the onconeural antigens that 
apparently dissociated from the affinity resin during sample preparations. We found 
1 peptide from amphiphysin, 14 from CV2 and 4 from HuD in the marker set. For 
unknown reasons, several human Plasminogen peptides were found in the Yo patient 
samples. Although the latter behavior was selective, we rejected these and also other 
serum components other than immunoglobulins. After these rejections, a set of 30 
potential markers remained. Two pairs of features that were found represented the 2+ 
and 3+ charge states of the same peptides, which leaves 28 unique peptides: 2 specific 
for CV2, 11 for HuD and 15 for Yo (Figure 2, Table 2). P-values were determined for each 
feature with a Kruskall-Wallis test (non-parametric ANOVA, corrected for ties) and found 
to be 0.005 or lower. Not all peptides were present in all individuals, suggesting that a 
panel of peptides will be required to develop a sensitive bio-assay. Based on the current 
samples and all markers, we would detect 0/10 Amp cases, 7/10 CV2 cases, 17/19 HuD 
cases, and 19/19 Yo cases. However, further independent validation is
required to properly assess the sensitivity that can be obtained with these markers.
Figure 2. Abundance of marker candidates. Two examples are shown of markers that were 
selected from the data. Abundances are plotted for all samples in the dataset, and the most 
probable sequence of the peptide is shown in the plot. TPENMRDK was present in 16/19 Yo 
samples, ITYSPNTSK was present in 11/19 HuD samples. A value of 1 was added to all data 
points to also allow the plotting of an abundance of 0 on the logarithmic axis.
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Table 2. Group-specific features identified from the dataset.
m/z z Sequence Confi-dence
Ig 
homologya
Amp 
n = 
10
CV2 
n = 
10
HuD 
n = 
19
Yo 
n = 
19
P value
475.2434 3 WWHHLSTLTSR 34 0 7 0 0 5.5E-08
586.6333 3 YYWWQRLPTTSTTR IGLV1 0 5 0 0 1.4E-05
505.7594 2 ITYSPNTSK 33 IGHV6 0 0 11 0 7.9E-06
414.8735 3 – 0 0 10 0 3.1E-05
521.7283 2 QHMMSQHK 9 0 0 8 0 4.1E-04
670.7657 2 CGGMYYDYAPK 23 IGHV3 0 0 7 0 1.4E-03
482.2487 2 LEMTVQAR 42 0 0 7 0 1.4E-03
419.5449 3 RENMSVHAGVR 14 0 0 7 0 1.4E-03
530.7611 2 YQAWTTYK 23 0 0 7 0 1.4E-03
404.7195 2 ARLSMSK 11 0 0 7 0 1.4E-03
630.2904 2 NSYNDYAVSAR 63 IGHV6 0 0 6 0 4.4E-03
732.3613 2 YKNYNDYAVSVK 43 IGHV6 0 0 6 0 4.4E-03
488.5770 3 43 IGHV6 0 0 6 0
816.3728 2 SVTPEDTAVYYCARb 95 IGHV6 0 0 6 0 4.4E-03
503.7358 2 TPENMRDK 32 0 0 0 16 3.7E-09
620.9439 3 CFWNMELGVVEMSSR 25 0 0 0 16 3.7E-09
930.9108 2
410.5117 3 WMYSNHGYR 0 0 0 11 7.9E-06
410.5117 3 YMPPWFGCR 0 0 0 11 7.9E-06
511.7344 2 MYFSPSYK 0 0 0 9 1.2E-04
543.5950 3 REYNFNTTASQAAR 27 0 0 0 9 1.2E-04
476.8943 3 NKTNFSEFLDGR 38 0 0 0 8 4.1E-04
852.9618 2 ACPKAWRKANALYR 35 0 0 0 7 1.4E-03
973.9224 2 RQMNSPNGMHQLGCWK 25 0 0 0 7 1.4E-03
424.2188 2 HYVDSVKb 40 IGHV3 0 0 0 6 4.4E-03
763.3966 2 WGIGTMVTVSSASTKb 27 IGHJ3 0 0 0 6 4.4E-03
413.8777 3 WWWLANHAR 0 0 0 6 4.4E-03
520.7771 2 NGVAVPSPSGR 28 0 0 0 6 4.4E-03
1128.1498 3 WRWWRCWMWCYVQTFPTCEWWR 6 0 0 0 6 4.4E-03
887.0502 3 HMWWRWYMHYTSHDDVHQK 7 IGHV4 0 0 0 6 4.4E-03
Shown are the mass and charge of the feature that was found, the sequence that was obtained based on 
the MS/MS spectra, a confidence score for the sequence based on the MS/MS spectra, the most homologous 
IgG germline allele, and the number of individuals in which these markers were found. a. Smith–Waterman 
homology score > 35. b. Mascot database identification.
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MS/MS spectra
To further characterize the PNS antigen specific MS features, we compared the MS/MS 
spectra, which were available for 27 of the 28 potential markers. For each feature, we 
performed a similarity analysis on the MS/MS spectra recorded from all samples using 
unsupervised clustering based on pairwise dot products. As illustrated in Figure 3, the 
majority of MS/MS spectra recorded for this feature specific to the Yo-Ab patient group 
are similar, showing that they indeed relate to the same peptide. All of these spectra 
originated from samples of patients with Yo-Ab related PNS. In addition, some distinct 
spectra were included, even in absence of the Yo-specific peptide of interest in the 
samples from other patient groups. Such signals were dissimilar, as shown in cluster 
analysis for HuD and CV2 samples (Figure 3A) as well as in the spectra (Figure 3B). 
Such signals may originate from co-eluting material or from adjacent peptide features 
(Supplemental Figure 2).
Similar MS/MS results were obtained for the other antigen-specific features in our 
dataset. While the quality of these deviating spectra usually does not result in high 
confidence sequence information, it is prudent to remove them from the analysis in 
order to prevent improper sequence information for a feature. 
Figure 3. MS/MS fragmentation spectra associated with the marker peptides as found by 
the Progenesis software. Shown is data for peptide CFWNMELGVVEMSSR, 620.94393+, which 
was only found in Yo-Ab PNS samples. (A) Hierarchical clustering of spectra based on their 
similarity. The majority of spectra is similar and originates from Yo patients. MS/MS spectra 
originating from other patient groups (HuD, CV2) cluster separately, showing they probably 
relate to other co-eluting material. Thus, peptide CFWNMELGVVEMSSR is indeed unique to 
Yo associated PNS. (B) Waterfall plot of all spectra in this set. The bottom cluster of panel A 
is shown in the foreground of the waterfall plot. It can be appreciated that the Yo-related 
spectra in the background are all similar.
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Peptide sequences
Within the 28 potential marker peptides, 2 were identified in the Mascot database search 
as immunoglobulin peptides. For all but one of the remaining features de novo sequences 
could be constructed, although some were of limited quality. Some sequences were 
modified to a more plausible one after assessing homology to immunoglobulin germ 
line alleles using the Peaks Spider tool, or after manual inspection. As we used several 
methods to obtain peptide sequences, (Mascot search, de novo sequencing, adjusted 
de novo sequences), we constructed a general confidence parameter to describe the 
match to MS/MS spectra and sequence confidence. A pseudo-database was generated 
in Mascot containing the proposed peptide sequences. Then, a search was performed 
with the experimental MS/MS spectra, and we included the best score obtained for 
each feature in Table 2. The two features with mass 410.5117 are very similar, but do 
represent distinct peptides that could be found eluting sequentially in a sample. The de 
novo sequence information obtained for these features was of insufficient quality for 
comparison, but the MS/MS spectra were highly similar. Identical peptides except for 
the order of two adjacent amino acids could be a plausible explanation for these similar 
features.
Immunoglobulin germ line alignment (IMGT)
With the putative sequences of the features of interest, a comparison was made with 
immunoglobulin germline sequences in order to identify those with a homology. When 
the Smith-Waterman homology score exceeded 35, the allele was reported in Table 2. 
Features with such homology to IgG germline sequences generally also had a higher 
sequence confidence (p<0.05). With an additional homology search, it was verified that 
the peptides were not related to the antigens used in the affinity purification or to other 
serum contaminants.
dIsCussIOn
In the work described in this paper, we compared human immunoglobulin samples with 
a well-described affinity against onconeural antigens. Because of the huge potential 
diversity of
immunoglobulins, one might predict that the recombination and affinity maturation 
of immunoglobulins during the immune response should result in sequences of the 
antigen binding regions that are essentially random. In that case, our proteomic analysis 
of these samples would have revealed a collection of peptides from the constant regions 
that is shared among all patients, and a collection of peptides from the variable regions 
that are unique to each patient. Rather, we could identify 30 peptides that were shared 
between up to 16 individuals from our cohort, but that were also specific to only one of 
the four onconeural antigens that we investigated. This finding corroborates our earlier 
findings on our hypothesis that selection pressures in immunoglobulin development 
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leads to convergent paths in a subset of them, and results in shared sequences between 
individuals that reacted against a particular antigen.
The number of shared features found for each antigen varied considerably, between 
0 for amphiphysin and 13 for Yo. All affinity purifications yielded IgG material, and 
separate control experiments showed minimal non-specific yields when patient sera 
and antigen were not matched to each other. Thus, while the Amp samples must have 
contained Amp-specific IgG, our analysis failed to show marker peptides in them. It is 
possible that some antigens result in a very heterogeneous repertoire that contains few 
markers that are commonly shared. However, it is also very likely that the composition 
of the sample cohort played an important role in the number of markers found, as the 
most markers were found for the two groups of which the most patient samples were 
available (19 samples for both HuD and Yo). We chose to only partially compensate 
for the sample number of Amp and CV2 (10 samples each) in the thresholds for our 
marker detection, which reduces the number of markers that one can expect to find. 
Still, even when we consider the number of markers found in relation to thresholds and 
cohort size, the Amp patient group underperforms in terms of the number of potential 
markers found (Supplemental Figure 3).
After selection of specific features, the identification of the corresponding amino-acid 
sequences is of importance for the characterization and interpretation of peptide 
location in the immunoglobulin structure, as well as for the development of assays that 
are more suited for routine use such as multiple reaction monitoring (MRM) with stable 
isotope standards.22 Conventional database-driven identification as done by Mascot is 
of limited use as it is not feasible to capture the variability of IgG sequences within a 
population in a database. De novo sequencing is a powerful alternative, but prone to 
produce some mistakes. While it may not be appropriate to directly compare our Mascot-
derived confidence scores with normal Mascot results (where significant ion scores 
usually exceed 25), it appears clear that less than half of the markers could be robustly 
associated with a sequence. The markers with the most reliable sequences were also 
most frequently homologous to immunoglobulin variable regions. Interestingly, most 
of the HuD specific peptides showed homology to the IGHV6 allele. Based on chance, 
one would expect to see more variety and more of the highly common alleles of IGHV1, 
IGHV3 or IGHV4.23 This might suggest that immunoglobulins targeting the HuD antigen 
have a repertoire bias towards the IGHV6 allele. 
The markers that could not be aligned to immunoglobulin alleles partially had low 
confidence sequences associated with them. In addition, peptides from the highly 
variable CDR3 region are not expected to have high homology to the immunoglobulin 
germline alleles, and would fail to align to them for that reason. While we do not have 
direct evidence that these peptides relate to the CDR3 region, their presence would not 
be unexpected in our marker set.
In certain cases, the quality of de novo sequences can be improved by combining 
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the information of fragmentation spectra obtained from the different samples, and 
by comparison of sequences to the germline sequences they descended from. In 
continuing work, we intend to confirm the complete and correct sequence of some 
of the peptides in the samples by comparison with synthetic peptides, establish MRM 
assays for them, and apply these for validation work. 
 In our pilot studies that were published earlier10, feasibility was tested in vitro and 
in animal models. Paraneoplastic disease was chosen as a representative model for 
an autoimmune disease in humans that might be suitable for proteomic study of 
immunoglobulins. The clinical symptoms of PNS are well described and autoantibodies 
reactive with specific onconeural antigens have been identified for a series of syndromes. 
The antigens themselves are available as fusion proteins and currently used in reliable 
assays for PNS diagnostics.24 The availability of these onconeural antigens makes it 
possible to enrich for antibodies that are specific for PNS. However, our feasibility tests in 
rat sera were performed on samples that were subjected to repeated immunizations and 
boosts. The PNS patients have been exposed to a more diverse immune challenge from 
their tumor, which includes the response against the onconeural antigen. This exposure 
is of a more chronic nature, which may affect the extent of the antibody response. 
Their levels might be lower than in the case of an immunization, and antibodies have 
had a longer period to accumulate somatic mutations. These factors potentially result 
in markers that are more complex but less abundant, and thus a more challenging 
target for discovery. It is therefore of great interest to find that immunoglobulin-derived 
antigen-specific peptides could be identified in samples from human patients, rather 
than from an immunization model in a laboratory animal strain. These data suggest 
that the immune response in PNS is focused on a restricted set of epitopes, which is 
also corroborated by epitope scanning data in other work.9,25 It also suggests that the 
convergence of immunoglobulin sequences in response to an antigen is maintained in 
a human population that is genetically more diverse than a laboratory animal strain, 
and thus that this approach has potential for practical applications. Although diagnostic 
methods for the detection of onconeural antibodies in PNS are well-established, a new 
approach of finding common CDR motifs in autoimmune diseases can be valuable in 
cases where current assays are laborious or cumbersome (e.g. cell based assays or 
radioimmunoassays), or in cases where the antigen is still unknown, but the clinical 
picture well defined and assays and/or immunohistochemistry also point at a distinct 
antigen. With further technological developments, it may be possible to expand the 
sequence of marker peptides to cover the entire variable domain of an immunoglobulin. 
With that, it might eventually even be possible to identify novel antigens that were the 
target of an immune response in a particular patient population.
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suPPleMenTARy dATA
Supplementary Figure S1.  Errors in abundance quantification for label-free analyses. A. MS 
signal for a sample from a HuD-Ab PNS patient, containing a peptide from the HuD antigen 
AINTLNGLR. The software integrates signals in the green region of interest for abundance 
metrics. B. The same region of interest as in panel A is also used for this sample from a Yo-Ab 
PNS patient. The sample does not contain the peptide AINTNGLR, but signals in the region of 
interest still result in a reported abundance for the peptide.
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Supplementary Figure S2.  Sources of error in assigning MS2 spectra to a feature. All panels 
show MS data for the Yo-Ab specific feature identified as CFWNMELGVVEMSSR (Green 
region of interest). Red circles indicate the time and mass where an MS2 spectrum was 
triggered, and subsequently assigned to this feature. A. Yo-Ab PNS patient sample. Peptide 
CFWNMELGVVEMSSR is present, and MS2 spectrum conformed to the majority shown in 
Figure  2. B. Yo-Ab PNS patient sample. Peptide CFWNMELGVVEMSSR is present, but MS2 
spectrum did not conform to the majority shown in Figure 2, and was triggered by a distinct 
peptide. C. HuD-Ab PNS patient sample. Peptide CFWNMELGVVEMSSR is not present, and 
MS2 spectrum did not conform to the majority shown in Figure 2, and was triggered by a 
distinct peptide.
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Supplementary Figure S3. Number of group-specific features detected as function of the 
selection parameter. The number of features found was divided by the group size to correct 
for differences in sample numbers.
Supplementary Figure S4.  HuD-Ab affinity purification using HuD coated beads. The figure 
shows Western Blot detection on nitrocellulose using AP-labeled anti-human IgG. The upper 
panel shows the affinity purification of an HuD-Ab serum over HuD antigen coated beads. 
The first lane shows the total amount of IgG loaded on the beads. Most IgG does not bind to 
the beads and is present in the pass through (lane u). After washing, the HuD specific IgG is 
eluted (eluate) and clearly represents a small fraction of the total IgG. The lower panel shows 
the same procedure performed with a Yo-Ab serum over HuD antigen coated beads. In the 
eluate no IgG is detectable, reflecting absence of HuD specific IgG in Yo-Ab serum.
55
M
ass spectro
M
etric d
etectio
n
 o
f an
tig
en
-specific iM
M
u
n
o
g
lo
bu
lin
 peptid
es in
 pn
s
3
RefeRenCes
1. de Beukelaar J, Sillevis Smitt P. Managing
paraneoplastic neurological disorders.
Oncologist 2006;11:292-305.
2. Dalmau J, Rosenfeld M. Paraneoplastic
syndromes of the CNS. Lancet Neurol
2008;7:327-40.
3. Schroeder HW, Jr., Cavacini L. Structure and
function of immunoglobulins. The Journal of
allergy and clinical immunology 2010;125:S41-
52.
4. Xu JL, Davis MM. Diversity in the CDR3 region of 
V(H) is sufficient for most antibody specificities. 
Immunity 2000;13:37-45.
5. Weinstein JA, Jiang N, White RA, 3rd, Fisher
DS, Quake SR. High-throughput sequencing 
of the zebrafish antibody repertoire. Science 
2009;324:807-10.
6. Foreman AL, Lemercier B, Lim A, et al. VH gene
usage and CDR3 analysis of B cell receptor
in the peripheral blood of patients with PBC.
Autoimmunity 2008;41:80-6.
7. Foreman AL, Van de Water J, Gougeon ML,
Gershwin ME. B cells in autoimmune diseases:
insights from analyses of immunoglobulin
variable (Ig V) gene usage. Autoimmun Rev
2007;6:387-401.
8. Scheid JF, Mouquet H, Ueberheide B, et al.
Sequence and structural convergence of broad
and potent HIV antibodies that mimic CD4
binding. Science 2011;333:1633-7.
9. Manley GT, Smitt PS, Dalmau J, Posner JB. Hu
antigens: reactivity with Hu antibodies, tumor
expression, and major immunogenic sites. Ann
Neurol 1995;38:102-10.
10. VanDuijn MM, Dekker LJ, Zeneyedpour L, Smitt PA, 
Luider TM. Immune responses are characterized 
by specific shared immunoglobulin peptides 
that can be detected by proteomic techniques.
J Biol Chem 2010;285:29247-53.
11. Dekker LJ, Zeneyedpour L, Brouwer E, van Duijn 
MM, Sillevis Smitt PA, Luider TM. An antibody-
based biomarker discovery method by mass
spectrometry sequencing of complementarity
determining regions. Anal Bioanal Chem 2010.
12. Obermeier B, Mentele R, Malotka J, et al.
Matching of oligoclonal immunoglobulin
transcriptomes and proteomes of cerebrospinal 
fluid in multiple sclerosis. Nat Med 2008;14:688-
93.
13. Moll JW, Antoine JC, Brashear HR, et al.
Guidelines on the detection of paraneoplastic
anti-neuronal-specific antibodies: report from 
the Workshop to the Fourth Meeting of the
International Society of Neuro-Immunology
on paraneoplastic neurological disease,
held October 22-23, 1994, in Rotterdam, The
Netherlands. Neurology 1995;45:1937-41.
14. Graus F, Delattre JY, Antoine JC, et al.
Recommended diagnostic criteria for
paraneoplastic neurological syndromes. J
Neurol Neurosurg Psychiatry 2004;75:1135-40.
15. Fathallah-Shaykh H, Wolf S, Wong E, Posner
JB, Furneaux HM. Cloning of a leucine-zipper
protein recognized by the sera of patients
with antibody-associated paraneoplastic
cerebellar degeneration. Proc Natl Acad Sci U S
A 1991;88:3451-4.
16. DeCamilli P, Thomas A, Cofiell R, et al. The 
synaptic vesicle-associated protein amphiphysin 
is the 128-kD autoantigen of stiff-man syndrome 
with breast cancer. J Exp Med 1993;178:2219-23.
17. Yu Z, Kryzer T, Griesmann G, Kim K, Benarroch
E, Lennon V. CRMP-5 neuronal autoantibody:
marker of lung cancer and thymoma-related
autoimmunity. Ann Neurol 2001;49:146-54.
18. Ahamed T, Chilamkurthi S, Nfor BK, et al.
56
Selection of pH-related parameters in ion-
exchange chromatography using pH-gradient 
operations. J Chromatogr A 2008;1194:22-9.
19. de Costa D, Broodman I, Vanduijn MM, et al.
Sequencing and quantifying IgG fragments and
antigen-binding regions by mass spectrometry. J 
Proteome Res 2010;9:2937-45.
20. Ehrenmann F, Kaas Q, Lefranc MP. 
IMGT/3Dstructure-DB and IMGT/
DomainGapAlign: a database and a tool for
immunoglobulins or antibodies, T cell receptors, 
MHC, IgSF and MhcSF. Nucleic Acids Res
2010;38:D301-7.
21. Camacho C, Coulouris G, Avagyan V, et al.
BLAST+: architecture and applications. BMC 
Bioinformatics 2009;10:421.
22. Gallien S, Duriez E, Domon B. Selected reaction
monitoring applied to proteomics. J Mass
Spectrom 2011;46:298-312.
23. IMGT®; the international ImMunoGeneTics
information system ®. 2011. 
24. Monstad SE, Knudsen A, Salvesen HB, Aarseth
JH, Vedeler CA. Onconeural antibodies in sera
from patients with various types of tumours.
Cancer immunology, immunotherapy : CII
2009;58:1795-800.
25. Graus YF, Verschuuren JJ, Degenhardt A, et
al. Selection of recombinant anti-HuD Fab
fragments from a phage display antibody library 
of a lung cancer patient with paraneoplastic
encephalomyelitis. J Neuroimmunol
1998;82:200-9.
57
M
ass spectro
M
etric d
etectio
n
 o
f an
tig
en
-specific iM
M
u
n
o
g
lo
bu
lin
 peptid
es in
 pn
s
3

Multiplex serology of paraneoplastic 
antineuronal antibodies
Peter Maat, Eric Brouwer, Esther Hulsenboom, 
Martijn VanDuijn, Marco W.J. Schreurs,
Herbert Hooijkaas, Peter A.E. Sillevis Smitt
Journal of Immunological Methods, May 2013; 398(1-2):125-132
4
Back to table of contents
60
AbsTRACT
Paraneoplastic neurological syndromes (PNS) are devastating neurological disorders 
secondary to cancer, associated with onconeural autoantibodies. Such antibodies 
are directed against neuronal antigens aberrantly expressed by the tumor. The 
detection of onconeural antibodies in a patient is extremely important in diagnosing 
a neurological syndrome as paraneoplastic (70% is not yet known to have cancer) 
and in directing the search for the underlying neoplasm. At present six onconeural 
antibodies are considered ‘well characterized’ and recognize the antigens HuD, CDR62 
(Yo), amphiphysin, CRMP-5 (CV2), NOVA-1 (Ri), and Ma2. The gold standard of detection 
is the characteristic immunohistochemical staining pattern on brain tissue sections 
combined with confirmation by immunoblotting using recombinant purified proteins. 
Since all six onconeural antibodies are usually analyzed simultaneously and objective 
cut-off values for these analyses are warranted, we developed a multiplex assay based 
on Luminex technology. Reaction of serial dilutions of six onconeural standard sera 
with microsphere-bound antigens showed lower limits of detection than with Western 
blotting. Using the six standard sera at a dilution of 1:200, the average within-run 
coefficient of variation (CV) was 4% (range 1.9–7.3%). The average between-run within-
day CV was 5.1% (range 2.9–6.7%) while the average between-day CV was 8.1% (range 
2.8–11.6%). The shelf-life of the antigen coupled microspheres was at least two months. 
The sensitivity of the multiplex assay ranged from 83% (Ri) to 100% (Yo, amphiphysin, 
CV2) and the specificity from 96% (CV2) to 100% (Ri). In conclusion, Luminex-based 
multiplex serology is highly reproducible with high sensitivity and specificity for the 
detection of onconeural antibodies. Conventional immunoblotting for diagnosis of 
onconeural antibodies in the setting of a routine laboratory may be replaced by this 
novel, robust technology.
KeywORds
Paraneoplastic neurological syndromes; Onconeural autoantibodies; Multiplex 
serology; Cancer
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InTROduCTIOn
Paraneoplastic neurological syndromes (PNS) are defined as neurological syndromes 
that often associate with cancer.1 The discovery that many PNS are associated with 
antibodies that are directed against neural antigens expressed by the tumor (onconeural 
antibodies) has suggested that most PNS are immune-mediated.2-4 The detection of 
onconeural antibodies is extremely useful in indicating the presence and type of an 
underlying tumor and in diagnosing a neurological syndrome as paraneoplastic.5 In 2004, 
an international panel of neurologists suggested two levels of evidence (‘definite’ and 
‘possible’) to define a neurological syndrome as paraneoplastic, based on the presence 
or absence of cancer, and the definitions of ‘well characterized’ onconeural antibodies 
and ‘classical’ clinical syndrome.6 According to this set of criteria, in the absence of a 
detected cancer, only ‘well characterized’ onconeural antibodies can be used to classify 
the associated disorder as ‘definite’ PNS.5 The ‘well characterized’ onconeural antibodies 
are those for which there exist recognizable patterns on routine immunohistochemistry 
and for which immunoblotting on recombinant proteins must be used to confirm their 
specificity .5 Other criteria are (2) the number of cases associated with tumors; (3) the 
description of well characterized neurological syndromes associated with them; (4) 
the unambiguous identification of the antibodies among different studies; and (5) the 
frequency in patients without cancer. Based on these five criteria there are at present 
six ‘well characterized’ onconeural antibodies, directed against the antigens HuD, CDR62 
(Yo), amphiphysin, CRMP-5 (CV2), NOVA-1 (Ri), and Ma2 .5
Immunoblotting, required for confirmation of the specificity of the onconeural 
antibodies, was originally performed by Western blotting with the purified 
recombinant proteins as substrate.7 This technology has been more and more 
replaced by commercially available dot blots that combine the purified recombinant 
onconeural antigens produced either in Escherichia Coli (EUROIMMUN AG, Lübeck, 
Germany) or insect cells (Ravo Diagnostika, Freiburg, Germany) on a single strip, 
allowing the detection of all six different autoantibodies in a single assay.8-10 More 
recently, an in vitro transcription–translation and immunoprecipitation technique 
has been described that is potentially more sensitive but also more laborious.11,12 
Since different onconeural antibodies can be associated with the same clinical 
findings13 and the same antibody can occur with different clinical syndromes 14,15, all 
six well characterized onconeural antibodies are generally tested simultaneously.16 
A relatively new ‘multiplexing’ technology uses color-coded polystyrene beads 
(xMAP, Luminex, Austin, TX) as a solid support for the target protein. The beads are 
filled with 2 fluorescent dyes in various ratios to produce potentially 100 different 
bead sets that can be distinguished by their internal color. The Luminex analyzer 
resembles a flow cytometer with two lasers. Excitation with the red laser allows the 
identification of the bead set while the green laser is used to excite the reporter 
fluorescent label bound to each bead.17 This technology provides quantitative 
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results with predefined objective cut-off scores while immunohistochemistry, 
Western blotting and dot blots require visual analysis by an experienced observer. 
In this paper we develop a multiplex assay based on Luminex xMAP technology to 
provide more objective criteria to separate background from low signal and compare 
results with Western blotting for the confirmation of six onconeural antibodies using 
sera from 119 patients with ‘definite’ PNS, 40 autoimmune control samples and 100 
blood bank controls. We found that multiplex serology is highly reproducible with a 
high sensitivity and specificity for the detection of onconeural antibodies. In addition, 
the shelf life of beads with covalently linked onconeural antigens was at least 2 months.
MeThOds
Human sera
From our database we selected 119 patients with a diagnosis of ‘definite’ paraneoplastic 
neurological syndrome .5 All patients had onconeural antibodies directed against HuD 
(54), Yo (23), amphiphysin (25), CV2 (16), Ri (12) or Ma2 (11). 19 patients had multiple 
onconeural antibodies: anti-Hu and anti-CV2 in 9; anti-Hu and anti-amphiphysin in 5; 
anti-Hu and anti-Ri in 2; anti-Hu, anti-amphiphysin and anti-CV2 in 1; anti-Hu, anti-Yo 
and anti-amphiphysin in 1; and anti-amphiphysin and anti-CV2 in 1. IgG titers of the 
paraneoplastic antibodies were determined by endpoint titration on rat cerebellar 
sections using peroxidase immunohistochemistry as described before.18 From all 
patients clinical information was retrieved from the treating neurologist.
A syndrome was classified as encephalomyelitis (EM) when 2 or more of the following 
structures were affected: the limbic system, basal ganglia, brainstem, medulla, basal 
ganglia, cerebellum, optic nerves and peripheral nerves.5 Syndromes with unifocal 
affection were classified according to the affected area, including limbic encephalitis 
(LE), brainstem encephalitis (BE), cerebellar ataxia (CA), opsoclonus-myoclonus (OM), 
sensory neuronopathy (SN), peripheral neuropathy (PNP), stiff-person syndrome (SPS) 
and Lambert–Eaton myasthenic syndrome (LEMS). Characteristics of patients and 
sera are depicted in Table 1.     All sera were aliquoted and stored at − 80 °C until 
use. The study was approved by the Erasmus MC institutional review board. Negative 
control samples included 100 blood bank controls while autoimmune control samples 
were collected from 20 patients with rheumatoid arthritis, 10 patients with SLE and 10 
patients with Sjögren’s syndrome. 
Recombinant antigen production and purification 
cDNAs encoding the antigens HuD 7, CDR62 (Yo) 19, CRMP-5 (CV2) 20, NOVA-1 (Ri) 21 and 
Ma2 22 were ligated into pET-21b vector (Novagen/ Merck4Biosciences, Darmstadt, 
Germany). This vector encodes a N-terminal T7 tag while a polyhistidine (6xHis) region is 
added to the C-terminus. Amphiphysin 23 was ligated into the pTrcHisC vector (Novagen/ 
Merck4Biosciences) that has 6xHis at the N-terminus. All vectors were transfected and 
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Table 1. Characteristics of patients and sera.
Hu-Ab Yo-Ab Amphiphysin-Ab CV2-Ab Ri-Ab Ma2-Ab
General
N (M/F) 54 (27/27) 23 (1/22) 25 (16/9) 15 (9/6) 12 (3/9) 11 (7/4)
Age (mean) 66 63 66 68 62 59
Range 32–86 43–83 55–87 55–83 53–77 23–88
Antibody
Titer (median) 4800 12,800 3200 9600 3200 38,400
Range 100–204,800 400–409,600 400–819,200
1600–
1,000,000
400–
25,600
1600–
1,000,000
Neurologya
EM 12 2 3 4 2
LE 2 4 2 1
BE (+ LE) 1 1 1 5
CA 8 22 3 4 1 2
OM 5
SN 17 2 4 1
PNP 10 10 1 1
SPS 1 1
LEMS 1
Other 1
No neuro S&S 2 2
No information 1
Tumor
Any tumor 47 21 19 13 10 8
Lung 42 10 9 4 2
   SCLC 33 6 6 3
   NSCLC 4 1 1 2
   Radiological 5 3 3
Small cell cancer 2 4
Neuro-endocrine 
cancer
2 1
Renal cell cancer 1 1
Gastro-intestinal 1 1
Gynecological 14 1
   Ovarian 11
   Endometrium 2
   Cervix 1
   Tuba 1
   Breast 1 7 1 1 5
Lymphoma NHL 1
Thymoma 1 1
Thymic cancer 1
Testis 3
Bladder 1
No tumor 6 2 6 1 2 3
No information 1 1
EM, encephalomyelitis; LE, limbic encephalitis; CA, cerebellar ataxia; OM, opsoclonus-myoclonus; SN, sensory 
neuronopathy; SPS, stiff person syndrome; LEMS, Lambert–Eaton myasthenic syndrome; S&S, signs and 
symptoms; (N)SCLC, (non)small cell lung cancer; NHL, Non-Hodgkin Lymphoma.  a Most prominent clinical 
syndrome (one syndrome per patient).
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induced in E. coli strain BL21(DE3)pLysS (Novagen) as described before.7 After E. coli 
lysis, His-tag purification was performed on HisTrap columns (HisTrap FF, GE Healthcare, 
Diegem, Belgium) using a 20500 mM imidazole gradient in a buffer containing 8 M 
urea, 0.1 M sodium phosphate and 0.3 M sodium chloride (pH 8.0). Elution fractions 
containing the recombinant proteins were analyzed for purity by SDS-PAGE and Colloidal 
Coomassie Blue staining (Novex®, Invitrogen, Carlsbad, CA). Subsequently, Western blot 
detection with an anti-T7 monoclonal antibody (Merck Millipore, Darmstadt, Germany) 
was performed. Elution fractions with the highest concentration of recombinant 
protein were subjected to further purification by ion exchange chromatography on 
HiTrapQ HP columns (GE Healthcare) using a buffered pH gradient of 12 to 2.5 in a 
buffer containing 8 M urea, 0.01 M sodium phosphate, 0.01 M citric acid, 0.01 M glycine, 
0.01 M tricine and 0.01 M aminocaproic acid. Fractions containing the highest purity of 
recombinant proteins were pooled, the buffer was exchanged to 8 M urea and 0.1 M 
sodium phosphate (pH 8.0) using a desalting column (Hitrap Desalting, GE Healthcare), 
and the sample was concentrated to 1 mg onconeural antigen/ml by ultrafiltration 
(Ultra-4 30 kDa NWCO, Millipore, Amsterdam, The Netherlands), analyzed by SDS-PAGE 
as mentioned above. Aliquots were stored at −80 °C.
Western blotting of recombinant onconeural antigens
Recombinant purified onconeural antigens (0.2–1.66 μg) were loaded on separate 12% SDS-
PAGE curtain gels and subsequently blotted to nitrocellulose membranes (GE Healthcare), 
as previously described.7 Pre-stained SDS-PAGE Broad Range Standards (Bio-Rad, Hercules, 
CA) were added on both sides of the gels. Blots were cut into 4 mm strips and kept at −20 °C 
until use. Strips were incubated in serum diluted in TBS 1:200. Between steps strips were 
washed with TBS-T (0.05% Tween-20, Sigma Aldrich, Zwijndrecht, The Netherlands) and 
TBS. Strips were then incubated with alkaline phosphatase labeled secondary antibodies 
(Vector AP-3000, Burlingame, CA) and stained with AP Color Kit (Bio-Rad). 
Antigen coupling
For all assays, xMap microspheres (Luminex, Austin, TX) were used. Covalent coupling of 
purified recombinant onconeural proteins to the microspheres was performed according 
to the manufacturer’s instructions. All centrifugation steps were performed for 2 min 
at 12.000 x g and the microspheres were resuspended by vortexing and sonification 
for 20– 30 s. To create binding curves, 12.5 x 106 microspheres were pelleted and the 
supernatant was removed. The microspheres were washed once with 250 μl of water 
and resuspended in 160 μl of 100 mM monobasic sodium phosphate pH 6.2. 20 μl of 50 
mg/ml Sulfo-NHS (N-hydroxysulfosuccinimide) (Thermo Fisher Scientific, Rockford, IL). 
Immediately, 20 μl of 50 mg/ml EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
HCl) (Thermo Fisher Scientific) was added. The microspheres were then incubated for 
20 min at room temperature with gentle mixing. After pelleting, the microspheres were 
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washed twice with 500 μl of 50 mM MES (2-(N-morpholino)ethanesulfonic acid sodium 
salt) (Sigma Aldrich) pH 5.0 and resuspended in 500 μl of MES. Initially, a serial dilution 
of the antigens was made and antigens were added from 0.7 to 333 pmol per 1 x 106 
microspheres and the total volume was set to 1000 μl with MES. After vortexing, the 
suspension was incubated for 2 h with mixing at room temperature. The microspheres 
were pelleted and 1000 μl of PBS/TBN (PBS (Lonza, Basel, Switzerland) pH 7.4 with 0.02% 
Tween-20 (Sigma Aldrich), 0.1% BSA (Life Technologies, Paisley, UK) and 0.05% sodium 
azide (Sigma Aldrich)) was added. The microspheres were vortexed and incubated for 30 
min with mixing at room temperature. Finally, the coupled microspheres were washed 
twice with PBS/BN (PBS pH 7.4 with 1% BSA and 0.05% sodium azide) and taken up 
in 500 μl of PBS/BN. Microsphere suspensions were counted using a hemacytometer, 
set to a concentration of 2 x 106 microspheres/ml and stored in the dark at 4 °C. For 
the remainder of the experiments, 25 x 106 microspheres were prepared as described 
above and resuspended in 500 μl of MES. Antigens were added in an amount of 100 
pmol per 1 x 106 microspheres, the total volume was set to 1500 μl with MES and 
coupling, counting and storage were performed as described above. In addition to 
these covalently coupled microspheres, also one set of microspheres was prepared as 
negative control by leaving out the capture antigen.
Multiplex assay
Sera were diluted in PBS/BN. Bead sets carrying different antigens were mixed, and 
50 μl of mixed beads (5000 per set) were combined with 50 μl of diluted serum in 96-
well plates with filter bottoms (MABVN1250 plates, Merck Millipore) prewetted with 
PBS/BN. Alternatively, instead of diluted serum, anti-His was added in 50 μl of PBS/
BN (final dilution 1:500). The mixture was incubated for 30 min at room temperature 
in the dark on a plate shaker at 800 rpm, then washed twice with 200 μl of PBS/BN 
followed by resuspension of the microspheres in 50 μl of PBS/BN. The plate was then 
incubated with 50 μl PE-conjugated anti-human IgG (Jackson Immunoresearch, Suffolk, 
UK) or 50 μl PE-conjugated anti-mouse IgG (Caltag Medsystems, Buckingham, UK) for 30 
min with mixing at room temperature in the dark. After one wash with 200 μl of PBS/
BN the microspheres were resuspended in 100 μl of PBS/BN. Reporter fluorescence of 
the beads was determined with the Luminex 100 (Luminex) analyzer and expressed as 
median fluorescent intensity (MFI) of at least 100 microspheres per set per well, with a 
maximum analysis time of 1 min. To calculate the antigen-specific MFI, the MFI of the 
control bead set was subtracted from the antigen MFI. A negative result was set at zero. 
For each onconeural antibody, one positive serum was selected as a standard that was 
added to each 96 well plate to determine assay reproducibility and precision. These 
standard sera were aliquoted and stored at −80 °C.
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Monoplex assay
5000 microspheres in 50 μl of PBS/BN were combined with 50 μl of diluted serum in 96-
well plates with filter-bottom prewetted with PBS/BN. Alternatively, instead of diluted 
serum, anti-His was added in 50 μl of PBS/BN (final dilution 1:500). The mixture was 
incubated, washed and resuspended as described above. The plate was then incubated 
with either 50 μl PE-conjugated anti-human IgG or 50 μl PE-conjugated anti-mouse IgG 
(Caltag Medsystems, Buckingham, UK) for 30 min with mixing at room temperature in 
the dark. Subsequent washes and fluorescence analysis was performed as described 
above.
Statistical analysis
The program Graphpad Prism version 5.01 (2007, Graphpad software Inc. La Jolla, CA) 
was used for statistical analysis. The average antigen-specific MFI and standard deviation 
of all 140 negative control samples were calculated for all bead sets. A sample was 
regarded positive when its antigen-specific MFI was higher than the average antigen 
specific MFI plus 3 times the standard deviation of the control samples. Differences in 
antigen-specific MFI in carry over experiments were analyzed using ANOVA. Stability of 
the antigen-coupled microspheres was assessed by linear regression through MFI data 
obtained at 7 different time points. When the 95% confidence interval of the slope of 
the fitted line included 0, we concluded that no significant decay of MFI signal over time 
had occurred.
ResulTs
Antigen binding curves
Microspheres were covalently coupled in triplicate with serial dilutions of the 6 
onconeural antigens. Bound antigen was quantified by the monoclonal anti-His (1:500) 
antibody (Figure S1) directed against the 6xHis region present in either the C-terminus 
(Hu, Yo, Ri, Ma2, CV2) or N-terminus (amphiphysin) of the onconeural proteins. At a 
concentration of 67 pmol of protein per 106 microspheres, all proteins had (almost) 
reached saturation and a concentration of 100 pmol per 106 microspheres was used 
for all further experiments. Anti-His detected no amphiphysin-specific signal indicating 
either no binding of ampiphysin to the beads or masking of the N-terminal 6xHis region 
(as opposed to the C-terminal 6xHis region in the other 5 antigens). Polyclonal human 
autoantibodies recognize larger regions and naturally folded structures of proteins and 
we therefore also performed binding studies followed by quantitation using human 
sera (1:200 dilution) reactive with the corresponding antigens. In contrast to the results 
obtained with anti-His, amphiphysin-specific MFI is detected by human anti-amphiphysin 
antibody (Amp-Ab) in a concentration dependent manner indicating efficient binding of 
amphiphysin antigen to the microspheres (Figure 1).
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figure 1. Binding curves of 6 recombinant purified onconeural proteins on Luminex xMap 
microspheres. Luminex xMap microspheres were coupled with serial dilutions (range 0.7–333 
pmol/106 microspheres) of the 6 recombinant purified onconeural antigens. Bound antigen 
was quantified using human sera containing the corresponding antibodies. All human sera 
were used at a dilution of 1:200. Data points represent mean values of 2 or 3 independent 
experiments; error bars represent SD.
Antigen carry over
To determine the carry over of proteins from one microsphere set to another, we coupled 
25 x 106 microspheres to HuD and prepared 25 x 106 mock coupled microspheres by 
omitting the capture antigen. Then 1 x 104 HuD-microspheres were mixed with 1 x 
104 mock-coupled microspheres. After one week, we performed a multiplex assay on 
the earlier mixed microspheres and on 1 x 104 freshly mixed HuD and mock coupled 
microspheres. In addition a monoplex assay was performed with 5 x 103 HuD and 
mock coupled microspheres. No significant change in HuD-specific MFI was observed 
between the microsphere sets that had been stored mixed for one week, were freshly 
mixed or analyzed in a monoplex assay. These results indicate that no significant carry 
over of HuD protein to the mock-coupled microspheres had occurred (Figure S2).
Dynamic range and detection limit of multiplex serology
To determine the dynamic range and detection limit of the multiplex assay, we incubated 
the antigen loaded beads with serial dilutions (1:10 to 1:106) of the 6 standard sera 
(Figure 2). Differentiation of negative and positive sera was allowed over a wide range. 
The signal of a positive serum was higher than the mean plus 3 SD of the 5 negative 
sera, at ultimate dilutions ranging from 1 x 105 (CV2) to >106 (5 other antigens; Table 2). 
We then compared the detection limit of the multiplex serology with Western blotting, 
using the same serial dilutions (Figure S3). For all 6 standard sera the lower limits of 
detection were reached at higher dilutions with multiplex serology than with Western 
blotting (Table 2). At a serum dilution of 1:200 all assays were in the dynamic range with 
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good signal to noise ratios varying from 37 (CV2) to 191 (Yo). Therefore we decided to 
use a standard 1:200 dilution of patient sera for further assessment of the sensitivity 
and specificity of multiplex serology (Figure 2). 
Table  2. Signal to noise ratio and detection limit of multiplex serology compared to 
Western blotting.
Standard serum Signal to noise ratioa Endpoint titerb Endpoint titerc
Serum dilution 1:200 Multiplex assay Western blot
Anti-HuD 75 > 106 5 × 103
Anti-Yo 191 > 106 2 × 104
Anti-Ri 68 > 106 2 × 104
Anti-amphiphysin 38 > 106 2 × 103
Anti-Ma2 47 > 106 104
Anti-CV2 37 105 2 × 103
a Signal to noise ratio is determined at a serum dilution of 1:200 as the ratio between the antigen MFI and the MFI 
on non-coupled microspheres.  b Endpoint titer is defined as the highest titer with an antigen specific MFI of the 
positive standard serum  that is higher than the mean MFI plus 3SD of the 5 negative sera at the same dilution. 
c Endpoint titer is defined as a clearly visible band at the appropriate molecular weight.
Reproducibility of multiplex serology 
To examine the reproducibility of the multiplex assay, we determined the within-
run, between-run within-day and between-day coefficients of variation (CVs) (Table 
3). To determine the within-run variation, the six standard sera were analyzed 
three times as technical replicates in one run. The average within-run CV was 
4.0% (range 1.9–7.3%). The between-run within-day variation was analyzed by 
performing three separate runs on one day resulting in an average CV of 5.1% 
(range 2.9–6.7%). The six human serum samples were finally analyzed on five 
different days resulting in an average between-day CV of 8.1% (range 2.8–11.6%). 
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figure 2. Multiplex assay of serial dilutions of six standard sera containing paraneoplastic 
antibodies. Antigen-coupled microspheres were incubated with serial dilutions (1:10 to 
1:106) of the six standard sera and antigen-specific MFI was plotted
Table  3. Reproducibility of multiplex serology. For each antigen, the within-run, 
between-run within-day, and between-day coefficients of variation (CVs) are presented.
Antigen
Within-run
CV (%)
Between-run
within-day CV (%)
Between-day
CV (%)
HuD 6.5 5.0 6.6
Yo 2.6 8.8 2.8
Ri 1.5 4.4 8.7
Amphiphysin 4.6 1.0 9.0
Ma2 4.6 4.8 11.7
CV2 5.4 5.2 9.7
70
Table  4. Sensitivity and specificity of Luminex multiplex serology for onconeural 
antibodies.
Antibody Sensitivity Specificity
HuD-Ab 93% 97%
Yo-Ab 100% 97%
Amphiphysin-Ab 100% 97%
CV2-Ab 100% 96%
Ri-Ab 83% 100%
Ma2-Ab 91% 99%
Stability of the coupled microspheres 
To test the stability of antigen coupled microspheres over time, we coupled all six 
antigens to 12.5 x 106 microspheres each. The antigen-coupled microspheres were 
stored separately at 4 °C. Multiplex serology was performed on days 1, 21, 24, 25, 28, 
63 and 255 after coupling (Figure S4). Although a decreasing trend was observed, the 
antigen-specific MFI did not change significantly over time for any of the six standard 
sera. Figure S4 shows that the antigen-coupled microspheres continued to perform 
adequately after storage in excess of two months. 
Thirty-two false positive onconeural antibody results were recorded in 29 samples 
in the multiplex assay (Table S1). Of these 32 false positive results, 16 were also 
positive on Western blot but did not show the characteristic staining pattern on 
immunohistochemistry. Twenty false positives were detected in 19 samples from PNS 
patients with well-characterized onconeural antibodies (Table S3). In one sample, from 
a patient with anti-HuD associated PNS, additional antibodies against Yo and CV2 were 
falsely detected. False positive reactions against the onconeural antigens occurred at 
different frequencies: anti-HuD in 2; anti-Yo in 3, anti-amphiphysin in 4, anti-Ma2 in 
2; and anti-CV2 in 9. Interestingly, of the 9 PNS patients with falsely positive anti-CV2 
results, 6 had small cell tumors known to be associated with anti-CV2. The other 3 had 
no identified tumor but harbored anti-HuD (2x) or anti-HuD and anti-amphiphysin (1x) 
antibodies, strongly suggesting an underlying malignancy.
Two of 40 autoimmune control and 8 of 100 blood bank control samples tested falsely 
positive for an onconeural antibody in the multiplex assay (Table S3). While CV2 gave 
9/20 false positive results in the 119 PNS sera, only 1/12 of the false positive results in 
the 140 blood bank and autoimmune controls were anti-CV2.
dIsCussIOn
The serologic method presented here combines a well-validated expression and 
purification system for recombinant proteins with a high-throughput multiplex 
suspension array. All six purified onconeural antigens were efficiently bound to Luminex 
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xMap beads as a dose dependent signal was obtained in the binding curve, when 
probed with the standard patient sera. However, when we used the anti-His antibody, 
directed against the 6xHis metal binding motif used for purification of all six proteins, 
amphiphysin was not recognized. The lack of reactivity of amphiphysin coupled beads 
with anti-His may be explained by masking of the epitopes due to refolding of protein 
during binding, storage and/or analysis. Interestingly, the amphiphysin construct had 
the 6xHis motif cloned in the N-terminus while it was in the C-terminus of the other 5 
constructs. We used anti-His to quantitate the amount of bound protein. However, when 
comparing the binding curves of the onconeural proteins (excluding amphiphysin), the 
maximum MFIs varied approximately twofold (3400 MFI for Yo-beads versus 1582 MFI 
for CV2-beads). These variations are not explained by the differences in the molecular 
weights of the proteins (Table S4) and may be caused by differences in coupling 
efficiency or by partial masking of the antigen due to folding of the protein.
The covalent binding of the antigens to the beads resulted in no detectable carry over of 
protein and stability of the beads over many months, as previously reported.24 
We compared the detection limit of Luminex serology and Western blotting side by side 
for the six standard onconeural antibody containing sera by endpoint titration. For all 
standard sera, multiplex serology has a lower limit of detection than Western blotting 
indicating potential clinical application. For testing of serum samples in a routine 
setting we decided to dilute samples 1:200. This dilution was for all six onconeural 
antigens within the dynamic range of the assay with a good signal to noise ratio. In 
addition, this dilution has previously been used for Western blotting 7and is close to the 
recommended 1:100 dilution for a commercial dot blot system which uses the same 
onconeural antigens produced in a similar E. coli system (EUROIMMUN AG, Lübeck, 
Germany).
After demonstrating good reproducibility of the multiplex assay (Table 3) we determined 
the sensitivity and specificity of the assay using the standard 1:200 dilution. Our sample 
set contained 119 samples from patients with ‘definite’ PNS and ‘well characterized’ 
onconeural antibodies. This means that the serum samples from PNS patients had a 
characteristic immunohistochemical staining pattern and were confirmed with Western 
blotting using recombinant antigens. For all six antigens, the sensitivity ranged between 
83% and 100% and the specificity from 96% to 100%. Looking at these numbers 
differently (Tables S1 and S2), we can see that 7 out of 119 PNS sera did not give a positive 
signal in the multiplex assay and can be designated false negatives. By definition, these 
sera contained antibodies that were recognized both by immunohistochemistry and 
were confirmed by Western blotting. One could argue in case of the false negative anti-
HuD results that 3 out of 4 false negatives were low-titer sera (1:400) in the IHC assay 
and therefore could easily have been missed in the multiplex assay, implying that both 
assays have a similar sensitivity. However, the fourth false negative anti-HuD and the 
other 3 false negative sera were definitely not low-titer with titers ranging from 800 to 
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6400. In addition, the Luminex assay appeared to have a lower level of detection than 
Western blotting, at least for our 6 standard sera. An alternative explanation may be 
that the proteins after covalent linking to a microsphere and in an aqueous environment 
may expose antigens that are different from the antigens that are accessible both on 
denatured Western blots and by immunohistochemistry, e.g. by aberrant folding of the 
protein.
On the other hand, 32 false positive results were observed, 20 of which in the PNS 
group with well-characterized onconeural antibodies and 12 in the autoimmune and 
blood bank controls. Almost half of the false positive results in the PNS group (9/20) was 
directed against the CV2 antigen whereas only 1/12 false positives in the control group 
aberrantly recognized CV2. All of the 9 PNS patients with false positive CV2 reactivity 
in the multiplex assay had an underlying small cell tumor or were likely to have an 
underlying (lung) malignancy. In addition, 3 out of 9 samples also reacted with the CV2 
antigen on Western blot (without showing the characteristic immunohistochemical 
staining pattern). Therefore it is likely that at least some of these ‘false positive’ anti-CV2 
sera are indeed true positives, but that they have an anti-CV2 titer that is insufficient 
for detection by the immunohistochemistry that is used as a reference method. To 
understand the clinical meaning of a positive anti-CV2 result in the multiplex assay (or 
on Western blot or dot blot), in the absence of a characteristic immunohistochemical 
staining pattern, it requires further research by studying larger cohorts of patients with 
specific tumors (e.g. patients with small cell lung cancer or thymoma) and controls.
Compared to immunoblotting, multiplex serology provides objective cut-off levels 
and does not require a trained person to separate background from low signal. Other 
advantages include high throughput (96-well format) and versatility (e.g. addition of 
newly identified onconeural antigens). We conclude that multiplex serology is highly 
reproducible with a high sensitivity and specificity for the detection of onconeural 
antibodies and that the shelf-life of beads with covalently linked onconeural antigens is 
at least 2 months. Immunoblotting may be replaced by this novel robust technology for 
the detection of onconeural antibodies in the setting of a routine laboratory. 
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suPPleMenTARy dATA
figure s1. Binding curves of 6 recombinant purified onconeural proteins on Luminex xMap 
microspheres. Luminex xMap microspheres were coupled with serial dilutions (range 
0.7333 pmol/106 microspheres) of the 6 recombinant purified onconeural antigens. Bound 
antigen was quantified using anti-His (1:500) monoclonal antibody. In the amphiphysin 
construct, the 6 × His region is encoded in the N-terminus while it is encoded in the C-terminus 
of the other five constructs. This N-terminal position of 6 × His in amphiphysin may explain 
the lack of amphiphysin-specific signal with anti-His.
figure s2.  Antigen carry over. HuD and mock coupled microspheres were prepared and 
stored mixed and separately. After one week multiplex serology was performed on 
microspheres that had been stored mixed for one week or were freshly mixed just prior to 
multiplex serology. In addition, a monoplex assay was performed on non-mixed HuD coupled 
microsphere. Serology was performed using an HuD-Ab containing standard serum. One 
week of mixed storage of HuD-coupled and mock-coupled microspheres did not result in 
significant decrease of HuD-specific MFI of the HuD-coupled microspheres (ANOVA, p = 0.94) 
nor was an increase in HuD-specific MFI noted in the mock-coupled microspheres (ANOVA, 
p = 0.28)
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figure s3.  Endpoint titration of six standard sera on Western blot. Western blot strips of 
the HuD (A), Yo (B), Ri (C), amphiphysin (D), Ma2 (E) and CV2 (F) onconeural antigens were 
incubated with serial dilutions of the corresponding standard serum. Endpoint titers were 
defined as the highest dilution with a clearly visible band at the appropriate molecular 
weight. Lanes 1–12 correspond to serial dilutions 1:100 (1); 200 (2); 500 (3); 1000 (4); 2000 (5); 
5000 (6); 10,000 (7); 20,000 (8); 50,000 (9); 100,000 (10); 200,000 (11); and 500,000 (12).
Figure S4. Stability of coupled microspheres over time. Microspheres were coupled with 6 
onconeural antigens and stored. At days 1, 21, 24, 25, 28, 63 and 255 multiplex serology 
was performed in duplicate using 6 standard sera. Lines were fitted through the mean MFI’s 
at all timepoints using linear regression. A negative trend was observed, although the 95% 
confidence intervals of the slopes of all 6 fitted included 0, indicating no significant decay of 
the MFI signal over time.
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Table s1. Sensitivity and specificity of Luminex-based multiplex serology for onconeural 
Ab determination, compared to gold standard. False negative multiplex results are 
colored yellow and false positive results orange.
HU PNS+ PNS- SENS SPEC
LMNX+ 50 6 93% 97%
LMNX- 4 199
YO PNS+ PNS-
LMNX+ 23 6 100% 97%
LMNX- 0 230
RI PNS+ PNS-
LMNX+ 10 0 83% 100%
LMNX- 2 247
AMP PNS+ PNS-
LMNX+ 25 7 100% 97%
LMNX- 0 227
MA2 PNS+ PNS-
LMNX+ 10 3 91% 99%
LMNX- 1 245
CV2 PNS+ PNS-
LMNX+ 15 10 100% 96%
LMNX- 0 234
Table s2. False negative Luminex-based serology results
PNS
Total number of samples 119
HuD 4
Yo -
Amphiphysin -
CV2 -
Ri 2
Ma2 1
Number of false negative samples (%) 7 (6%)
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Table s3. False positive Luminex-based serology results
PNS Autoimmune Bloodbank controls
Total number of samples 119 40 100
HuD 2 1 3
Yo 3 1 2
Amphiphysin 4 3
CV2 9 1
Ri
Ma2 2 1
Number of false positive samples (%) 19 (16%)* 2 (5%) 8 (8%)**
* One anti-HuD sample contained two false positive reactivities (against Yo and CV2)
** Two bloodbank control samples contained two false positive reactivies (one sample CV2
and HuD; the other Ma2 and Yo)
 Table s4. Calculated molecular weight of the six onconeural recombinant proteins
Onconeural antigen Molecular weight (kD)
HuD 43
Yo 50
Ri 56
Amp 75
CV2 62
Ma2 40
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AbsTRACT
Objective
Anti-Tr is among the better described autoantibodies in paraneoplastic cerebellar 
degeneration (PCD) combined with Hodgkin lymphoma (HL); however, the Tr antigen 
remains unidentified.
Methods
We used immunoprecipitation of total rat brain extract followed by mass spectrometry 
to identify the antigen recognized by anti-Tr–positive sera. By Western blotting and 
cell-based assays, we tested a total of 12 anti-Tr–positive and 246 control sera and 
determined the region of the epitope recognized by the anti-Tr antibodies. Deletion 
and mutant constructs were generated to further map the antigenic region.
Results
Mass spectrometry analysis of immunopurified rat brain extract using 4 different anti-
Tr–positive sera led to the identification of Delta/Notch-like epidermal growth factor-
related receptor (DNER) as the Tr antigen. All but 1 of 246 control samples were negative 
in the HeLa cell-based screening assay, whereas 12 of the 12 anti-Tr–positive sera 
stained hemagglutinin-tagged DNER-expressing cells. Only 1 control subject with HL 
but no ataxia was found to be both DNER and Tr positive. Using deletion constructs, we 
pinpointed the main epitope to the extracellular domain. Knockdown of endogenous 
DNER in hippocampal and N-glycosylation mutations abolished the anti-Tr staining, 
indicating that glycosylation of DNER is required for it to be recognized by anti-Tr 
antibodies.
Interpretation
DNER is the antigen detected by anti-Tr–positive sera. Presence of anti-Tr antibodies in 
patients with PCD and HL or HL only can now be screened quickly and reliably by using 
a cell-based screening assay. 
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InTROduCTIOn
Paraneoplastic cerebellar degeneration (PCD) is a heterogeneous group of disorders 
that are characterized by subacute cerebellar ataxia coinciding with the presence of 
specific tumor types and antineuronal antibodies.1-3 The association between 1 specific 
tumor type, Hodgkin lymphoma (HL), with PCD has long been known4 and was followed 
by the identification of antibodies against cerebellar Purkinje cells in several of these 
patients’ sera.5 Later called anti-Tr antibodies, these recognize a specific staining in 
the cerebellum, with punctuate immunoreactivity detected in the large dendritic tree 
as well as the soma of the Purkinje cells, but not in the axons.5-7 This characteristic 
immunoreactive pattern is considered to be a good hallmark for the presence of anti-Tr 
antibodies, but requires further confirmation by epitope blocking. For this, rat cerebellar 
slices show absent immunoreactivity with the biotinylated immunoglobulin G (IgG) from 
a positive anti-Tr serum when preincubated with undiluted serum that required the 
testing.8 To aid this diagnosis, and to understand the pathogenic nature of PCD, we 
aimed to identify the antigen recognized by anti-Tr antibodies.
subJeCTs And MeThOds
Patients
The most relevant clinical features of 11 of the 12 anti-Tr–positive patients are given 
in Table 1. Clinical information was lacking from Tr-positive Patient 5. All patients 
suffered subacute and severe truncal and limb ataxia with nystagmus and/or cerebellar 
dysarthria. Ten patients were diagnosed with HL, and in all of them the cerebellar 
symptoms preceded the detection of HL. The patients’ disability was assessed using a 
modified Rankin scale9 (Supplementary Materials and Methods).
Antibodies and Expression Constructs
For immunocytochemistry, antibodies were used in the following dilutions: mouse anti–
β-galactosidase (Promega, Leiden, the Netherlands) 1:2,000, goat anti–Delta/Notch-
like epidermal growth factor (EGF)-related receptor (DNER; R&D Systems, Abingdon, 
UK) 1:400 to 1:2,000, rabbit anti-hemagglutinin (HA; Santa Cruz Biotechnology, 
Heidelberg, Germany) 1:400, patients’ sera 1:50 to 1:20,000. Cy3-conjugated donkey 
antihuman antibody (Jackson ImmunoResearch, Newmarket, UK), Alexa 488- and Alexa 
568-conjugated secondary antibodies (Molecular Probes, Breda, the Netherlands), and
fluorescein isothiocyanate-conjugated antigoat antibody (Jackson ImmunoResearch)
were used in a 1:400 dilution. For Western blotting, horseradish peroxidase (HRP)-
conjugated donkey antihuman (Calbiochem, Darmstadt, Germany) 1:10,000 and HRP-
conjugated swine antirabbit, antimouse, or antigoat (Dako, Heverlee, Belgium) 1:2,500
antibodies were used.
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Full-length wild-type HA-tagged mouse DNER cDNA in pDisplay was kindly provided 
by M. Kengaku (Kyoto, Japan) and was previously described.10 A DNER construct 
allowing biotinylation (DNER-GFP-bio), and the deletion and glycosylation mutants 
were generated by polymerase chain reaction and cloning in pGW1.11 Full details of 
these constructs and all other materials and methods are given in the Supplementary 
Materials and Methods.
ResulTs
Identification of DNER as Tr Antigen by Mass Spectrometry
To identify the antigen recognized by Tr antibodies, we performed immunoprecipitation 
experiments followed by mass spectrometry on crude rat brain extracts using 4 
different anti-Tr–positive sera and 3 control sera containing antibodies against the Hu 
antigen, metabotropic glutamate receptor 1 (mGluR1), or glutamate receptor 1 (GluR1). 
Size fractionation of the purified complexes on sodium dodecyl sulfate–polyacrylamide 
gel electrophoresis and subsequent staining with Coomassie blue showed no apparent 
protein band shared by all 4 anti-Tr–positive sera (Figure1A). We nevertheless cut each 
lane into 15 slices, digested them with trypsin, and performed mass spectrometry. The 
mass spectrometry data of each anti-Tr serum was first analyzed and compared to the 
results obtained with the Hu, mGluR1, and GluR1 control sera, leaving DNER as the 
unique protein identified by the anti-Tr sera only, making DNER a good candidate as Tr 
antigen.
DNER Is the Tr Antigen in Cell-Based Assay
We next performed a cell-based assay to find further evidence for DNER as the Tr 
antigen. HeLa cells expressing full-length HA-tagged DNER were incubated with anti-HA 
antibodies and either of 2 anti-Tr sera, an anti-Tr cerebrospinal fluid (CSF), and a control 
serum. The 2 anti-Tr sera and CSF strongly labeled cells expressing HA-DNER, but not 
untransfected cells (stained with DAPI only; see Figure1B, top 3 panels). In contrast, 
the staining was absent in control sera known to detect Hu, mGLUR1, or GluR1 (see 
Figure1B, lower panel and data not shown). We next tested all 12 anti-Tr sera as well 
as 246 control samples (Table 2), using the same cell-based screening assay. All anti-
Tr sera positively stained HeLa cells expressing HA-DNER, whereas all but 1 control 
samples were negative (see Figure1B and data not shown). Interestingly, the 1 control 
sample that contained anti-DNER antibodies was from a patient suffering from HL 
without any signs of ataxia. Testing this serum on rat brain sections resulted in the 
characteristic punctate staining typical for Tr (data not shown). As DNER is normally 
expressed in pyramidal hippocampal neurons, we performed costaining in primary 
hippocampal neuron cultures. Under permeabilizing conditions, we detected punctuate 
somatodendritic anti-DNER staining of endogenous DNER, which fully colocalizes with 
86
figure 1. Identification of Delta/Notch-like epidermal growth factor-related receptor (DNER) 
as the Tr antigen. (A) Coomassie-stained gel of total rat brain extracts immunoprecipitated 
with anti-Tr–positive sera and used for mass spectrometry analysis. (B) HeLa cells expressing 
hemagglutinin (HA)-DNER (green) are positively stained by 2 anti-Tr sera (Tr9 and Tr6, 1:200, 
red) and cerebrospinal fluid (csf) of the same patient (Tr6, 1:100, red) but not by the control 
sera (ctrl, 1:200, red). The merged images reveal nontransfected cells by DAPI staining. Scale 
bar = 10μm. (C) Western blot analysis of total HEK293T cell extracts expressing HA-DNER 
(input) and purified HA-DNER. Untransfected (untr) HEK293T cells (mock) are used as control. 
HA-DNER was purified by immunoprecipitation using anti-HA antibodies. Asterisks denote 
background bands also present in untransfected HEK293T cells. (D) Representative images of 
hippocampal neurons (days in vitro, 11) stained with anti-DNER (green) and anti-Tr serum Tr9 
(red). Zoom indicates punctuate DNER staining in neurites that strongly colocalize with anti-
Tr serum. Scale bar = 20μm. (E) Representative image of hippocampal neuron (days in vitro, 
7 + 1) transfected with HA-DNER and surface stained with both rabbit anti-HA (green) and 
anti-Tr serum Tr9 (red). Zoom indicates strong, but not perfect surface colocalization, due to 
the presence of endogenous DNER at the surface (arrowhead). Scale bar = 20μm.
Tr-positive sera. These results further confirm that DNER is the Tr antigen.
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To determine whether the anti-Tr sera could detect the extracellular domain of DNER, 
we overexpressed HA-DNER in hippocampal neurons. Surface staining with both anti-
HA and anti-Tr sera showed similar reactivity of both antibodies in the somatodendritic 
compartment (see Figure1E). This indicates that the DNER epitope is available to the 
anti-Tr antibodies on the surface of neurons.
Table 2. Control Samples
Sample No.
Blood bank controls 31
Hodgkin lymphoma without ataxia 55
Hodgkin lymphoma with paraneoplastic cerebellar ataxia 10
Non-Hodgkin lymphoma without ataxia 14
Non-Hodgkin lymphoma with paraneoplastic cerebellar ataxia 9
Idiopathic cerebellar ataxia 17
Other autoimmune disease
SLE 10
Reumatoid arthritis 20
Paraneoplastic cerebellar degeneration with known antibodies
Anti-Yo 20
Anti-Ri 10
Anti-Hu 20
Anti-Ma 10
Anti-amphiphysin 10
Anti-CV2 10
Total 246
SLE = systemic lupus erythematosus
DNER Is the Tr Antigen by Western Blot Analysis in Most but Not All Anti-Tr Sera
Western blot analysis of cerebellar or purified Purkinje cell extracts with anti-Tr sera had 
so far not identified a common Tr antigen.6,12 Because Western blot analysis is a more 
commonly used method for detecting autoimmune antibodies,13 we tested whether 
this method could be used for anti-Tr diagnostic purposes. For this, we subjected 
total HEK293T cell extracts expressing HA-DNER and purified HA-DNER (by anti-HA 
immunoprecipitation [IP]) to Western blotting. Of the 12 anti-Tr–positive sera tested, 
only 3 could recognize total input directly (represented by Tr10 in Figure1C). The other 
9 sera were negative (represented by Tr9 in Figure1C). Loading the gel with purified HA-
DNER, as seen by both anti-HA and anti-DNER antibodies, increased the number to 11 
positive sera (see Tr9 Figure1C). However, serum Tr6, positive for DNER staining in the 
cell-based assay, remained negative. We therefore conclude that Western blotting is 
unreliable for diagnosing anti-Tr antibodies.
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DNER Blocks Anti-Tr Antibody Reactivity on Brain Sections
Presence of anti-Tr antibodies is usually diagnosed by strict immunohistochemical criteria 
of rat frozen cerebellar sections: cytoplasmic labeling of Purkinje cells, combined with 
a characteristic punctuated somatodendritic staining in the molecular layer (Figure2A 
and 2A′).7 Staining rat brain slices with the commercial antibody against DNER resulted 
in the identical somatodendritic, punctuate staining of Purkinje cells (Figure2B and 2B′). 
Both anti-Tr sera and anti-DNER antibodies stained isolated pyramidal neurons in the 
hippocampus (data not shown), as described before.6,10,13 The characteristic punctuate 
staining of anti-Tr sera is only 1 prerequisite of the diagnosis; the diagnosis is usually 
confirmed by performing antigen-blocking experiments.2,8 For this, cerebellar sections 
are first preincubated with undiluted anti-Tr sera that require testing and subsequently 
incubated with diluted biotinylated standard anti-Tr serum. In all 7 cases analyzed this 
way the tested anti-Tr sera abolished the characteristic staining pattern of the standard 
anti-Tr serum (Figure2C–E).
In addition, we performed cerebellar immunohistochemistry with anti-Tr–positive 
sera from which the anti-DNER antibodies were depleted. Sera incubated with DNER-
GFP-bio coupled to streptavidin beads prior to the immunohistochemistry lost their 
Tr-characteristic staining of Purkinje cells (compare Figure2G to F). In contrast, eluted 
anti-DNER antibodies showed staining of the Purkinje cells similar to the full serum 
(compare Figure2H to F).
Knockdown of DNER Removes Tr Staining in Hippocampal Neurons
To further demonstrate that DNER is the only protein detected by anti-Tr–positive 
sera, we performed DNER knockdown experiments. Two independent short hairpin 
RNA (shRNA)-producing constructs directed against DNER were generated and 
transfected into hippocampal neurons. As endogenous DNER is expressed in pyramidal 
hippocampal neurons, we counted all transfected neurons as judged by the presence 
of β-galactosidase and checked for reactivity with anti-DNER and anti-Tr. In control 
transfections, 73% of the β-galactosidase–expressing neurons (118 of 162) were positive 
for both DNER and Tr (Figure3A, top panel). In contrast, transfection with 2 independent 
shRNA constructs targeting DNER removed both DNER staining, as observed by the 
commercial anti-DNER antibodies, and Tr staining (Tr9; see Figure3A, lower panel) in 
all transfected neurons (133 and 134 neurons, respectively, for construct 1 and 2; see 
Figure3B), further confirming the anti-Tr specificity of DNER.
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figure 2. Immunohistochemistry of anti–Delta/Notch-like epidermal growth factor-related 
receptor (DNER) and anti-Tr sera on rat cerebella. (A, B) Sagittal section of rat brain stained 
with serum of a patient known to contain (A) the anti-Tr antibodies (B) or commercial anti-
DNER. (A′, B′) Higher magnification shows that anti-DNER antibodies lead to the identical 
dotlike somatodendritic staining as described for anti-Tr sera. (C–E) Standard blocking 
procedure currently used to test for presence of anti-Tr antibodies in sera. (C) Punctate 
staining after incubation with standard biotinylated serum. (D, E) Staining disappears when 
previously incubated with (D) unbiotinylated serum from the same patient or (E) serum 
from another patient. (F–H) Depletion of anti-DNER antibodies from anti-Tr–positive sera (F) 
obliterates the anti-Tr staining pattern (G). The eluted fraction, containing purified anti-DNER 
antibodies, retains the normal punctuate staining (H). Note that a lower dilution was used in 
F–H (1/20,000) than in A,C–E (1/400). Scale bar = 200μm in A, B and 25μm in A′, B′, C–H. 
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figure 3. Knockdown of Delta/Notch-like epidermal growth factor-related receptor (DNER) abolishes 
Tr reactivity in hippocampal neurons. (A) In neurons transfected with a control (CTRL) construct, 
normal DNER (green) and Tr (red) reactivity is observed (upper panel). In all neurons transfected 
with constructs expressing short hairpin RNA (shRNA) against DNER and β-galactosidase (blue), 
both DNER expression and Tr reactivity are lacking (lower panel). Scale bar = 20μm. (B) Summary 
of DNER knockdown experiments. Quantification of the number of Tr- and DNER-positive neurons 
expressing control shRNA (n = 162), DNER-shRNA#1 (n = 133), or DNER-shRNA#2 (n = 134). 
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Figure 4. Tr epitope mapping of Delta/Notch-like epidermal growth factor-related receptor (DNER). 
(A) The upper panel gives a schematic representation of DNER to indicate the epitope regions.
Numbers depict amino acid; light gray boxes indicate epidermal growth factor (EGF) domains; SP = 
N-terminal signal peptide; TM = transmembrane domain. Lower panel: Epitope mapping of DNER
by expressing hemagglutinin (HA)- or myc-tagged DNER deletion constructs (green) in HeLa cells
stained by anti-Tr sera (red) displays 2 groups of patients: Tr9 detects 1 epitope encompassing
aa 128–308 only, whereas Tr8 detects a second epitope within aa 302–675. Scale bar = 10μm. (B)
Summary of the cell-based Tr epitope mapping experiments with the 13 different anti-Tr sera,
including the Tr-positive serum from the Hodgkin lymphoma (HL) patient without ataxia. nd = not
determined. (C) Western blot analysis reveals that tunicamycin treatment of HA-DNER–expressing
HEK293T cells inhibits the glycosylation of DNER as seen by the reduction in molecular weight.
The anti-Tr–positive sera (Tr9 and Tr5) no longer recognize unglycosylated DNER. (D) Mutating
4 N-glycosylation sites in DNER1-737 abolishes the recognition by the anti-Tr sera (Tr9 and Tr10)
as analyzed on Western blotting. (E) Mutating 4 N-glycosylation sites in DNER128-308 completely
abolishes the recognition by 9 anti-Tr sera, whereas the remaining 3 sera only gave minimal
reactivity (see also B).
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Mapping of the Tr Epitope in DNER
To identify the epitope recognized by Tr-positive sera (including the anti-Tr serum 
from the HL patient without ataxia), we generated different deletion mutants of DNER. 
We expressed all mutants in HeLa cells and scored whether the different anti-Tr sera 
reacted with DNER. All anti-Tr sera were found to recognize the extracellular domain 
of DNER, specifically the region between the second and third EGF-like domain (myc-
DNER128-308). Interestingly, 2 different Tr epitopes are identified within the 13 anti-Tr 
sera. Seven of 13 sera recognized only the DNER region between amino acids 128 and 
308, and were negative for the DNER fusion protein lacking this part (represented by Tr9 
in Figure4A, HA-DNERΔ128-304). In addition, 6 sera recognized a second epitope within 
the DNER region of amino acid 302-675 and were positive for the DNER fusion protein 
lacking DNER128-308 (represented by Tr8 in Figure4A, myc-DNER302-675 and HA-
DNERΔ128-304, respectively). An overview of the epitopes recognized by all 13 different 
anti-Tr sera using the cell-based assays is given in Figure 4B. Recognition of the second 
epitope did not correlate with age, neurological symptoms, underlying type or stage of 
HL, or functional status of the patients (see Table 1).
DNER Glycosylation Is Required for Tr Antigenicity
DNER is highly glycosylated.13 To understand the role of glycosylation in the antigenicity 
of DNER, we incubated HEK293T cells, expressing HA-DNER without or with glycosylation 
inhibitor tunicamycin (20μg/ml, for 24 hours), and analyzed anti-HA immunoprecipitated 
extracts using Western blot analysis. The removal of glycosylated chains in the majority 
of DNER protein was confirmed by the reduction in molecular mass of DNER to 90kDa, 
close to the expected molecular mass (see Figure4C). Although nonglycosylated DNER 
could still be recognized by the commercial anti-DNER antibody (data not shown), 
both anti-Tr–positive sera tested no longer recognized the unglycosylated protein. This 
was confirmed by the lack of staining by anti-Tr sera of Hela cells expressing DNER 
constructs lacking the N-terminal signal peptide, which block DNER targeting into the 
endoplasmic reticulum and prevent glycosylation (data not shown). Glycosylation 
prediction software NetNGlyc (www.cbs.dtu.dk/services/NetNGlyc/) reveals the presence 
of 4 N-glycosylation sites in the common DNER epitope (amino acids 128–304). We 
mutated all 4 N-glycosylation sites into alanines (HA-DNERΔG1-4) and analyzed anti-Tr 
reactivity by immunoprecipitation followed by Western blotting. The commercial anti-
DNER polyclonal antibodies recognized mutated DNERΔG1-4, albeit with lower affinity. 
However, the 2 anti-Tr–positive sera tested no longer recognized the mutated DNER (see 
Figure4D, Tr9 and Tr10). The role of N-glycosylation for Tr antigenicity was further studied 
using the cell-based assay in which we expressed myc-tagged DNER128-308ΔG1-4. Two 
of the anti-Tr sera still recognized mutated DNER, but only very weakly (see Figure4E, Tr5 
and Tr8), whereas all other sera were negative. This strongly indicates the importance of 
N-glycosylation in recognition of the main DNER epitope by anti-Tr sera.
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dIsCussIOn
In this study, we report the presence of anti-DNER antibodies in serum of anti-Tr–positive 
PCD patients and provide evidence that DNER is the long sought Tr antigen. All 12 anti-
Tr–positive sera tested detected DNER in a cell-based assay, whereas 245 of 246 control 
sera did not (see Table 2). The only DNER-positive control serum was from a patient 
with HL without ataxia and demonstrating the characteristic Tr immunoreactivity on 
rat brain sections. We mapped the main epitope for all 13 anti-Tr sera (including the 
serum from the HL patient without ataxia) to an extracellular region of 176 amino acids 
between amino acids 128 and 304, and determined that Tr antigenicity is dependent 
on N-glycosylation of this region. Whether this is caused by recognition of the glycogen 
chains or due to the folding of the protein remains to be determined. Consistently, anti-
Tr sera depleted of DNER-antibodies no longer displayed the typical somatodendritic 
punctuate staining. Because tissue of DNER-null mice was not available, we used shRNA 
constructs to knock down DNER in hippocampal neurons and demonstrated absence 
of both DNER and Tr staining in transfected pyramidal neurons. These data strongly 
indicate that the EGF-related receptor DNER is the Tr antigen. Finally, we show that 
Western blotting is unfit for diagnosing anti-Tr antibodies.
In recent years, progress has been made in the identification of various antineuronal 
antibodies in different ways. Overlapping expression patterns led to the identification 
of antibodies against mGluR1 in PCD associated with HL14 and anti–N-methyl-D-
aspartate receptor (NMDAR) antibodies in limbic encephalitis.15 Recently, IP followed 
by mass spectrometry (MS) analysis directed the identification of antibodies against 
the glutamate receptor subunits GluR1 and GluR216, the gamma amino butyric acid B 
receptor 1 and 2 subunits17, mGluR518, and leucine-rich, glioma inactivated 1 protein19, 
subsequently confirmed by a candidate protein approach20, in limbic encephalitis. 
In these cases, clear bands were already visible on Coomassie-stained gels after 
immunoprecipitation. As this was not the case here we took advantage of the fact that 
all anti-Tr sera recognize the same epitope (see Figure2C–E and Bernal et al8). This 
enabled us to analyze in detail the entire peptide data set obtained by IP-MS to identify 
proteins that were precipitated by all 4 anti-Tr sera. In the future, additional neuronal 
antigens associated with other neuronal autoimmune disorders could be identified in 
this way. The success rate will largely depend on the excellent clinical and serological 
characterization of the patients combined with sensitive MS analyses.
Although the main epitope recognized by all 12 anti-Tr–positive sera from PCD patients 
was mapped to an extracellular 176 aa region between EGF domains 2 and 3, 5 of 
these sera could recognize a second epitope, also in the extracellular region of DNER. 
The clinical phenotype, known in 4 of these 5 patients, was not different from the 7 
other patients (see Table 1). The 13th anti-Tr–positive serum from the nonataxic HL 
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patient also detected both epitopes, identically to the 5 PCD patients. Therefore, the 
lack of neurological symptoms in this patient is not explained by an alternative epitope 
recognition pattern and remains unexplained. However, the presence of paraneoplastic 
antibodies in patients with cancer is well known and, for example, anti-Hu antibodies 
occur in up to 16% of small cell lung cancer patients without neurological symptoms.21
It is unclear what caused the presence of anti-DNER antibodies in our patients. Previous 
studies using anti-Tr IgG from 2 patients could demonstrate expression of Tr antigen in 
only 1 of 15 HL samples tested.8 In preliminary studies (not shown) we could not detect 
DNER protein in HL biopsies either. On the other hand, the association between HL and 
anti-Tr is very strong although not absolute. In the largest Tr-series described8, 25 of 28 
anti-Tr patients harbored an underlying HL, whereas in the other 3 patients no tumor 
was detected. Also in our series, 12 of 13 anti-Tr–positive patients had HL, whereas in 
Patient 4 no tumor was detected (see Table 1). More recently, Briani et al3 reported 18 
anti-Tr–positive patients, 11 of whom had HL. Of the other 7 patients, 3 had no tumor, 
2 had an underlying non-Hodgkin lymphoma, and 1 each suffered from tongue or lung 
cancer. The more pleiotropic picture in the latter study may have partially resulted 
from lack of central immunohistochemistry review and/or blocking studies. The cell-
based diagnostic DNER assay that becomes available with this study will facilitate 
demonstration of reactivity with the same antigen by all putative anti-Tr sera. The lack 
of DNER and mGluR115 expression by HL in PCD patients with anti-Tr or anti-mGluR1 
antibodies suggests that the immune response is not triggered directly by expression of 
the autoantigen by the tumor. Other mechanisms such as dysregulation of the immune 
system in HL and an etiologic role for viral infections have been postulated previously.22
The Tr antigen DNER is expressed throughout the brain during development and 
adulthood, but is highly expressed in the Purkinje cells in a punctuate somatodendritic 
manner.10,13 Similar to the subacute cerebellar ataxia observed in anti-Tr–positive 
patients, mice lacking DNER exhibited motor incoordination in the fixed bar and 
rotarod tests.23 Moreover, the cerebellum from knockout mice showed significant 
retardation in morphogenesis and persistent abnormality in fissure organization.23 
Based on the extracellular location of the DNER epitopes, accessible to antibodies 
even in the brain, as previously shown for mGluR1 autoantibodies and the ataxia in 
DNER knockout mice, we hypothesized that anti-Tr may cause ataxia by interfering 
with DNER function. We therefore tested the effect of anti-Tr antibodies on neuronal 
morphology in both cerebellar organotypic and primary hippocampal neuron cultures. 
However, although treating slices or dissociated neurons for 2 weeks with anti-Tr–
positive sera led to marked endogenous staining of Purkinje cells and hippocampal 
neurons, no obvious abnormalities in morphology were observed in these in vitro 
assays (data not shown). Because DNER has been suggested to mediate neuron–glia 
interactions through Notch signaling24, future experiments should focus on the effect of 
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Tr antibodies on the communication between Purkinje cells and Bergmann glia in the 
cerebellum. Alternatively, the anti-Tr antibodies may not be pathogenic but biomarkers 
of a concomitant cytotoxic T-cell immune response, as proposed in other forms of 
PCD.22,25 Recently, several new forms of autoimmune encephalitis caused by antibodies 
that interfere with the function of neuronal cell surface proteins such as NMDAR27 
or AMPA17 have been described. These disorders were often found to be reversible, 
with fairly good prognosis after thorough immunotherapy. In contrast, our patients 
showed either none or little improvement on the modified Rankin scale (see Table 1), 
strongly suggesting a nonreversible phenotype. This finding is consistent with previous 
observations in anti-Tr–associated PCD.8  and with the total loss of cerebellar Purkinje 
cells observed at autopsy.8 Despite the reactivity with an extracellular epitope, the lack 
of effect of anti-DNER antibodies on neuronal morphology, the poor prognosis, and the 
loss of Purkinje cells at autopsy all suggest a concomitant cytotoxic T-cell response.22,25
The identification of DNER as Tr antigen in this study simplifies the method for 
determining the presence of anti-Tr antibodies in patients with subacute cerebellar 
symptoms. Instead of using the strict immunohistochemical criteria6 followed by a 
blocking experiment8,  a simple cellular assay based on the expression of exogenous 
DNER can now be used. Importantly, the detection of anti-Tr antibodies in patients with 
subacute cerebellar ataxia warrants a thorough search for an underlying HL.
ACKnOwledgeMenTs
We thank the patients and physicians who supplied us with clinical information on the 
patients, Dr M. Kengaku for kindly providing us with DNER constructs, and N. Keijzer 
and M. Kuijpers for technical assistance with neuronal cultures
96
suPPleMenTARy dATA
Primers used:
Name sequence (5’-3’)
dnerF1 Ccagtgtgctggaattcg
dnerR1 ctgGTCGACaaatcttttgttttaatcag
dnerΔ1F cggctatgaaggtcttaactgtgctagcaactgtgttccgg
dnerΔ1R ccggaacacagttgctagcacagttaagaccttcatagccg
dnerR2 ctgGTCGACcaaatcttttgttttaatcag
dnerE2R ctggtcgactggttgttcacagttaagacc
dnerE2F cctgaattcggtcttaactgtgaacaacc
dnerE3R caggtcgacggaacacagttgctagcc
dnerE3F caggaattcgctagcaactgtgttccg
dnerTMR gcagtcgactatggccgggaggagccc
delG1F gatgttgcctgtgggGCtgcTagCtccaacaactctgcg
delG1R cgcagagttgttggaGctAgcaGCcccacaggcaacatc
delG2F gccagttccGCcaactctgcgggtgg
delG2R ccacccgcagagttgGCggaactggc
delG3F gaagtgccacagGCcactAGTgtaaagattcggcagg
delG3R cctgccgaatctttacACTagtgGCctgtggcacttc
delG4F cttcattggttttgtgGCtgactctgttgc
delG4R gcaacagagtcaGCcacaaaaccaatgaag
Constructs:
HA-DNER1-737 PCR:dnerF1/dnerR1, EcoRI-SalI into pGW1
DNER GFPbio PCR:dnerF1/dnerR2, EcoRI-SalI into pGW1-GFPbio
HA-DNER1-134 PCR:dnerF1/dnerE2R, EcoRI-SalI into pGW1
myc-DNER128-308 PCR:dnerE2F/dnerE3R, EcoRI-SalI into pGW1, insert recloned into AscI-Noti GW-Spmyc
myc-DNER304-675 PCR:dnerE3F/dnerTMR, EcoRI-SalI into pGW1, insert recloned into AscI-NotI pGW-Spmyc
HA-DNERΔ128-304 PCRdnerF1/dnerΔ1F/dnerΔ1R/dnerR1, EcoRI-SalI into pGW1
HA-DNERΔG1-4 consecutively: delG1,2,3,4F/R&dnerF1/dnerR1, EcoRI-SalIinto pGW1
The template for all contructs was the HA-DNER in pDISPLAY, kindly provided by M. Kengaku.10 All DNER 
constructs were subcloned in pGW1 expression vectors for optimal neuronal expression.11 A linker encoding 
the sequence ASGLNDIFEAQKIEWHEGGG, which is the substrate of biotin ligase BirA was inserted into 
the AscI EcoRI sites after the GFP in pGW1-GFP.26 In pGW-SPmyc a linker encoding the signal peptide 
MNFIPVDIPLLMIFLVTTGGSALEKLAT was inserted before the myc-tag MEGKLISEEDL.
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AssessMenT Of PATIenT’s dIsAbIlITy
The patients’ disability was assessed using a modified Rankin scale (mRS). On the mRS a 
score of 0 represents an asymptomatic patient; 1, symptoms that do not interfere with 
lifestyle; 2, symptoms that lead to some restriction of lifestyle but do not prevent totally 
independent existence; 3, symptoms significantly interfere with lifestyle or prevent 
totally independent existence; 4, symptoms clearly prevent independent existence, 
although the patient does not need constant attention; 5, severe disability with total 
dependence requiring constant attention; 6, death from neurological cause.9
IMMunOPReCIPITATIOn And MAss sPeCTROMeTRy
Extracts were made from adult total rat brain using 1% NP40 lysis buffer (10mM Hepes, 
pH 7.5, 150 mM NaCl, 1% NP40 and complete protease inhibitor (Roche). 2.5 mg protein 
was precleared with 50 ul protA / protG sepharose, mixed 1:1, for 1 hour at 4oC and the 
supernatant was subsequently incubated overnight at 4oC with 10 ul sera. The following 
morning 50 ul protA / protG (1:1) sepharose was added and left to incubate for an 
additional 4 hours at 4oC. The sepharose beads were washed 5 times with lysis buffer 
and loaded on a 4-12% Bis-Tris gel (Invitrogen, Breda, Netherlands).  
Mass spectrometry was mainly performed as described before.26,27 For mass 
spectrometry analysis, 1D SDS-PAGE gel lanes were cut into 2-mm slices using an 
automatic gel slicer and subjected to in gel reduction with dithiothreitol, alkylation 
with iodoacetamide and digestion with trypsin (sequencing grade, Promega, Leiden, 
Netherlands), essentially as described previously.28 Nanoflow LCMS/MS was performed 
on an 1100 series capillary LC system (Agilent Technologies, Amstelveen, Netherlands) 
coupled to an LTQ linear ion trap mass spectrometer (Thermo, Breda, Netherlands) 
operating in positive mode and equipped with a nanospray source. Peptide mixtures 
were trapped on a ReproSil C18 reversed phase column (column dimensions 1.5 cm 
× 100 μm, packed in-house; Dr Maisch GmbH, Ammerbuch-Entringen, Germany) at 
a flow rate of 8 μl/min. Peptide separation was performed on ReproSil C18 reversed 
phase column (column dimensions 15 cm × 50 μm, packed inhouse; Dr Maisch GmbH, 
Ammerbuch-Entringen, Germany) using a linear gradient from 0 to 80% B (A = 0.1 M 
acetic acid; B = 80% (v/v) acetonitrile, 0.1 M acetic acid) in 70 min and at a constant 
flow rate of 200 nl/min using a splitter. The column eluent was directly sprayed into 
the ESI source of the mass spectrometer. Mass spectra were acquired in continuum 
mode; fragmentation of the 4 peptides was performed in data-dependent mode. Peak 
lists were automatically created from raw data files using the Mascot Distiller software 
(version 2.1; MatrixScience, London, UK). The Mascot search algorithm (version 2.2) 
was used for searching against the International Protein Index database (release 
number IPI_rat_20091106.fasta). The peptide tolerance was typically set to 2 Da and 
the fragment ion tolerance to 0.8 Da. A maximum number of 2 missed cleavages by 
trypsin were allowed and carbamidomethylated cysteine and oxidized methionine were 
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set as fixed and variable modifications, respectively. The Mascot score cut-off value for 
a positive protein hit was set to 31. Proteins present in the anti-Hu serum were omitted 
from the individual lists obtained by immunoprecipitation with the 4 anti-Tr positive 
sera. The remaining proteins of the 4 lists were compared by hand, leading to 12 
proteins identified in all 4 anti-Tr immunoprecipitations. These were all further checked 
for absence in the list obtained by the 2 remaining negative controls (mGluR1, GluR1).
CulTuRIng And IMMunOblOTTIng
HEK293T en HeLa cells were grown in DMEM:HAMF10 (1:1) medium containing 10%FBS 
and 1% penicillin/streptomycin at 37oC and 5%CO2. Cells were transiently transfected with 
various DNA constructs using Polyethylenimin (Polyscience, Eppelheim, Germany) and 
grown for 24 hours after transfection. For glycosylation experiments, cells were treated 
with Tunicamycin (20 ug/ml, Merck Chemicals) for 24 hours prior to immunoblotting. 
For immunoblotting cells were harvested in phosphate buffered saline (PBS) and lysed 
for 15 minutes at 4oC in 1% Triton, 20mM Tris pH7.5, 150mM NaCl supplemented 
with complete protease inhibitors (Roche, Woerden, Netherlands). After a 15 seconds 
sonification step, samples were spun for 5 minutes at 13.000rpm at 4oC. The supernatant 
was diluted in 2x Sample buffer (8% SDS/25% Glycerol/0.05M Tris pH 6.8/200mM DTT/
Bromophenol Blue/H2O) and separated on 8 or 10% SDS-PAGE gels, followed by 
blotting onto PVDF membranes (Biorad, Veenendaal, Netherlands). Blots were blocked 
with either 2% BSA/0.05% Tween/PBS (commercial antibodies) or with 0.05% Tween/ 
skimmed milk (patient sera) and incubated overnight at 4oC with the appropriate 
antibody. Blots were washed with 0.05%Tween/PBS or 0.05%Tween/skimmed milk 
for 3 times 5 minutes each at room temperature and incubated with the appropriate 
secondary antibody. After washing 3 times in 0.05% Tween/ PBS and once in PBS, blots 
were developed with Enhanced Chemiluminescent Western Blotting Substrate (Pierce, 
Etten-Leur, Netherlands).
IMMunOCyTOCheMIsTRy
For immunocytochemistry, HeLa cells were grown on Lab-tek chamber slides (Nunc, 
Uden, Netherlands) and fixed with 4% PFA for 10 minutes, followed by 3 washes of 
5 minutes each with PBS and 1 wash of 5 minutes with PBS+ (0.5% Protifar (Nutricia, 
Zoetermeer, Netherlands), 0.15% glycin, 0.05%Triton in PBS). Cells were stained with 
the primairy antibody (2 hours at room temperature) in PBS+, washed 3 times in PBS 
and subsequently incubated with secondary antibodies in PBS+ for 1 hour at room 
temperature. After 3 subsequent washes in PBS slides were mounted in Vectashield 
(Vector Laboratories, Peterborough, UK) and studied on a DMRBE microscope (Leica, 
Rijswijk, Netherlands). 
For surface staining of DNER, hippocampal neurons were incubated with serum of 
Tr9 diluted 1:50 and rabbit anti-HA diluted 1:100, in Neurobasal medium (NB) for 15 
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minutes at 37oC, followed by rinsing in NB at 37oC. After fixing the cells for 10 minutes 
in 4%PFA / 4%sucrose cells were washed three times with PBS, followed by incubation 
with secondary antibodies in GDB (0.1% gelatin, 16.7 mM Phosphate buffer and 450 
mM NaCl) for 1 hour at room temperature. After three subsequent washes in PBS the 
coverslips were mounted and studied as described above. Permeabilised staining of 
hippocampal neurons was performed by fixing the neurons in 4% PFA / 4% sucrose, 
3 washes with PBS and incubation of the primary antibodies in GDB+0.6% Triton, 
overnight at 4oC. After three washes with PBS, neurons were incubated with secondary 
antibodies for 1 hour at room temperature in GDB+ 0.6%Triton. Subsequent washing 
and mounting were as described above.
IMMunOhIsTOCheMIsTRy
Snap frozen rat brain and cerebellar cryosections were stained as described before.6 
Cryosectons of 6-8 µm were air-dried and fixed in acetone (4oC) for 10 minutes. 
Endogenous peroxidase was blocked with 0.3% H2O2 in PBS. Slides were treated 
with 10% goat serum for 30 minutes at room temperature (RT), incubated either 2 
hours at RT or overnight at 4oC with patient serum diluted in blocking serum (1:100 
or 1:400), with PBS washes between the different steps. Slides were incubated with 
biotin conjugated goat anti-human IgG antibodies (1: 2000, Vector, Peterborough, UK) 
in blocking serum for 45 minutes. After incubation with Vectastain Elite ABC complex 
(Vector Labs, Burlingame, CA) for 30 minutes, the reaction was developed with 0.05% 
diaminobenzidine and 0.01% H2O2 diluted in PBS with 0.5% Triton X-100 followed by 
staining with Diaminobenzidine tetrahydrochlorid dihydrate (DAB, Fluka, Zwijndrecht, 
Netherlands) slides were dehydrated with ethanol series (50-100%) and mounted with 
Pertex (Klinipath, Duiven, Netherlands).  
To test whether the different Tr-identified sera recognize a similar epitope, rat cerebellar 
sections were incubated with undiluted anti-Tr-positive serum for 3 hours at RT, after 
the initial blocking in goat serum. This was followed by overnight incubation at 4°C with 
biotinylated purified IgG (biotinylated using EZ-Link® Sulfo-NHS-LC-Biotinylation Kit 
(Pierce Biotechnology, Rockford Il, US), diluted 1:100 in PBS 1% BSA, from a serum which 
had been used in Tr-blocking experiments described before.8 Staining was developed 
as described above.
PuRIfICATIOn Of dneR ReACTIng AnTIbOdIes fROM TR seRuM
BioGFP-DNER was expressed in HEK293T cells for 24 hours, washed with cold PBS and 
lysed for 15 min on ice in 20mM HEPES pH7.5, 150 mM KCl, 1% Triton X-100, complete 
protease inhibitors (Roche, Woerden, Netherlands), followed by 2 times 10 seconds 
sonification steps. Extracts were spun at 13.000 rpm for 10 minutes after which the 
supernatant was incubated with preblocked (1% BSA, 0.05% Tween in PBS for 30 
minutes) Dynal M280 beads (Invitrogen, Breda, Netherlands) for 1 hour. Beads were 
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washed 5 times with HEPES pH7.5, 600mM KCl, 0.1% Triton X100 and subsequently 
incubated for 3 hours with patients sera diluted 1:15 in PBS containing 1% BSA and 
0.05% Tween at 4°C. The beads were washed 4 times with 20mM HEPES pH7.5, 600mM 
KCl, 0.1% Triton X100 and antibodies were eluted with 200mM glycine pH2.8, after which 
the pH was neutralized using 1/10th volume of 1M Tris, pH8.0. Both depleted serum 
and the purified antibodies were washed with PBS using Vivaspin sample concentrators 
(GE Healthcare, Hoevelaken, Netherlands) and stored in PBS containing 1%BSA.
dneR KnOCK dOwn In hIPPOCAMPAl neuROns
Primary hippocampal cultures were prepared from embryonic day 18 (E18) rat brains.29 
Cells were plated on coverslips coated with poly-L- lysine (30 μg/ml) and laminin (2 μg/ml) 
at a density of 75,000/well. Hippocampal cultures were grown in Neurobasal medium 
(NB) supplemented with B27, 0.5 mM glutamine, 12.5 μM glutamate and penicillin/
streptomycin as described in Jaworski et al.26 The following shRNA sequences targeting 
rat DNER  were used in this study: shRNA#1 (AAACCCTTGGTCACACTGA) and shRNA#2 
(GATTCTGTTGCTAAGTCCA). The complementary oligo’s were annealed and inserted 
into pSUPER. Hippocampal neurons were transfected at 7 days in vitro (DIV) using 
Lipofectamine 2000 (Invitrogen). DNA (3.6 μg /well) was mixed with 3.3 μl Lipofectamine 
2000 in 200 μl NB, incubated for 30 minutes and then added to the neurons in NB 
at 37°C in 5% CO2 for 45 min. Next, neurons were washed with NB and transferred 
in the original medium at 37°C in 5% CO2 for 4 days. Cells were co-transfected with 
β-galactosidase to identify the transfected cells.
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AbsTRACT
ObJeCTIVe
Autoimmune encephalitis associated with autoantibodies against the N-methyl-D-
aspartate receptor (NMDAR) often presents with behavioral change. Our objective was 
to describe in detail the psychiatric presentation and pathways to care in order to aid 
the early diagnosis of NMDAR encephalitis.
MeThOds
Sera and CSF from patients with suspected NMDAR encephalitis were tested on HEK 293 
cells transfected with the NR1 subunit of the NMDAR. Clinical information was obtained 
from the referring psychiatrists and neurologists and by review of the clinical records.
ResulTs
Samples from 15 patients (13 female, 2 male, mean age 24 years, range 5-56 years) 
tested anti-NMDAR positive. Twelve of the 15 patients (80%) presented with prominent 
psychiatric symptoms and 8 were initially referred to a psychiatric service. The most 
prominent initial psychiatric symptoms were anxiety in 7 (47%), behavioural change 
(often bizarre) in 6 (40%) and agitation in 5 (33%). All patients developed psychiatric 
symptoms in the first 6 weeks of illness. Thirteen patients received psychotropic 
medications: antipsychotics in 12 and benzodiazepines in 11. Treating physicians 
considered the psychotropic medication not effective in 11 patients resulting in many 
drug switches. At nadir, all patients were in a very poor condition. However, 8 patients 
(53%) recovered (almost) completely. Outcome tended to be better in patients who had 
received early immunotherapy or tumor removal.
COnClusIOns:
Autoimmune encephalitis and anti-NMDAR testing in serum and CSF should be 
considered in patients, especially young females, presenting with atypical psychiatric 
phenomena. Early diagnosis and treatment will likely improve the prognosis of NMDAR 
encephalitis.
Keywords: Anti-NMDAR Encephalitis, Anti-NMDAR antibodies, Psychotic disorders
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InTROduCTIOn
N-methyl-D-aspartate receptor (NMDAR) encephalitis is a severe form of encephalitis
associated with antibodies against the NR1 and NR2 subunits of the NMDAR and often
presents with severe psychiatric symptoms mostly in young women. In approximately
70% of patients, the encephalitis is preceded by a prodromal phase of one to two weeks
consisting of fever and malaise resembling a viral illness.1,2 The presentation of NMDAR
encephalitis itself is characterized by prominent emotional and behavioral change
followed by amnesia, seizures and in some cases a choreiform movement disorder,
evolving to a catatonic state. Autonomic instability and central hypoventilation often
lead to ICU admission, intubation and mechanical ventilation1-5 NMDAR encephalitis is
associated with ovarian teratomas in approximately 60% of patients, especially young
women.2-5 The disorder also occurs in children who often present with behavioral and
personality changes, later complemented by abnormal movements, epilepsy, sleep
dysfunction and speech problems.6-8 In children and adolescents, the frequency of non-
paraneoplastic cases is apparently much higher than in adults 6,9; only 9% of girls < 9
years of age had an underlying tumor.9 Recovery with no or only mild residual deficits
occurs in approximately three quarters of the patients.2,4,7,8 However, outcome depends
greatly on early diagnosis followed by immediate removal of the underlying tumor (if
present) and/or immunomodulatory therapy.2,4,5,7,8
Several lines of evidence strongly suggest that anti-NMDAR antibodies and other
antibodies against neuronal surface antigens are pathogenic by functional interference
with the receptor.10,11 This functional interference is reversible, at least initially,
resulting in a good outcome in most patients when treated early. In contrast, patients
with paraneoplastic limbic encephalitis associated with antibodies directed against
intracellular antigens have a poor prognosis that is probably related to irreversible
T-cell mediated damage.12,13
The differential diagnosis of NMDAR encephalitis is vast and includes psychotic
disorders, mood dysregulation disorders, sleep disorders and disorders of impulse
control.14 Also patients with a first episode of schizophrenia according to DSM IV criteria
can have an underlying NMDAR encephalitis.15 As a result patients are often initially
admitted for psychiatric evaluation and psychiatrists may encounter patients with
NMDAR encephalitis in all kinds of settings including emergency departments, inpatient
units, consultation services and outpatient offices.
To facilitate early recognition of this potentially lethal but highly treatable disorder, we
report the clinical findings in 15 Dutch patients with NMDAR encephalitis with special
focus on psychiatric symptoms and pathways to care in the early stages of the disease.
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PATIenTs And MeThOds
Patients
All available clinical records were retrospectively examined in detail for psychiatric and 
neurological signs and symptoms at presentation and during subsequent evolution of 
the syndrome. We defined symptoms as either neurological or psychiatric based on the 
interpretation by the attending physicians.
The results of brain MRI, EEG and CSF examinations were collected as were the results 
of tumor screening. We were able to review the MRI’s of 8/15 patients. In the other 7/15 
patients we could only read the results. In addition, the timing and type of treatment 
(symptomatic treatment, immunotherapy and/or tumor treatment) were scored. One 
of the patients presented here has been reported before.16 The study was approved by 
the Erasmus MC institutional review board.
Outcome
The patients’ disability was assessed using a modified Rankin scale (mRS).17 On the mRS 
a score of 0 represents an asymptomatic patient; 1, symptoms that do not interfere 
with lifestyle; 2, symptoms that lead to some restriction of lifestyle but do not prevent 
totally independent existence; 3, symptoms significantly interfere with lifestyle or 
prevent totally independent existence; 4, symptoms clearly prevent independent 
existence, although the patient does not need constant attention; 5, severe disability 
with total dependence requiring constant attention; 6, death from neurological cause. 
The outcome was assessed at least six months after the onset of symptoms. A patient 
was considered to have a good outcome when the mRS was 0-1. In all other patients the 
outcome was considered poor (mRS ≥ 2). Early treatment was defined as any tumor or 
immunomodulatory treatment started within two months from symptom onset. 
Statistical analysis
Due to the retrospective nature and objective of this study the symptoms and referrals 
were qualitatively assessed. The proportions of patients with a good outcome in the 
group receiving early treatment versus late or no treatment were compared using the 
Chi-square test (GraphPad Prism version 5, GraphPad Software Inc., La Jolla, CA).
Cell based assay for anti-NMDAR antibodies
The NMDAR1 subunit (NR1) complementary (c)DNA fused in frame to YFP was a kind 
gift from B. Laube.18 HEK293 cells (ATCC #CRL1537) were grown on glass coverslips in 
DMEM and Ham’s F10 (Gibco, Breda, Netherlands) supplemented with 10% FBS (Gibco) 
and 1% penicillin and streptomycin (Gibco). After 24h, cells were transfected with the 
YFP-tagged NR1 contruct using Fugene-6 (Roche, Woerden, Netherlands) at a ratio of 
3:1. After 24h, live cells were fixed with 4% paraformaldehyde (Sigma, MO) for 15 min, 
washed 5 min PBS with 0.2 % Triton X-100 (Merck, Darmstadt, Germany) followed by 
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two times 15 min in PBS with 0.5 % BSA (Sigma) and 7.0 mg glycine (Sigma) (PBS+) 
prior to incubation with patient sera (1:50 and 1:200) or CSF (undiluted and 1:5) for 1 h. 
After washing, cells were incubated for 1 h with anti-human CY3 1:200 made in donkey 
(Jackson ImmunoResearch, Westgrove, PA). The samples were visualized and scored by 
two independent observers using a Leica DM RXA microscope (Leica, Wetzlar, Germany). 
Histology
Deparaffinized 4 micron tissue sections from the patient’s teratoma were pretreated 
in citric acid (pH 6.0) at 100°C for 30 min for antigen unmasking. Slides were washed 
and incubated with mouse-anti NMADR1 antibody (BD Pharmingen, Franklin Lakes, NJ) 
at a 1:250 dilution. The PowerVision poly AP anti-mouse IgG multilink system (Leica 
Novocastra, Newcastle upon Tyne, UK) was used according to the manufacturer’s 
specifications for visualization. 
Characterization of inflammatory infiltrates in brain tissue obtained at autopsy was 
performed on non-pretreated deparaffinized 4 micron tissue sections using antibodies 
specific for CD3, CD5, CD4, CD8, CD56, CD20, CD79a, CD138, IgG, IgM, IgA, IgD, C4d and 
CD68 (BD Pharmingen). The PowerVision DAP substrate (Leica Novocastra) was used for 
visualization as described above.
ResulTs
Serum and/or CSF samples from 15 patients tested anti-NMDAR positive (Figure 1D-F). 
In three patients, the anti-NMDAR antibodies were only detectable in CSF and absent in 
the paired serum sample. Thirteen patients were adults (≥ 18 years). 
Clinical characteristics are summarized in Table 1. 
Initial presentation and referral
Supplementary Table S1 shows a detailed overview of the patients. At presentation, 
12 (80%) of the 15 patients had prominent psychiatric symptoms. Eight of the 13 (62%) 
adult patients were initially referred to a psychiatric service. Two children (5 and 8 
years of age) were first seen by a pediatric neurologist. The most prominent psychiatric 
symptoms at initial presentation of the patients were anxiety in 7 (47%), behaviorial 
change (often bizarre) in 6 (40%), agitation in 5 (33%), delusions in 4 (27%) and altered 
mood in 3 (20%) (supplementary Table S1).  
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Table 1. Clinical characteristics in 15 patients with NMDAR encephalitis
N=15
Age (years) 19 (5-56) a
Sex (F/M) 13 / 2
Predominant initial symptoms
    Psychiatric
    Neurological
12 (80%)
3 (20%)
Diagnostic delay (months)b 1.5 (0.4-99.6) a
Ancillary investigations
    CSF abnormal
    EEG abnormal
    MRI abnormal
13/14 (93%)
13/13 (100%)
6/15 (40%)
NMDAR antibody testing
    CSF positive
    Serum positive
13/13 (100%)
11/14 (79%)
Teratoma present 5 (33%)
Treatment
    Antitumor treatment
    Steroids
    IVIG
    Plasma Exchange
    Otherc
5/5 (100%)
12/15 (80%)
5/15 (33%)
2/15 (13%)
2/15 (13%)
Outcome
mRS≤2
mRS>2
10 (67%)
5 (33%)
aMedian (range); bDelay between onset of symptoms and final diagnosis (positive antibody testing); 
cOther therapies include electroconvulsive therapy (ECT) and rituximab in one and mitoxantrone in 
another patient ; IVIG, intravenous immunoglobulins; mRS, modified Rankin scale
Early symptoms
In the first 6 weeks after the onset of the syndrome, psychiatric symptoms were present 
in all fifteen patients (100%).  The most frequent psychiatric symptoms in the first 6 weeks 
(Table 2) were behavioral change in 14 (93%), including bizarre or childish behavior in 
9 (60%) and catatonia in 6 (40%). Perceptual disturbances (hallucinations) were present 
in 9 patients (60%), impaired consciousness in 9 (60%), anxiety or depression in 7 (47%) 
and disorientation in 6 (40%). Neurological symptoms during the first 6 weeks (Table 
3) included epileptic seizures in 12 (80%), choreoathetoid and complex movements
in 7 (47%), sleep disturbances in eight (53%), autonomic instability in seven (47%) and
central hypoventilation requiring admission to an intensive care unit for mechanical
ventilation in 6 (40%). The time interval between onset of symptoms and diagnosis of
NMDAR-encephalitis ranged between 2 weeks and 8.3 years (median 1.5 months).
Two patients were pregnant at presentation and both lost their pregnancies in the acute 
phase of their illness at 13 and 24 weeks of gestation.
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Table 2.  Psychiatric symptoms in the first 6 weeks of NMDAR encephalitis in 15 patients
Psychiatric symptoms n %
Disorders of sensorium and cognition 10 67
Consciousness 9 60
Orientation 6 40
Concentration 4 27
Memory 4 27
Intelligence 5 33
Judgment 6 40
Perceptual disturbances (hallucinations) 9 60
Thought process 7 47
Stream of thought 3 20
Content of thought (delusions) 4 27
Mood, feelings and affect 7 47
Anxiety 6 40
Depression 1 7
Behavior 14 93
Impulsive behavior 7 47
Bizarre (incl. childish) behavior 9 60
Apathy, neglect 4 27
Catatonia 6 40
Mutism or mumbling 3 20
Table 3.  Neurological symptoms in the first 6 weeks of NMDAR encephalitis in 15 
patients
neurological symptoms n %
Epilepsy 12 80
Generalized 8 53
Complex partial 8 53
Dyskinesias and movment disorders 7 47
Choreoathetoid and complex movements 7 47
Orofacial dyskinesias 2 13
Myoclonus 2 13
Autonomic instability 7 47
Sleep disturbances 8 53
Central hypoventilation (requiring intubation) 6 40
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Ancillary investigations
EEG was performed in 13 patients and showed abnormal slowing of the background 
pattern in all patients with additional epileptiform features in 9 of them.
MRI was abnormal in 6/15 patients (40%). MRI changes consisted of increased signal 
intensities in T2 and fluid-attenuated inversion recovery (FLAIR) images. The changes 
were typically localized in the medial temporal lobes in four patients (Figure 1A, arrows), 
with additional cortical localizations in one and post-gadolinium enhancement in 
another. One patient showed subcortical changes (thalamus and putamen) and another 
showed changes in the periventricular white matter.
CSF was abnormal in 13/14 patients. Abnormalities included WBC pleocytosis (8), 
oligoclonal banding (7) and an increased IgG index (7), indicating intrathecal antibody 
synthesis. Total protein concentration was normal in all CSF samples.
Underlying tumor
In 5 of the 15 patients an ovarian teratoma was detected 1-22 months after onset of 
the neuropsychiatric symptoms. In two patients the ovarian teratoma was detected and 
removed within a month after onset of symptoms (Figure 1B). Immunohistochemistry 
revealed expression of the NR1 subunit of the NMDA receptor in the ovarian teratoma 
(Figure 1C). In one 5 year-old patient multiple ovarian cysts were detected by MRI (no 
further follow-up data yet available). In two patients, the teratoma was detected almost 
two years after onset of symptoms and removed to prevent relapse of the NMDAR 
encephalitis. In the remaining 10 patients no teratoma or other tumours were detected.
Symptomatic treatment
Targeted management of psychiatric symptoms was mainly directed at psychotic 
symptoms, anxiety, agitation and mood and sleep disorders. Thirteen patients were 
treated with psychotropic medication including an antipsychotic drug combined with a 
benzodiazepine in 10 patients, antipsychotic medication only in 2 and benzodiazepine 
only in 1. Two patients received additional melatonin for insomnia. 
In only 2 of the 13 patients, the treating physicians felt that the medication was effective 
in controlling the psychiatric symptoms, resulting in many medication switches. The 
mean number of prescribed antipsychotic drugs was 1.8 (range 1-4) and the mean 
number of administered benzodiazepines was 1.7 (range 1-4).
Prescribed antipsychotics included the classical antipsychotics haloperidol (in 7 
patients), zuclopentixol (2), levopromazine (1) and pipamperon (1) and the atypical 
antipsychotics risperidon (6) and olanzapine (5). The following benzodiazepines 
were prescribed: lorazepam (7), diazepam (3), oxazepam (2) and to one patient each 
midazolam, clonazepam, alprazolam, nitrazepam, temazepam and clorazepate.
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Treatment and prognosis
Two patients died 2 weeks and 5 months after onset of symptoms (mRS 6). Follow-up in 
the other patients ranged from 3 months to 9 years (median 14 months). At the nadir 
of the disease, all patients were severely disabled and completely dependent (mRS 
5). The outcome was favourable (mRS <2) in 8 patients while 5 patients fared less well 
(mRS 2-4). Twelve patients received treatment with steroids combined with intravenous 
immunoglobulins (IVIg) in 5, plasma exchange in 2 and rituximab in one. Treatment was 
initiated 0.1 – 10 months after onset of symptoms (median 1.1 month). Three patients 
did not receive any form of immunotherapy, one died while the other two recovered 
with mild (mRS 1) to moderate (mRS 2) symptoms. 
All 5 patients with a pathologically proven and removed ovarian teratoma had an 
excellent prognosis (mRS 0). However, in two of these patients, the teratoma was found 
and removed long after recovery from the NMDAR encephalitis (22 months after onset 
of symptoms). 
In 2 patients the follow-up was shorter than 6 months and outcome was not yet evaluable. 
Of the evaluable patients, 7 had received early treatment, within 2 months from onset. 
In 6 of these early treatment patients, the outcome was good (mRS 0-1) while it was poor 
(mRS ≥ 2) in one. Of 6 evaluable patients with no or late treatment, the outcome was 
poor in 4 and favourable in 2 (P=0.053).
Autopsy in both deceased patients showed inflammatory changes in the brain, mainly 
in the medial temporal lobe and hippocampus (Figure S1). Inflammatory infiltrates 
consisted of CD8 positive T lymphocytes and CD20 positive B cells in perivascular cuffs 
and in the neuropil. Also CD68 positive macrophages and activated microglia were 
observed.
dIsCussIOn
Twelve of 15 patients (80%) with anti-NMDAR encephalitis had prominent psychiatric 
symptoms at first presentation. Eight adult patients were initially admitted to a psychiatric 
unit. The most common diagnosis was ‘atypical psychosis’, followed by schizophrenia, 
depression and panic attacks. Subsequently, patients developed seizures, decline of 
consciousness, catatonia, abnormal movements, autonomic instability and central 
hypoventilation. Thirteen patients received multiple psychotropic drugs with very limited 
symptomatic control. Most patients were young women and in 5 of them pathological or 
radiological evidence of an underlying teratoma was found. Early aggressive treatment 
consisting of tumor treatment (if present) and immunotherapy, correlated with a good 
outcome in 8 of 13 evaluable patients.
Evaluation of the initial stages of diagnostics and patterns of referral showed that a 
substantial proportion of the patients initially presented with symptoms suggestive of a 
psychiatric disorder. At the same time, clinical records indicated that most psychiatrists 
were aware of an atypical presentation of the symptoms early on, leading to the 
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suspicion of an ‘organic syndrome’, and subsequent consultation of a neurologist. 
Conversely, when patients were initially seen by a neurologist, an atypical presentation 
was also recognized, leading to psychiatric consultation. Generally, patients initially 
presented with little obvious biological alterations (focal neurological deficits, blood 
chemistry, MRI), which in many cases prompted further interpretation of symptoms as 
caused by a psychiatric syndrome. Recognition of the ‘neurological background’ of the 
syndrome usually came when either prominent EEG alterations were found, or when 
obvious neurological symptoms began to dominate the clinical picture (mostly seizures, 
and decline of consciousness). Our study and previous studies show that most of the 
patients with NMDAR encephalitis are initially evaluated by a psychiatrist. In the series 
of Dalmau et al.4 80% of the patients were initially evaluated by a psychiatrist while Irani 
et al.5 report early psychiatric symptoms in 77% of patients. 
In patients of 40 years or older, with no previous history of psychiatric illness, 
presentation with psychiatric symptoms should always raise suspicion of an underlying 
neurological or other disorder. In young female patients, de novo presentation with 
‘atypical’ psychosis, in particular when combined with unusual and complex behavioural 
changes, a diagnosis of NMDAR encephalitis should be considered.19
It is well known that expert clinical decision making greatly depends on clinical pattern 
recognition. It seems that the initial clinical presentation of patients with NMDAR 
encephalitis has elements of two apparently conflicting clinical patterns, contributing 
to diagnostic uncertainty. The dominant presentation of young, previously healthy 
women showing psychotic phenomena obviously invokes the clinical pattern of 
‘psychotic disorder/schizophrenia’. However, the alternative clinical pattern (seizures, 
movement alterations and speech impediments in patients with good premorbid 
functioning without psychiatric problems) invokes in psychiatrists the clinical pattern 
‘organic syndrome’. Diagnostic delay was caused by the relative absence of objective 
biological alteration in the early stages, in combination with unfamiliarity with this 
recently identified syndrome. In our series 4 out of 15 patients had been misdiagnosed 
as atypical psychosis or schizophrenia for months to years (range 4.2 to 99.6 months). It 
is well possible that more cases of NMDAR encephalitis with predominantly psychiatric 
symptoms are still misdiagnosed as primary psychiatric syndromes.15,20 On the other 
hand, a recent cross sectional study in 50 patients diagnosed with a psychotic disorder 
according to DSM IV criteria (including both first-episode as well as chronic schizophrenic 
inpatients) did not detect any anti-NMDAR antibodies.21
NMDAR-encephalitis is diagnosed by detection of anti-NMDAR antibodies in serum and/
or CSF. Importantly, in three of our patients (20%) the anti-NMDAR antibodies were 
exclusively detectable in CSF. Dalmau et al. 4 described intrathecal synthesis of anti-
NMDAR antibodies in 53 paired serum – CSF samples resulting in a higher normalized 
antibody concentration in CSF, using an ELISA specific for the NR1 subunit of NMDAR. 
Irani et al. 5 found higher absolute anti-NMDAR titers in serum than in CSF examining 
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14 matched serum – CSF sample pairs, using a cell-based assay. One CSF sample was 
negative while all other samples clearly showed intrathecal synthesis of anti-NMDAR. In 
our cell-based assay, a negative serum test does not rule out NMDAR encephalitis and 
when suspected, CSF should be examined as well. 
Negative serum titers in the presence of persistent CSF titers apparently occur in the 
setting of prolonged duration of the illness and after plasma exchange or other forms 
of immunotherapy.13 In addition, CSF will almost always be abnormal and may show 
lymphocytic pleocytosis, oligoclonal banding and intrathecal IgG synthesis. EEG was 
abnormal in 100% of our patients and in 80-92% of patients in other series.4,5 In contrast, 
MRI was normal in our series in 60% similar do the series of Dalmau et al.4 (45%) and 
Irani et al.5 (77%). 
Antibodies from patients with NMDAR encephalitis cause a selective and reversible 
decrease in NDMAR surface density and synaptic localization in hippocampal slices 
and in Lewis rats 22 and suppress induction of long-term potentiation in cultured 
hippocampal neurons.23 In addition, the intensity of NR1 staining is strongly reduced 
in the hippocampus from patients with NMDAR-encephalitis as compared to control 
brain.22 These findings indicate that the anti-NMDAR antibodies may be pathogenic by 
disturbing glutamatergic neurotransmission. Indeed, the common psychotic symptoms 
in NMDAR-encephalitis followed by amnesia 24 and seizures resemble the memory 
impairment and psychosis caused by NMDA receptor antagonists such as ketamine25 or 
the recreational drug phencyclidine, also known as “angel dust”.26,27 Moreover, there is 
evidence that in the schizophrenia syndrome altered activity of the NMDA receptor on 
GABA interneurons in the prefrontal cortex plays a role.28
The efficacy of both classical and atypical antipsychotics and benzodiazepines alone or 
in combination was very limited in this patient population, as previously described.14,29 
As a result, the 13 patients treated with psychotropic medication received 1-4 different 
antipsychotics and 1-4 different benzodiazepines. The limited efficacy of psychotropic 
medication may be related to profound NMDA receptor downregulation by the 
antibodies. The most effective treatment of the psychiatric symptoms consisted of 
tumor removal (if present) and immunotherapy. Similarly, encephalitis related seizures 
are notoriously difficult to treat with antiepileptic drugs and respond much better to 
immunotherapy.30,31 In the literature, no guidelines exist on the psychiatric treatment 
of autoimmune encephalitis and conclusions are difficult to draw because of the 
concurrent use of other treatment modalities.14 Generally, psychiatric and behavioral 
symptoms respond best when the immune response is suppressed or reversed. 
Amelioration of problematic symptoms depended on early aggressive immunotherapy, 
removal of the underlying tumor and intensive care.8,14
In a third of our patients, the encephalitis was triggered by an underlying teratoma. 
In young women, ultrasound or MRI are generally preferred over CT for teratoma 
screening.2 The cause of the anti-NMDAR immune response in the patients who do 
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not harbor an underlying tumor is not clear. Prodromal symptoms, which may indicate 
a triggering viral infection, were reported by 27% of our patients. In other series, 
prodromal symptoms were found in 27% – 86%.1,4,5,8
In conclusion, autoimmune encephalitis should be considered in patients, especially 
young females, presenting with atypical psychiatric phenomena. The diagnosis is made 
by anti-NMDAR testing in blood and/or CSF and if blood testing is negative and the 
condition is strongly suspected, testing for antibodies in CSF should be done. With 
subsequent early treatment, the prognosis of NMDAR encephalitis is relatively favorable.
figure 1. Case vignette of a patient with NMDAR encephalitis. A 21 year old female college 
student (Table 1; 4th row) training to become a primary school teacher was presented to the 
emergency room (ER) of a general hospital because of an acute confusional state. She had always 
been healthy and had no psychiatric or medical history. That morning while teaching, she had 
become agitated and confused after a request for a vacation was denied. At the ER, her behaviour 
apparently normalized and she was sent home with her mother after she was seen by an internist, 
a neurologist, as well as a psychiatrist. No medication had been given. The next day, she made 
statements like ‘I have to speak more softly, then the children will listen better’ and ‘I have to 
jump off the balcony’ and was acutely admitted to the psychiatry department. We saw an agitated 
patient in a catatonic state who followed commands but did not answer questions. The patient’s 
mother in retrospect recalled that her daughter had a depressed mood for a period of about two 
weeks, prior to the admission. Furthermore, after the admission the mother visited her daughter’s 
house and found it covered with yellow post-it papers with unintelligible ‘to-do reminders’. 
The clinical state at admission was described as ‘atypical psychosis’, and the possible underlying 
syndromes listed in the patient’s file were: stress induced psychotic disorder, drug-induced 
psychotic disorder, schizophrenia, mood disorder/mania, ‘decompensation as part of developing 
personality disorder’ or ‘psycho-organic’ (encephalitis or non-convulsive epilepsy). Interestingly, 
these two latter options were explicitly written down at admission. Diagnoses were made by a 
senior resident after telephone consultation of the supervising psychiatrist. 
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Initial treatment with benzodiazepines and haloperidol was started. Because the patient was 
unresponsive, entered other patients’ rooms and showed generally disturbed behaviour, seclusion 
was needed from the first day on. Routine neurological examination showed no abnormalities. 
Routine laboratory measurements showed slightly elevated C-reactive protein (12 mg/l, normal 
range 0-9 mg/l) and leucocytes (10.9 x 109 cells/l, normal range 3-10 x 109 cells/l), but no other 
abnormalities. Anti-NMDA receptor antibodies were not measured at the time. 
Over the next few days a clinical state emerged in which the patient was at times responsive 
(although with some slurred speech), but at other times nonresponsive, with inappropriate 
laughing or crying and unusual movements. Diagnosis was now: ‘catatonic psychosis’, possibly 
mania, and haloperidol treatment was changed to olanzapine. A neurologist was consulted who 
found no focal neurological deficits and no abnormalities on a CT-scan of the brain. Encephalitis or 
non-convulsive epilepsy was possible, but deemed very unlikely.  
Psychiatric examination after 6 days of admission read: in seclusion chamber; limitedly adequate 
and generally unresponsive; doesn’t know where she is; somnolent; slightly slurred speech; 
disorientated in all modalities; disorders of formal thought: loose words and remarks, thought 
content: fragmented ideas; mood: slightly anxious.
As the patient did not react to the medication regime, and psychoactive medication might cloud 
the clinical picture, olanzapine and benzodiazepine were stopped 6 days after admission.  
The patient continued to clinically deteriorate. Consciousness became increasingly often clouded. 
Agitated behaviour and responsiveness became absent. After 12 days on the psychiatry department 
there was no reaction to painful stimuli but she actively resisted attempts at opening her eyes. 
Because of decreased consciousness and general nonresponsiveness, she was transferred to the 
neurology ward and shortly after to the intensive care unit (ICU) where she was intubated because 
of central hypoventilation. 
Differential diagnosis now included (paraneoplastic) limbic and viral encephalitis. MRI of the brain 
showed medial temporal lobe (A, arrows) and insula (A, arrowheads) hyperintensities in fluid-
attenuated inversion recovery (FLAIR) images. A CT-scan of the abdomen showed a 2.5 by 2.3 cm 
left ovarian lesion (B, arrow). EEG showed a slow background pattern without epileptic phenomena. 
In the CSF there was a pleocytosis with 33 WBC/μl (normal <5 WBC/μl), mainly mononuclear cells. 
The main differential diagnosis of the pleocytosis was viral meningo-encephalitis or an immune-
mediated disorder. PCR for HSV and other neurotropic viruses was negative. 
The left ovary was subsequently excised and pathology showed a mature teratoma with neuronal 
tissue expressing the NR1 subunit of the NMDA receptor (C, red signal: AP-labeled anti-NR1 
antibody; 400x). The patient’s serum and CSF were tested for autoantibodies against the NR1 
subunit of NMDAR. HEK 293 cells were transfected with an YFP tagged construct containing the 
NR1 subunit; NR1 expressing cells become green fluorescent (D). Incubation of these transfected 
cells with the patient’s CSF followed by incubation with Cy3 labelled anti-human IgG secondary 
antibody showed red labelling of transfected cells only (E). Colocalization of the green and red 
signals to yellow was shown more clearly in F. 
During her stay at the ICU, she developed mild orofacial dyskinesias and athetoid movements in the 
left arm. She was subsequently treated with plasma exchanges and steroids. Her condition slowly 
improved and she was discharged from the ICU after four weeks. She fully recovered over the next 
6 months and started working as a primary school teacher one year after onset of symptoms.
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suPPleMenTARy dATA
Table s1. Initial referral and predominant initial symptoms in 15 patients with NMDAR 
encephalitis
Sex Age Delay (mo)a Initial referral to: Psychiatric symptomsb neurological symptomsb
M 18 4.2 Psychiatryc Paranoid delusions Central hypoventilation
 (ICU admission)
F 20 10.2 Psychiatry Auditory and visual 
hallucinations and delusions 
(initial diagnosis of pyschosis/
schizophrenia was made)
Epileptic seizures
F 17 2.5 Psychiatry Anxiety, ‘psychosis’, 
behavioral changes and 
catatonia
Epileptic seizures 
(after approx. 3 weeks)
F 21 0.8 Psychiatry (transfer 
to neurology after 
10 days)
Bizarre behavioral changes 
and delusions
(‘delirium-like organic 
syndrome’) 
Impaired  consciousness
F 56 1.7 Psychiatryd Auditory hallucinations, 
depressed mood, episodes 
of anxiety and severe 
agitation combined with 
bizarre behavior
Short-term memory 
impediments
Autonomic instability 
(hypothermia, hypotension, 
bradycardia) developed 
after 4 weeks, requiring ICU 
admission
F 18 1.3 Psychiatrye Acute panic attacks, strange 
movements of limbs and 
body and bizarre behavior 
Headache and nausea
F 50 1.1 Psychiatry (transfer 
to neurology after 
3 days)
Depressed mood, agitation 
and catatonia
Impaired consciousness
F 32 0.8 Psychiatry Panic attacks, severe 
agitation and derealization
Epileptic seizures
F 18 99.6 Neurology and 
psychiatryf
Catatonia, severe agitation 
and aggression, speech 
impediments (‘disorganized 
speech’)
Epileptic seizures
F 22 48.7 Neurologyg Anxiety, delusions, severe 
agitation and change in 
personality
Headache 
Impaired consciousness
F 19 2.9 Neurology Hallucinations and bizarre 
behavior developed over two 
weeks time
Epileptic seizures
F 5 1.5 Pediatric neurology Altered mood and agitation Epileptic seizures
M 8 0.8 Pediatric neurology Anxiety and behavioral 
changes
Speech disturbances
F 19 0.6 Neurology None mentioned Nausea, collapse, fever 
and dyskinesias 
F 34 0.4 Neurologyh Anxiety and altered and 
disorganized behavior 
Speech disturbances 
aDelay between onset of symptoms and final diagnosis
bSymptoms in normal fond emerged first; symptoms in italics developed later. 
cThis patient was diagnosed with epilepsy five years earlier. Initially the paranoid delusions were interpreted as 
arising from a separate (psychiatric) disorder.
dGeneral practioner referred the patient to the emergency department. The consulting neurologist and 
psychiatrist made a diagnosis of ‘mood disorder’, and the patient was subsequently admitted to a psychiatry 
department. 
eHeadache and nausea were present from the start of the episode. Neurological origin was however only 
considered as a likely cause after 4 weeks, based on  EEG alterations.
fThis patient was initially referred to neurology. Psychiatric consultation initially  focused on the management 
of agitation. Later, due to the absence of prominent biological alterations, the patient was transferred to a 
psychiatry department, and primarily psychiatric diagnoses and causes were considered. Finally a diagnosis of 
both epilepsy and personality disorder was made. A final diagnosis of NMDAR encephalitis was made 8 years 
later, after a psychiatric readmission for ‘post-epileptic psychosis’.
gPatient was first referred to neurology and viral meningitis was diagnosed based on symptoms and mild 
lymphocytic pleiocytosis in CSF. After 8 days transfer followed to psychiatry because of ‘psychotic decompensation’. 
Three days later she became increasingly unresponsive and was transferred to a neuro-ICU.
hNeurologists consulted psychiatrist because no obvious biological alterations (lab, MRI, EEG) could be found; 
psychiatrist diagnosed ‘organic syndrome’.
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AbsTRACT
ObJeCTIVe
To determine the clinical features and presence in CSF of antineuronal antibodies in 
patients with pathologically proven autoimmune encephalitis derived from a cohort of 
patients with suspected CJD.
MeThOds 
The Dutch Surveillance Centre for Prion Diseases (DSCPD) performed 384 autopsies on 
patients with suspected CJD over a 14-year period (1998 – 2011). Clinical information 
was collected from treating physicians.  Antineuronal antibodies were tested in CSF 
obtained postmortem by immunohistochemistry on fresh frozen rat brain sections; by 
Luminex assay for the presence of well characterized onconeural antibodies; and by cell 
based assays for antibodies against NMDAR, GABABR1/2,GABAAR GLUR1/2, LGI1, Caspr2 
and DPPX.
ResulTs
In 203 patients a diagnosis of definite CJD was made while in 181 a variety of other 
conditions was diagnosed, mainly neurodegenerative. In 22 of these 181 the 
neuropathologist diagnosed autoimmune encephalitis. One patient was excluded 
because of lack of clinical information. Inflammatory infiltrates were predominantly 
perivascular and consisted mainly of T cells. The predominant locations were basal 
ganglia and thalamus (90%) and temporal lobes and hippocampus (81%). In 6 patients 
(29%) antineuronal antibodies were detected in postmortem CSF, directed against Hu, 
NMDAR, GABABR1/2, Caspr2 and an unidentified synaptic antigen in two. The most 
frequent symptoms were dementia (90%), gait disturbance (86%), cerebellar signs (67%) 
and neuropsychiatric symptoms (67%). Immunopathological and clinical findings did 
not differ between autoantibody negative patients and the patients with antineuronal 
antibodies.
COnClusIOns
It is important to consider immune-mediated disorders in the differential diagnosis of 
rapidly progressive neurological deficits.
Key words: autoimmune encephalitis, Creutzfeldt-Jakob disease, paraneoplastic 
neurological syndrome, NMDAR, Caspr2, GABABR
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InTROduCTIOn
Autoimmune encephalitis and sporadic Creutzfeldt-Jakob disease (sCJD) may present 
with similar clinical, radiological, electrophysiological and laboratory findings.1-4 In 
sCJD, the course of disease is fatal while autoimmune encephalitis associated with 
antibodies directed against neuronal surface antigens (NSA-Abs) usually responds well 
to treatment.5,6 
We encountered several patients with rapidly progressive dementia diagnosed as 
possible or probable sCJD, who at autopsy at the Dutch Surveillance Centre for Prion 
Diseases (DSCPD) turned out to have suffered from potentially treatable autoimmune 
encephalitis. We retrospectively reviewed all prion-negative autopsy brain reports 
from the DSCPD to determine the number of pathologically confirmed cases of 
autoimmune encephalitis in a cohort of patients with suspected sCJD. In addition, we 
determined the clinical, radiological and neurophysiological characteristics of patients 
with pathologically confirmed autoimmune encephalitis and examined the CSF for the 
presence of antineuronal autoantibodies. 
MeThOds
Patients
The Dutch Surveillance Centre for Prion Diseases (DSCPD) performed 384 autopsies 
on patients with suspected CJD over a 14-year period (1998 – 2011).7 At brain autopsy, 
definite CJD was diagnosed in 203 patients based on the presence of spongiosis and 
positive prion staining. In 181 patients, neuropathology showed a variety of other 
conditions, mainly neurodegenerative disorders. In 22 patients the pathologist identified 
inflammatory infiltrates consistent with a diagnosis of autoimmune encephalitis. Of 
these 22 patients, we collected clinical information from treating physicians, including 
discharge notes, laboratory, neurophysiology and radiology results. One patient lacked 
sufficient clinical information and was excluded from the study. 
Based on the clinical information, the 21 patients with pathologically proven autoimmune 
encephalitis were retrospectively classified as probable, possible or no CJD according to 
CDC’s Diagnostic Criteria for Creutzfeldt-Jakob Disease, 2010
(http://www.cdc.gov/ncidod/dvrd/cjd/resources/CDCs_Diagnostic_Criteria_for_CJD-
2010.pdf).
Local ethical committee approval was obtained for research on retained tissues after 
written informed consent was given by the patients during life or their next of kin after 
death (Medical Ethics Committee of the University Medical Centre Utrecht 11-531/C). All 
information was analyzed anonymously.
Antineuronal antibody testing
Post-mortem derived CSF samples from all cases were stored at -800C until testing. 
As sampling was done post-mortem, no serum samples were available at the DSCPD. 
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All CSF samples were tested for autoimmune encephalitis associated antineuronal 
antibodies in several assays at a dilution of 1:2. CSF samples were tested on fresh 
frozen rat brain sections for auto-antibodies against neuronal cell surface antigens, as 
previously described.8 Antibodies against the onconeural antigens HuD, CDR62 (Yo), Tr 
(DNER), amphiphysin, CRMP-5 (CV2), NOVA-1 (Ri), Ma1/2 and Zic4 were assayed, using 
another immunohistochemistry protocol9 combined with a recently described multiplex 
bead-based assay.10 In addition, CSF samples were tested on cultured hippocampal 
neurons and on HeLa cells overexpressing NMDAR1, GABABR1/2, GABAAR, GLUR1/2 and 
DPPX as previously described.11,12 Finally, samples were tested in a commercial assay 
(EUROIMMUN, Lübeck, Germany) for anti-LGI1 and anti-Caspr2 antibodies (previously 
tested as VGKC-complex antibodies). The sensitive assays on frozen rat brain sections 
and cultured hippocampal neurons detect clinically relevant (high titer) GAD65 and 
LGI1 antibodies in CSF, precluding under reporting of antibodies by the lack of serum 
availability. 
Neuropathology
Brains were removed at autopsy and selected tissue samples were immediately 
frozen and stored at -800C while the rest of the brain was fixed in formalin and used 
for histological and immunological purposes. Histopathological examination was 
performed as described before.7,13 In short, relevant sections were stained for alpha-
synuclein, ubiquitin, amyloid beta and tau in all patients. In a subset of patients 
additional immune stainings were carried out for B cells (CD20), T cells (CD3, CD4 and 
CD8) and macrophages (CD68).
ResulTs
Pathology consistent with autoimmune encephalitis was found at autopsy in 22 out of 
384 (6%) patients with clinically suspected CJD, constituting 12% (22/181) of the patients 
who turned out at autopsy not to have suffered CJD. Because one patient lacked 
sufficient clinical information, we present here the clinical, pathological and serological 
findings in 21 patients with pathologically confirmed autoimmune encephalitis. Detailed 
information on the patients is summarized in Tables S1 and S2.
Neuropathology
In all 21 patients inflammatory infiltrates were present (Fig. S1). Gliosis was observed in 
10 (48%) patients while vasculitis was seen in none. The infiltrates were predominantly 
perivascular in 15 (71%), predominantly parenchymal in 5 (24%) and both perivascular 
and parenchymal in one (5%) patient. The infiltrates consisted of CD3 positive T cells in 
14/15 (93%) of patients tested. CD8 positive cells were observed in 7/8 (88%) and CD4 
positive cells in 4/5 (80%) of patients examined. In 8/12 (67%) of patients CD20 positive 
B cells were present, mainly in the perivascular infiltrates. CD68 positive cells were seen 
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in 11/13 (85%) of patients.
Infiltrates were mainly located in the basal ganglia and thalamus 19 (90%), temporal 
lobes and hippocampus 17 (81%), cerebellum 12 (57%), frontal lobes 11 (52%), other 
cortical areas 12 (57%), brainstem 7 (33%) and periventricular white matter 4 (19%). 
Neuropathological changes were far more extensive than MRI changes. 
Postmortem CSF testing for antineuronal antibodies
Antineuronal antibodies were detected in 6/21 (29%) of the postmortem collected CSF 
samples. Five of these antibodies were directed against NSA. One each was directed 
against GABAB1/B2, NMDAR and Caspr2 whilst two CSF samples harbored antibodies 
against an unidentified synaptic antigen (Figure 1). One additional sample contained 
antibodies against the intracellular onconeural Hu antigen. Of the four known 
antibodies detected in CSF, the Hu antibody had been described long before the time of 
the patient’s illness while GABAB1/B2, NMDAR and Caspr2 antibodies were first reported 
after the death of the respective patients. Three of the six patients with antineuronal 
antibodies presented with limbic encephalitis, two with encephalomyelitis and one 
with Morvan syndrome (associated with anti-Caspr2 antibodies). Further clinical 
findings in the six patients with pathologically confirmed autoimmune encephalitis and 
antineuronal antibodies are summarized in Table 1 and supplementary information (1). 
The phenotypes associated with the known antibodies are classical for these disorders. 
The localization and cellular composition of the inflammatory infiltrates found at 
autopsy did not differ between the antibody positive and negative patients (Table S3). 
Summarizing, 5/21 (24%) patients with pathologically confirmed autoimmune 
encephalitis had CSF autoantibodies directed against NSA (three against well-defined 
and two against unknown antigens). 
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figure 1. Unidentified synaptic antigen in CSF of two patients with autoimmune encephalitis.
In two patients a synaptic staining pattern in the hippocampus was observed not 
corresponding to any of the known antigens tested. One patient was a 73 year old male with 
limbic encephalitis (A,B; patient #11) and the other a 77 year old male with encephalomyelitis 
(C, D; patient #18). Immunohistochemistry was performed as described in the method 
section (A, C). To confirm the synaptic staining pattern in these two patients, CSF samples 
were incubated (1:2 dilution) live with primary hippocampal cultures (B, D) as previously 
described. 12
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Table 2. Clinical characteristics in 21 patients with autoimmune encephalitis and 
suspected CJD
Characteristic
All 
(n=21)
CSF antibody 
positive (n=6)
No CSF antibody
 (n=15)
Male / female 15 / 6 4 / 2 11 / 4
Median age (years) at onset (range) 72 (37 – 82) 70 (50 – 77) 72 (37 - 82)
Mean age at onset (years) 68 67 69
Median disease duration (months, range) 3.3 (1.0 – 12.3) 4.4 (1.3 – 12.3) 3.3 (1.0 – 11.5)
Mean disease duration 4.2 4.4 4.2
Diagnosis according to CDC criteria (2010) for sCJD:
      Probable
      Possible
      No
8 (38%)
6 (29%)
7 (33%)
1 (17%)
3 (50%)
2 (33%)
7 (47%)
3 (20%)
5 (33%)
Table 3. Symptoms in 21 patients with autoimmune encephalitis and suspected CJD 
All CSF antibody positive No CSF antibody
Main symptoms N N N
Dementia 19 (90%) 6 (100%) 13 (87%)
Cerebellar signs 14 (67%) 3 (50%) 11 (73%)
Myoclonus 10 (48%) 4 (67%) 6 (40%)
Extrapyramidal signs 7 (33%) 2 (33%) 4 (27%)
Akinetic mutism 5 (24%) 1 (17%) 4 (27%)
Pyramidal signs 5 (24%) 1 (17%) 4 (27%)
Visual symptoms 2 (10%) 1 (17%) 1 (7%)
Other symptoms N N N
Gait disturbance 18 (86%) 5 (83%) 13 (87%)
Neuropsychiatric 14 (67%) 5 (83%) 9 (60%)
  Apathy/social withdrawal 8 (38%) 2 (33%) 6 (40%)
  Agitation/anxiety 9 (43%) 4 (67%) 5 (33%)
  Hallucinations 5 (24%) 3 (50%) 2 (13%)
Disorder of frontal brain* 13 (62%) 5 (83%) 8 (53%)
Epilepsy 7 (33%) 5 (83%) 2 (13%)
Aphasia 6 (29%) 2 (33%) 4 (27%)
Autonomic dysfunction 4 (19%) 1 (17%) 3 (20%)
Central hypoventilation 2 (10%) 0 2 (13%)
*Including bradyphrenia, perseveration, utilization, echolalia, disinhibition
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Clinical characteristics
All 21 patients with autoimmune encephalitis suffered from a rapidly progressive illness 
with a median duration of 3.3 months and died within 13 months of first symptoms (Table 
2 and Tables S1-2). In retrospect, 14 of the 21 (67%) autoimmune encephalitis patients 
fulfilled the clinical 2010 CDC criteria for possible or probable sCJD while seven (33%) did 
not. In the subgroup of six patients with antineuronal antibody associated autoimmune 
encephalitis, also 67% (four patients) fulfilled CDC criteria for possible or probable sCJD 
(Table 2). The most frequent main symptoms included dementia (90%), cerebellar signs 
(67%), myoclonus (48%) and extrapyramidal signs (33%) (Table 3). Other symptoms that 
were frequently present included gait disturbance (86%), neuropsychiatric (67%) and 
frontal lobe symptoms (62%). There were no clear differences in clinical presentation 
of autoimmune encephalitis with or without detectable antineuronal antibodies in CSF 
(Table S5). Only four patients received immunotherapy consisting of steroids in two, 
intravenous immunoglobulins (ivIg) in one and both ivIg and steroids in one. None of 
the patients showed substantial improvement and immunotherapy was discontinued 
in all four.
Additional investigations
The CSF had been examined in 18 of the 21 patients and was abnormal in 14/18 (78%) 
showing increased protein in 14 (78%) pleiocytosis in 10 (56%) and positive 14-3-3 
protein in 9 (50%) (Table 4A).
EEG was performed at least once in 19 of the patients and was abnormal in 18/19 (95%) 
with an increase of slow wave activities in 15/19 (79%). Seven of the patients showed 
triphasic periodic complexes that were considered compatible with CJD in 6 (32%). 
Epileptiform abnormalities were registered in 7 (37%) of the patients (Table 4B). 
MRI was abnormal in 10/17 (59%) of patients, showing increased signal on T2 weighted 
or FLAIR images (Table 4C). Imaging abnormalities were located in the medial temporal 
lobes in 3, periventricular in 5 (most likely vascular lesions in 3), basal ganglia and 
thalamus in 2 and brainstem in 1. None of the patients had MRI changes typical of sCJD, 
according to 2010 CDC criteria, although most investigations lacked DWI sequences.
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Table 4A. CSF findings in 18/21 patients with autoimmune encephalitis
All Csf antibody positive no Csf antibody
CSF sampled (N/N) 18 / 21 6 / 6 12 / 15
Protein or cell count: N N N
Abnormal 14 (78%) 4 (67%) 10 (83%)
Normal 2 (11%) 0 2 (17%)
Not known 2 (11%) 2 (33%) 0
White cell count:
Median (x10E9/L; range) 12 (0-47) 16 (8-47) 11 (0-33)
Increased (>5x10E9/L) 10 (56%) 4 (67%) 6 (50%)
Normal 4 (22%) 0 4 (33%)
Not known 4 (22%) 2 (33%) 2 (17%)
14-3-3 protein
Positive 9 (50%) 2 (33%) 7 (58%)
Negative 5 (28%) 3 (50%) 2 (17%)
Not tested 4 (22%) 1 (17%) 3 (25%)
Table 4b. EEG in 19/21 patients with autoimmune encephalitis
All Csf antibody positive no Csf antibody
EEG performed (N/N) 19 / 21 6 / 6 13 / 15
EEG overall abnormal 18 (95%) 5 (83%) 13 (100%)
Increase in slow wave activities 15 (79%) 4 (67%) 11 (85%)
Triphasic periodic complexes 7 (37%) 3 (50%) 4 (31%)
    Complexes compatible with CJD 6 (32%) 2 (33%) 4 (31%)
Table 4C. MRI findings in 17/21 patients with autoimmune encephalitis
All Csf antibody positive no Csf antibody
MRI performed (N/N) 17 / 21 6 / 6 11 / 15
MRI overall
Abnormal 10 (59%) 4 (67%) 6 (55%)
Normal 7 (41%) 2 (33%) 5 (45%)
T2/FLAIR increased signal
Yes 10 (59%) 4 (67%) 6 (55%)
No 7 (41%) 2 (33%) 5 (45%)
Gadolineum enhancement
Yes 0
No 17 (100%)
133
Path
o
lo
g
ically co
n
firm
ed
 au
to
im
m
u
n
e en
cePh
alitis in
 su
sPected
 creu
tzfeld
t-Jako
b d
isease
7
The autoimmune encephalitis patients with antineuronal autoantibodies in their CSF 
did not clearly differ from the antibody negative patients in CSF, EEG and MRI findings 
(Table 4A-C).
Areas with increased T2/FLAIR signal included periventricular white matter (5), 
mesiotemporal lobe and hippocampus (3), brainstem (3), basal ganglia and thalamus 
(2), cortex (2) and internal capsule (1). Generalized atrophy was present in five patients, 
bifrontal atrophy in two, and hippocampal atrophy in one patient.
Associated tumors
In nine patients (43%) a tumor was present. Based on criteria published by an EU 
consortium, the etiology of the neurological syndrome could be classified as definitely 
paraneoplastic in five and possibly paraneoplastic in two.14 The tumor was probably 
unrelated in two of the patients precluding a paraneoplastic etiology. Detailed clinical 
and oncological findings are presented in supplementary Table S2 and supplementary 
information (2). 
dIsCussIOn
The first main finding of this study is that approximately 7% of patients with suspected 
CJD have autoimmune encephalitis at autopsy. Secondly, antineuronal autoantibodies 
could be demonstrated in the CSF from six of 21 (29%) patients with pathologically 
confirmed autoimmune encephalitis. One case each of anti-Hu, GABAB1/B2, NMDAR, 
Caspr2 was detected, while two CSF samples had antibodies against an unidentified 
NSA. Thirdly, in retrospect 67% of the patients fulfilled the 2010 CDC criteria for probable 
or possible CJD, both in the antibody positive and negative group. 
Several other studies have addressed the clinical overlap between prion disorders 
and autoimmune encephalitis. Chitravas et al.3 performed a retrospective clinical 
and neuropathological review of prion-negative brain autopsy cases referred to the 
US National Prion Disease Pathology Surveillance Center. Neuropathology diagnosed 
an immune-mediated disorder in 26/304 (8.5%) of the prion-negative cases with 
histology, including primary angiitis of the CNS (7), ADEM (6), limbic encephalitis (6), 
neurosarcoidosis (4), paraneoplastic cerebellar degeneration (2) and granulomatosis 
with polyangiitis (Wegener’s) (1). This study did not report the antineuronal antibody 
status of the patients. In contrast to our study, most of the misdiagnosed patients did 
not fulfill WHO criteria for CJD. 
Grau-Rivera et al.1 examined the frequency of NSA-Abs in the CSF of patients with 
suspected or pathologically confirmed CJD. NSA-abs were detected in 6 of 346 patients 
(1.7%) with rapid neurologic deterioration suggestive of CJD during life. In contrast to our 
study, none of these 6 patients fulfilled the diagnostic criteria for probable or possible 
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CJD. The target antigens included Caspr2, LGI1, NMDAR, aquaporin 4, Tr (DNER), and an 
unknown protein. All patients improved or stabilized after appropriate treatment. None 
of the 49 patients with definite CJD had NSA-abs. Another study reported serum NSA-
Abs in <5% of patients with sCJD, all at very low titers.2  Our study is the first to test CSF 
of all patients identified with autoimmune encephalitis at autopsy. CSF is proven more 
sensitive and specific to detect NSA-Abs as shown for NMDR,15 AMPAR,16 and GABABR.
17 
In 50% of our patients with autoimmune encephalitis tested, the CSF 14-3-3 protein 
was elevated (part of the CDC’s 2010 diagnostic criteria) casting further doubt on the 
utility of this test in the diagnosis of CJD.18  EEG was also not very useful as triphasic 
waves were present in 32% of our autoimmune patients. None of our autoimmune 
encephalitis patients showed sCJD specific MRI abnormalities, supporting the higher 
specificity of sCJD MRI criteria over 14-3-3.18,19 However, DWI was not performed in most 
of our patients and we do not know whether DWI would have retained its specificity in 
this series. On the other hand, 56% of patients had an increased WBC count (>5x10E9/L) 
in their CSF. Although the pleiocytosis was usually mild it does provide a clue to an 
extensive search into an inflammatory etiology.
Other studies describing clinical overlap between prion and autoimmune disorders 
focused primarily on rapidly progressive dementia, detecting a 2% to 9% prevalence of 
immune-mediated CNS disorders.20-22 In a series of patients with suspected autoimmune 
dementia and good response to immunotherapy, almost 9% of the disorders had 
initially been diagnosed as sCJD.23 In particular, patients with encephalitis associated 
with LGI1-Abs may present with myoclonus-like movements and other symptoms that 
can be mistaken for CJD.4 
In general, the prognosis of autoimmune encephalitis appears to be determined by 
the involved immunopathogenic mechanisms.24 Disorders associated with antibodies 
directed against intracellular antigens are probably T cell mediated and respond poorly 
to immunotherapy. Most paraneoplastic neurological disorders with onconeural 
antibodies belong to this category. On the other hand, in disorders associated with NSA-
Abs, the antibodies are probably pathogenic and these disorders respond favorably 
to first and second line immunotherapy. Examples include NMDAR,5 LGI125,26 and 
Caspr226,27 encephalitis. The immunopathology of NSA-Abs associated encephalitis 
shows mild to moderate, mainly perivascular, lymphocytic infiltrations containing both 
B and T cells, antibody producing cells and IgG deposits.28-30 It is possible that we missed 
some cases with ‘burned out’ or with very bland neuropathology and the 22 cases that 
we identified represent an underestimation. The encephalitis associated with anti-Hu 
or Ma2 antibodies is characterized by extensive B and T cell lymphocytic infiltrations, 
containing T cells expressing markers of cytotoxicity such as TIA-1, granzyme B, perforin 
and Fas/Fas-ligand.30-32 In our series, immunopathological findings did not differ 
between autoantibody negative patients and the patients with NSA-Ab (Table S3), nor 
did clinical, CSF, radiological or electrophysiological characteristics (Tables S4-S8). The 
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immunopathological mechanism in the 15 autoimmune encephalitis patients without 
detectable autoantibodies remains unclear. It cannot be excluded that some of these 
patients harbored NSA-Abs that were degraded by postmortem interval or during 
storage at -800C in low protein CSF.
Obviously all limitations based on the retrospective nature of the study are applicable. 
In addition, bias was introduced by the fact that all patients had ‘suspected CJD’ and had 
come to autopsy. In particular the poor outcome of the patients with a median survival 
of 3.3 months (range 1.0 – 12.3 months) in this study of autoimmune encephalitis was 
largely determined by this inclusion bias. 
In conclusion, it is important to consider both prion and immune-mediated disorders 
in the differential diagnosis of rapidly progressive neurological deficits, knowing that 
EEG and 14-3-3 in CSF do not discriminate sufficiently to distinguish the two. Detection 
of specific antineuronal antibodies in serum and/or CSF can establish a diagnosis of 
autoimmune encephalitis and guide appropriate treatment.
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suPPleMenTARy dATA
SuPPlemeNTary INFormaTIoN (1)
PATIenTs wITh AnTIneuROnAl AuTOAnTIbOdIes In Csf OR seRuM
PATIenT 6, AnTI-hu
A 74-year old man was admitted to the hospital because of a progressive gait disturbance 
with orthostatic hypotension followed by rapidly progressive dementia, pyramidal and 
cerebellar signs, myoclonus and focal epileptic seizures. 
Brain MRI showed generalized atrophy, periventricular leuko-araiosis and multiple 
lacunar lesions. EEG showed epileptiform activity, slowing and triphasic periodic 
complexes. CSF showed moderately elevated 14-3-3 protein. Paraneoplastic antibody 
testing showed anti-Hu and anti-Zic4 antibodies in serum (test result came in after the 
patient had died). Despite an extensive search, no tumor was detected. 
The patient developed pneumonia and died 2.6 months after presentation. At autopsy 
a 3 cm tumor was found in the apex of the lower lobe of the right lung. Microscopy 
showed limbic encephalitis and ganglionitis of the gut. The tumor was SCLC.
Comment
The patient presented with rapidly progressive symptoms indicating involvement 
of many different areas of the nervous system, consistent with paraneoplastic 
encephalomyelitis. A paraneoplastic etiology was confirmed by detection of a lung 
tumor at autopsy and the presence of anti-Hu antibodies. Moderately increased 14-3-3 
protein has been reported in many rapidly progressive disorders with neuronal loss, 
including anti-Hu associated limbic encephalitis. 33
PATIenT 15, AnTI-gAbAB1/2
A 70-year old woman was admitted to the hospital after a single vehicle accident, probably 
caused by an epileptic seizure. On neurological examination she was disoriented without 
focal signs. During admission, her behavior became increasingly childish and frontal 
(e.g. disinhibition while eating). She developed hallucinations and delusions followed by 
episodes of obtundation. The family suggested that in the 1-2 months before admission 
she was more irritable, aggressive and sometimes disinhibited.
Brain MRI was normal while EEG showed left temporal epileptiform activity. CSF analysis 
showed normal protein, 14 WBC, IgG-G index 1.12. PCR for neurotropic viruses and 
Borrelia serology were negative. 
She died one week after admission. Autopsy (brain only) showed lymphocytic perivascular 
infiltrates and microgliosis in the frontal and temporal lobes and hippocampus (Fig. S1).
Comment
A subacute onset with seizures, confusion and behavioral problems is typical of 
autoimmune encephalitis associated with antibodies against the GABAB receptor.
34 In 
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approximately 50% of the patients an underlying tumor, usually SCLC, can be detected. 
The majority of patients have an abnormal MRI and improve after immunotherapy and 
tumor treatment (if a tumor is found). In this patient the MRI was normal, although 
the diagnostic value was limited by movement artefacts. No tumor search had been 
performed and no treatment had been started, mainly due to lack of diagnosis. 
PATIenT 17, AnTI-nMdAR
A 49-year old woman was admitted to a psychiatric hospital because of apathy and 
catatonia. Six months earlier, her husband had first noted that she was more irritable. 
A month before admission she became more emotional, complained of headache 
and photophobia and working on a computer became difficult to impossible. A few 
days before admission her behavior became chaotic. Hyperactivity (e.g. washing) and 
moments of complete apathy alternated. She could hardly stand or walk. At nights 
there was dystonic positioning and twisting movements of her hands. On examination 
she lay in bed with her eyes opened, did not follow commands and did not speak 
(E4M4V1). There were no focal signs. Myoclonic jerks were observed in her face, around 
her mouth and left hand. After 3 days she was transferred to a general hospital because 
of decreased consciousness, admitted to the ICU and intubated. 
Brain MRI was normal and EEG showed multifocal status epilepticus. CSF analysis 
showed 47 WBC with normal protein and glucose. She developed treatment resistant 
multifocal status epilepticus requiring multiple inductions of phenobarbital coma. On 
suspicion of limbic encephalitis, she was treated with methylprednisolone (1000 mg/d, 
during 3 days), prednisone (60 mg/d oral) and IVIG without improvement. Just before 
the patient’s admission, a series of young women presenting with prominent psychiatric 
symptoms, seizures, memory deficits, and decreased level of consciousness associated 
with ovarian teratomas had been published. 35 Therefore, both ovaries were removed, 
but no teratoma was found at pathological examination. 
She never regained consciousness and died 5 months after ICU admission. Autopsy 
showed perivascular lymphocytic infiltrations in centrum semiovale, basal ganglia and 
hippocampus.
Comment
The clinical picture is typical of anti-NMDAR encephalitis and with current knowledge 
the patient would have been treated with second line immunotherapy (e.g. rituximab 
and/or cyclophosphamide).5
PATIenT 21, AnTI-CAsPR2
A 55-year old man developed over three months progressive compulsive behavior, 
ataxia, dysarthria, insomnia and extrapyramidal signs. 
Brain MRI showed increased signal on T2 weighted images in both medial temporal 
lobes. CSF showed normal concentration of 14-3-3 protein.
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After choking on a piece of bread he was found without pulse and was resuscitated. In 
the ICU he developed multiple organ failure, persistent status epilepticus and ultimately 
became asystolic and died 3.3 months after onset. Autopsy demonstrated extensive 
hypoxic changes in the cerebral cortex and loss of cerebellar Purkinje cells. Additional 
staining showed extensive lymphocytic infiltrates. 
Comment
The clinical presentation with neuropsychiatric symptoms, ataxia and insomnia is 
consistent with anti-Caspr2 associated Morvan syndrome.30,36
PATIenT 18, synAPTIC 
A 77-year old man was admitted with rapidly progressive cognitive deterioriation. 
Symptoms started with hallucinations and delusions followed by unsteady gait, trouble 
finding and understanding words, urinary incontinence and fluctuating levels of 
consciousness. On examination he was anxious and agitated while showing disinhibited 
behaviour. He showed dressing apraxia, perseveration, utilisation behaviour and 
echolalia. He had second degree nystagmus, gait ataxia, sporadic myoclonus and 
positive frontal release signs. 
MRI showed aspecific probably vascular white matter lesions and mild hippocampus 
atrophy (Scheltens grade II). The CSF showed 18 WBC/ml (95% lymphocytes), total 
protein 0.7 g/l (mildly elevated), normal tau and negative 14-3-3 protein, positive 
oligoclonal bands (more than in serum). Negative cytology.
EEG showed increase of slow wave activities and appearance of triphasic periodic 
complexes.
During admission his condition rapidly worsened with increasing anxiety, agitation 
and myoclonus. He died approximately 5 weeks after onset of symptoms. At autopsy 
perivascular inflammatory infiltrates consisting of B and T cells were noted in 
hippocampus and basal ganglia with local infiltration of the parenchyma (also consisting 
of B and T cells) (Fig. S1).
Comment
The patient fulfilled the criteria of probable CJD (see Methods) and did not receive 
immunotherapy.  Autopsy showed typical autoimmune or paraneoplastic encephalitis. 
The unspecified synaptic antibody detected in CSF collected postmortem (Fig. S2) may 
have contributed to the pathogenesis.
PATIenT 11, synAPTIC
A 73-year old male patient presented with confusion and auditory hallucinations. Later 
he developed seizures. On examination he was disinhibited, the MMSE was 22 out of 30 
and myoclonus was observed. 
MRI showed increased T2 signal in the left hippocampus. CSF showed a mononuclear 
pleiocytosis of 8 cell/l, elevated tau and positive 14-3-3 protein. PCR for neurotropic 
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viruses was negative as was anti-viral serology. EEG was normal.
The patient died of aspiration pneumonia, 4.7 months after onset of symptoms. Autopsy 
showed perivascular B and T cells mainly in the basal ganglia and hippocampus. In 
addition, in the basal ganglia intraparenchymal T cells were observed. CD68 positive 
macrophages were present in affected  areas with perivascular and intraparenchymal 
distribution.
Comment
The patient did not receive immunotherapy; the unspecified synaptic antibody detected 
in CSF collected postmortem (Fig. S2) may have contributed to the pathogenesis.
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SuPPlemeNTary INFormaTIoN (2)
Nine patients with a tumor
In two patients (#3 and #4) the tumor was unrelated. A 75 year-old man had a curative 
resection of colorectal cancer 14 years before onset of encephalomyelitis symptoms; and 
a 52 year-old man was treated 3 years before onset of symptoms of encephalomyelitis 
with a curative lobectomy for T2N0M0 NSCLC. CT-scan of the thorax and autopsy did 
not show tumor recurrence.
In seven patients the tumor or its recurrence was within 5 years of the onset of a 
classical paraneoplastic syndrome or within 2 years of onset of a non-classical syndrome 
suggesting an etiological link between the tumor and the autoimmune encephalitis.14
 A 78 year-old man (#2) was diagnosed with diffuse large cell lymphoma of the stomach, 
2.6 months after onset of symptoms of encephalomyelitis. After the first cycle of 
R-CHOP his condition further deteriorated and antitumor therapy was deferred. A 73
year-old patient (#5) received local treatment for prostate cancer 10 months before
onset of limbic encephalitis. A 72 year-old male patient (#7) had surgery for bladder
cancer, followed by local chemotherapy two months before onset of limbic encephalitis
and cerebellar ataxia. Additionally, he had been treated 7 years earlier with surgery
(colostomy), radiotherapy and chemotherapy for rectal cancer. A 67 year-old male
patient (#8) received maintenance therapy with rituximab for minimally symptomatic
Waldenström macroglobulinemia when the symptoms of limbic and brainstem
encephalitis began. A 37 year-old woman (#9) was diagnosed 4 years before onset of
limbic encephalitis and cerebellar ataxia with follicular lymphoma and treated with 6
cycles of R-CHOP. Two years later she had a recurrence and was treated again with 6
cycles of R-CHOP followed by rituximab maintenance.
In two patients the tumor was only diagnosed at autopsy. A 74 year-old woman (#1)
had at autopsy pancreatic cancer metastatic to mediastinal lymph node. She presented
11 months earlier with symptoms of encephalomyelitis. The other patient was a 74
year-old man (#6) with a small cell lung cancer (SCLC) at autopsy who had presented
2.6 months earlier with rapidly progressive limbic and brainstem encephalitis. He had
anti-Hu (titer 3200) and anti-Zic4 antibodies in serum and CSF.
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Table s3. Neuropathological findings in 21 patients with autoimmune encephalitis and 
suspected CJD 
Predominant localization of 
infiltrates:
NSA-Abs positive 
(n=5)
Anti-Hu positive 
(n=1)
Antibody negative 
(n=15)
All patients 
(n=21)
Perivascular 4 1 10 15
Parenchymal 1 4 5
Perivascular and parenchymal 1 1
Composition of infiltrates:
CD3 positive 5/5 Nt 9/10 14/15
CD8 positive 1/1 Nt 6/7 7/8
CD4 positive 1/1 Nt 3/4 4/5
CD20 positive 3/4 Nt 5/8 8/12
CD68 positive 2/2 1/1 8/10 11/13
NSA-Abs, antibodies directed against neuronal surface antigens; Nt, not tested
144
suPPleMenTARy fIguRes 
figure s1 Neuropathology in autoimmune encephalitis associated with antibodies directed 
against GABAB1/2 and an unidentified synaptic antigen
(A,B) CD3 positive T cells in the hippocampus of a 70 year old woman with limbic encephalitis 
and GABAB1/2 antibodies in the CSF (patient #15). Note T cells both in the parenchyma and 
perivascularly; magnification 5x (A) and 20x (B) objective respectively. (C) CD3 positive T cells 
in the temporal cortex of a 77 y old man with rapidly progressive encephalomyelitis with 
antibodies in the CSF against unknown epitope (patient #18); magnification 10x  objective. 
(D) CD3 positive T cells in the globus pallidus of a 73 y old psychotic and epileptic patient with 
antibodies in the CSF against unknown epitope (patient # 11); magnification 20x objective.
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The aim of this thesis was to study new methods of autoantibody detection, to identify 
novel paraneoplastic antigen(s) and to describe clinical syndromes associated with 
newly detected antineuronal antibodies. In this chapter the main findings of the studies 
will be summarized and discussed.
Paraneoplastic neurological syndromes (PNS) are devastating neurological disorders 
secondary to cancer, that are associated with onconeural autoantibodies. Such 
antibodies are directed against neuronal antigens aberrantly expressed by the tumor.1 
The detection of onconeural antibodies in a patient is extremely important in diagnosing 
a clinical neurological syndrome as paraneoplastic, as 70% of patients is not yet known 
to have cancer. If tested positive, it warrants and directs the search for the underlying 
neoplasm. In chapter 2, at the onset of the studies described in this thesis, we review 
the literature on paraneoplastic neurological syndromes and associated antibodies and 
cancers. 
The presence of IgG autoantibodies against onconeural antigens in serum is a 
hallmark of PNS. The ‘well characterized’ onconeural antibodies include anti-HuD, 
Yo (CDR62), CV2 (CRMP5), amphiphysin (Amp), Ri (NOVA) and Ma2. In chapter 3, we 
tested the hypothesis that primary amino-acid structures of the antigen binding part 
of antibodies from various individuals share common sequences that are specific for 
each auto-antigen. The hypervariable complementarity determining regions (CDRs) of 
immunoglobulins form the binding surface for the antigen which evoked the immune 
response. Estimates on the total possible variation in immunoglobulins vary depending 
on the assumptions being made from 1013 to more than 1050.2,3 Based on these numbers, 
one could statistically assume that antibody sequences found in a person must be 
unique, and that such antibodies will not be found in other subjects. However, evidence 
is emerging that this may not be correct and that antibodies are subjected to selection 
pressures after rearrangement and affinity maturation, driving developing B cells and 
antibodies in convergent directions. Indeed, similar CDR3 sequences were found in 
different human subjects following tetanus toxin immunization and a sequencing project 
revealed identical CDR3 sequencing shared among several zebra fish in an untreated 
population.4,5 In a previous study, we tested the feasibility of antibody sequences as 
biomarkers by immunizing rats with either dinitrophenol or HuD.6 Proteomics analysis 
of affinity purified IgG detected peptides that were differentially present in one of the 
two treatment groups. Based on these experiments, we selected 60 patients with PNS, 
associated with antibodies against well-described antigens HuD, Yo, Amp or CV2. We 
used recombinant antigen coated magnetic beads to immunoprecipitate antigen-
specific antibodies.  The affinity purified IgG samples were separated using SDS-
PAGE and IgG heavy chains were excised, trypsinized and subjected to tandem mass 
spectrometry. We selected masses that uniquely identified a PNS autoantibody group, 
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and used MS/MS fragmentation spectra to obtain information on peptide sequences. 
Out of 19,173 unique masses, 28 immunoglobulin-derived peptides were found 
exclusively in samples from a single autoantibody defined PNS group. These results 
confirm that specific peptide structures exist in the antigen binding site of IgG that are 
shared between individuals harboring autoantibodies against the same onconeural 
antigen. Thus, the immune response in these patients followed converging paths during 
the rearrangement, selection and maturation of immunoglobulin sequences. The 
identified peptides can be applied in the diagnosis of PNS, but these data also indicate 
that a similar approach in a variety of other diseases involving an immune response 
would have an appealing outlook.
Chapter 4 is focused on the six ‘well characterized’ onconeural antibodies that recognize 
the antigens HuD, CDR62 (Yo), amphiphysin (Amp), CRMP-5 (CV2), NOVA-1 (Ri), and 
Ma2.7 The ‘gold standard’ for detection of these antibodies is immunohistochemistry 
on frozen rodent brain sections followed by Western blotting with the recombinant 
onconeural antigen as substrate. All six onconeural antibodies are usually analyzed 
simultaneously because clinical syndromes associated with these antibodies often 
overlap and more than one onconeural antibody can be present in a single patient.8 In 
most laboratories multiple dot-blots are used that lack objective cut-off values. Hence, 
we set out to develop a quantitative multiplex assay based on Luminex technology.9 
Reaction of serial dilutions of six onconeural standard sera with microsphere-bound 
antigens showed lower limits of detection than with Western blotting. Using the six 
standard sera at a dilution of 1:200, we reached low average within-run coefficients of 
variation (CV) of 4% (range 1.9–7.3%). The average between-run within-day CV was 5.1% 
(range 2.9–6.7%) while the average between-day CV was 8.1% (range 2.8–11.6%). The 
shelf-life of the antigen coupled microspheres was at least two months. The sensitivity 
of the multiplex assay ranged from 83% (Ri) to 100% (Yo, amphiphysin, CV2) and the 
specificity from 96% (CV2) to 100% (Ri). The lower specificity of anti-CV2 antibody 
detection may relate to the difficult recognition of anti-CV2 staining pattern in rat 
brain immunohistochemistry. We conclude that Luminex-based multiplex serology is 
highly reproducible with high sensitivity and specificity for the detection of onconeural 
antibodies. Conventional immunoblotting for diagnosis of onconeural antibodies in the 
setting of a routine laboratory may be replaced by this novel, robust technology.  
In chapter 5 we focus on the until then only well described, but still not characterized 
anti-TR antibody. The association between Hodgkin lymphoma and paraneoplastic 
cerebellar degeneration (PCD) has long been known and was followed by the 
identification of antibodies against cerebellar Purkinje cells in several of these patients’ 
sera.10 These antibodies were later called anti-Tr and recognize a specific staining in the 
cerebellum with punctate immunoreactivity in the large dendritic tree as well as the 
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soma of the Purkinje cells but not in the axons.11-13 This characteristic staining pattern 
can diagnose anti-Tr but requires cumbersome confirmation by epitope blocking. 
Despite many attempts at identification, the anti-Tr target antigen remained elusive. 
We used four different anti-Tr positive sera to immunoprecipitate the target antigen 
from total rat brain extract.  Mass spectrometric analysis of the rat brain extract 
immunoprecipitates led to the identification of Delta/Notch-like epidermal growth 
factor-related receptor (DNER) as the Tr antigen. We then tested 12 anti-Tr positive sera 
and 246 negative controls in a DNER transfected HeLa cell based assay. All 12 anti-Tr 
sera tested positive in the cell-based assay, as did one of 246 control samples. The 
latter sample was derived from a patient with Hodgkin lymphoma but no ataxia. On 
immunohistochemistry, this patient’s sample also showed the characteristic anti-Tr 
staining pattern. Western blotting using purified DNER as substrate could detect most 
but not all anti-Tr sera (11 out of 12). Using deletion constructs, we pinpointed the 
main epitope to the extracellular domain. Both knockdown of endogenous DNER in 
hippocampal and N-glycosylation mutations abolished the anti-Tr staining, indicating 
that glycosylation of DNER is required for it to be recognized by anti-Tr antibodies. Thus 
we identified DNER as the antigen recognized by anti-Tr sera. Anti-Tr antibodies can 
now be screened for quickly and reliably by using a cell-based assay. Meanwhile, two 
anti-DNER assays have become commercially available.
In 2007 a novel antineuronal autoantibody was described, reactive with of the N-methyl-
D-aspartate receptor (NMDAR).14 The clinical syndrome was highly characteristic 
with prominent psychiatric symptoms and amnesia followed by seizures, frequent 
dyskinesias, autonomic dysfunction, and decreased level of consciousness often 
requiring ventilatory support. Many of the patients were young females with an 
underlying teratoma. In Chapter 6 we describe in detail the psychiatric presentation 
and pathways to care in the first Dutch patients with NMDAR encephalitis, in order to 
aid the early diagnosis of this treatable disorder. Sera and cerebrospinal fluid (CSF) 
from patients with suspected NMDAR encephalitis were tested in ELISA on HEK293 
cells transfected with the NR1 subunit of the NMDAR. Samples from 15 patients (13 
female, 2 male, mean age 24 years, range 5–56 years) tested anti-NMDAR positive. 
Importantly, in 3 of our patients (20%) the anti-NMDAR antibodies were exclusively 
detectable in CSF. Clinical information was obtained from the referring psychiatrists 
and neurologists and by review of the clinical records. Twelve of the 15 patients (80%) 
presented with prominent psychiatric symptoms and 8 were initially referred to a 
psychiatric service. The most prominent initial psychiatric symptoms were anxiety in 
seven (47%), behavioral change (often bizarre) in six (40%) and agitation in five (33%). 
All patients developed psychiatric symptoms in the first 6 weeks of illness. Thirteen 
patients received psychotropic medications: antipsychotics in 12 and benzodiazepines 
in 11. Treating physicians considered the psychotropic medication not effective in 11 
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patients resulting in many drug switches. At nadir, all patients were in a very poor 
condition. However, eight patients (53%) recovered (almost) completely. Outcome 
tended to be better in patients who had received early immunotherapy or tumor 
removal. So, autoimmune encephalitis and anti-NMDAR testing in serum and CSF 
should be considered in patients, especially young females, presenting with atypical 
psychiatric phenomena. Anti NR1 NMDAR antibodies cannot be detected using ELISA 
or immunoblots with membrane proteins indicating that the recognized epitope has 
a specific extracellular conformation.18  Analysis of antibody profiles in patients with 
psychiatric sequelae of other autoimmune disease, such as mixed connected tissue 
diseases showed a cross-reactivity of anti-double stranded DNA antibodies with the 
NR2 subunit of the NMDAR, detected in ELISA assays.19 However, the relationship 
between comorbid autoimmune disease and primary psychiatric disorders is still 
unclear and the full clinical picture is distinct compared to specific NMDAR NR1 antibody 
mediated encephalitis.20,21 More recently the clinical spectrum of glutamate receptor 
antibody mediated encephalitis has been more unraveled, showing a “kaleidoscope” of 
different antibody mediated encephalitis syndromes.21 Pathogenic mechanisms seem 
to differ between Abs. In NMDAR encephalitis antibody binding and crosslinking lead 
to receptor internalization. Blocking of the  GABA(B) receptor leads to altered  receptor 
function. GABA(A) antibodies cause translocation of the receptor to extrasynaptic sites. 
Binding of antibodies against the secreted synaptic peptide LGI1 inhibits its binding 
to postsynaptic membrane protein ADAM22 and subsequently decrease of AMPAR 
function.21-23 Moreover the role of distinct antibodies in other autoimmune disease, 
such as mixed connected tissue disease (e.g. systemic lupus erythematosus), which 
have other antigen recognition profiles, remains controversial with respect to their role 
in causing neuropsychiatric symptoms.24
Paraneoplastic and autoimmune encephalitis are often subacute presenting with 
rapidly progressive neurological deficits. The rapidly progressive cognitive defects 
have a challenging differential diagnosis that also contains sporadic Creutzfeldt-Jakob 
disease (sCJD). 25-30 We encountered several patients with rapidly progressive dementia 
diagnosed as possible or probable sCJD, who at autopsy at the Dutch Surveillance 
Centre for Prion Diseases (DSCPD) turned out to have suffered from potentially 
treatable autoimmune encephalitis. Chapter 7 aims to determine the clinical features 
and presence in CSF of antineuronal antibodies in patients with pathologically proven 
autoimmune encephalitis derived from a cohort of patients with suspected CJD. 
Within a cohort of 384 autopsies of suspected CJD performed over a 14-year period 
(1998-2011) the neuropathologist diagnosed 22 cases of autoimmune encephalitis 
based on pathological and immunohistochemical findings. Immunohistochemistry 
identified antineuronal antibodies in postmortem CSF from 6 patients (29%), directed 
against HuD, NMDAR, GABABR1/2, Caspr2 and an unidentified synaptic antigen in two. 
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Neuropathology showed inflammatory infiltrates that were predominantly perivascular 
and consisted mainly of T cells. The predominant locations were basal ganglia and 
thalamus (90%) and temporal lobes and hippocampus (81%).
The most frequent symptoms were dementia (90%), gait disturbance (86%), cerebellar 
signs (67%) and neuropsychiatric symptoms (67%). Immunopathological and clinical 
findings did not differ between autoantibody negative patients and the patients with 
antineuronal antibodies. This study confirms that it is important to consider both prion 
and immune-mediated disorders in the differential diagnosis of rapidly progressive 
neurological deficits. Detection of specific antineuronal antibodies in serum and/or CSF 
can establish a diagnosis of autoimmune encephalitis and guide appropriate treatment.
This thesis describes various aspects of antibody mediated neurological disease, 
combining clinical and molecular aspects. The list of candidate antibodies is growing and 
one goal of future research could be the detection of novel antibodies.31 One approach 
could be to take the clinical syndrome as the entry point, focusing e.g. on subacute 
cerebellar ataxia, atypical first psychosis or epilepsy syndromes. Using a prospective 
approach allows better collection of detailed clinical information and estimation of the 
prevalence.
Although immunoassays such as Western blotting, ELISA and immunohistochemistry 
are extremely sensitive, aspecific background binding can be problematic, depending 
on the antigen and type of assay. In chapter 3, we investigated the feasibility of 
characterizing IgG antibodies by the aminoacid sequence of their variable region rather 
than by their antigen binding characteristics. Combining top-down proteomic mass 
spectrometric approaches (larger peptides such as complete Fab fragments) could 
narrow down the large number of nonspecific peptides. Future studies could confirm 
the specificity of detected antibody peptide sequences by comparison with the results 
of RNA sequencing of isolated antigen specific B-cells or plasma-cells isolated from 
serum or CSF. These developments are facilitated by the still ongoing improvents of the 
mass spectrometry instruments.
Finally, detailed analysis of the inflammatory infiltrates in autopsied cases could shed 
more light on the immunopathogenic mechanisms involved in paraneoplastic and 
autoimmune encephalitis. The Dutch Surveillance Centre for Prion Diseases is valuable 
source of prospectively collected brain tissues including many cases with pathologically 
proven autoimmune encephalitis (chapter 7). Detailed immunopathological analysis, 
including markers of B and T cell activation, can relatively easily be carried out.
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Het doel van dit proefschrift was om nieuwe methoden van autoantistof bepaling 
te bestuderen, om nieuwe paraneoplastische antigenen te identificeren en klinische 
syndromen geassocieerd met nieuw ontdekte anti-neuronale antistoffen te beschrijven. 
In dit hoofdstuk worden de belangrijkste bevindingen van het onderzoek samengevat en 
besproken.
Paraneoplastische neurologische syndromen (PNS) zijn ernstige neurologische 
aandoeningen die indirect het gevolg zijn van kanker. Bij patiënten die lijden aan PNS 
kunnen in het bloed onconeuronale antistoffen gevonden worden. Dit zijn antistoffen 
gericht tegen antigenen die normaliter alleen voorkomen in zenuwweefsel. In PNS komen 
deze antigenen ook tot expressie in de onderliggende tumor. De detectie van deze 
antistoffen bij een patiënt is  van groot belang omdat bij 70% van de patiënten die zich met 
een een klinisch paraneoplastisch neurologisch syndroom presenteren, de tumor zelf nog 
niet bekend is. Als de test positief is, moet men dus op zoek naar de onderliggende tumor. 
In hoofdstuk 2 bespreken we de huidige kennis over paraneoplastische neurologische 
syndromen en bijbehorende antistoffen en tumoren.
De aanwezigheid van IgG autoantistoffen tegen onconeurale antigenen in serum is 
een kenmerk van PNS. De ‘goed gekarakteriseerde’ onconeurale antistoffen omvatten 
anti-HuD, anti-Yo (CDR62), anti-CV2 (CRMP5), anti-amphiphysine (Amp), anti-Ri (NOVA) 
en Ma2. In hoofdstuk 3 testen we de hypothese dat tussen individuen met eenzelfde 
onconeurale antistof gemeenschappelijke aminozuur volgordes bestaan als we specifiek 
kijken naar het antigeen-bindende deel van het antistof molecuul. Als deze bestaan 
zijn ze mogelijk uniek voor deze antistof. Het antigeen bindende deel van een antistof 
bevat de ‘complementary determining regions’ (CDR’s), deze zijn hypervariabel. De CDR3 
is het belangrijkste in de antistofbinding. Schattingen van de totale mogelijke variatie 
in deze CDR’s leiden tot een variatie in IgG’s van 1013 tot meer dan 1050! Op basis van 
deze schattingen zou men kunnen aannemen dat statistisch gezien antistofsequenties 
in een persoon uniek zijn en niet in andere individuen zullen worden aangetroffen. Er 
zijn echter aanwijzingen  dat antistoffen een soort selectie ondergaan en dat in B-cellen 
een mechanisme optreedt van antistofselectie en bindingsrijping die leidt tot beperking 
in die diversiteit. Zo werden inderdaad na inenting met tetanus toxine soortgelijke CDR3 
aminozuur volgorden aangetroffen bij verschillende proefpersonen. Genetisch onderzoek 
onthulde ook gemeenschappelijke CDR3 coderende DNA sequenties in één populatie. In 
een eerdere studie hebben we de haalbaarheid van antistofsequenties als biomarkers 
getest door het immuniseren van ratten met hetzij dinitrofenol of HuD. Proteomics 
analyse van affiniteit gezuiverde IgG’s toonde gemeenschappelijke peptiden specifiek 
voor een van de behandelingsgroepen. Op basis van deze experimenten, hebben we 60 
patiënten met PNS, geassocieerd met antistoffen tegen HuD, Yo, Amp of CV2 geselecteerd. 
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We gebruikten magnetisch geladen micro-bolletjes gecoat met recombinant antigeen om 
antigeen specifieke antistoffen te isoleren. De affiniteit gezuiverde IgG-monsters werden 
gescheiden door SDS-PAGE en IgG zware ketens werden uitgesneden, getrypsiniseerd 
en onderworpen aan tandem massaspectrometrie.  We selecteerden massa’s die uniek 
geïdentificeerd werden binnen een PNS groep en bekeken de MS / MS fragmentatie 
spectra om informatie over peptide sequenties te verkrijgen. Binnen 19.173 unieke 
gevonden massa’s werden 28-immunoglobuline afgeleide peptiden geïdentificeerd die 
uitsluitend gevonden werden in monsters van een enkele autoantistof gedefinieerde 
PNS groep. Deze resultaten bevestigen dat specifiek peptide structuren bestaan in de 
antigeenbindingsplaats van IgG die worden gedeeld tussen individuen die autoantistoffen 
tegen het zelfde onconeurale antigeen herbergen. Dit bevestigt ook dat bij een rijpende 
immuun respons er selectie bestaat van aminozuur sequenties binnen immunoglobulines. 
De geïdentificeerde peptiden kunnen worden toegepast bij de diagnose van PNS. Deze 
benadering is mogelijk ook toepasbaar bij een verscheidenheid van andere antistof 
gerelateerde ziektebeelden.
Hoofdstuk 4 richt zich op de zes ‘goed gekarakteriseerde’ onconeurale antistoffen gericht 
tegen de antigenen HuD, Yo(CDR62), amphiphysine (Amp), CV2(CRMP-5), Ri(NOVA-1), en 
Ma2. De ‘gouden standaard’ voor detectie van deze antistoffen is immunohistochemie 
op coupes van rattenbrein gevolgd door Western blotting met het recombinante 
onconeurale antigeen als substraat. Alle zes onconeurale antistoffen worden gewoonlijk 
gelijktijdig geanalyseerd omdat klinische syndromen geassocieerd met deze antistoffen 
vaak overlappen en meerdere onconeurale antistof kunnen voorkomen in één patient. 
In de meeste laboratoria worden meervoudige ‘dot-blots’ gebruikt, die echter geen 
duidelijke grenswaarden hebben. Daarom ontwikkelden we een kwantitatieve multiplex 
assay gebaseerd op de Luminex® technologie. Testen van seriële verdunningen van 
zes standaard PNS sera met microbolletjes gecoat met antigenen toonden lagere 
detectielimieten dan met Western blotting. Bij de standaard sera vonden we in een 
verdunning van 1:200 een lage gemiddelde ‘within-run’ variatiecoëfficiënt (CV) van 4% 
(range 1,9-7,3%). Het gemiddelde ‘within- day’ CV was 5,1% (range 2,9-6,7%), terwijl het 
gemiddelde ‘between-day’ CV 8,1% (range 2,8-11,6%) was. De houdbaarheid van het 
antigeen gekoppelde microbolletjes was ten minste twee maanden. De gevoeligheid 
van de multiplex assay varieerde van 83% (Ri) tot 100% (Yo, amphiphysin, CV2) en de 
specificiteit van 96% (CV2) tot 100% (Ri). De lagere specificiteit van anti-CV2 antistof 
detectie kan komen door de moeilijke herkenning van het anti-CV2 kleuringspatroon 
in de immunohistochemie. We concluderen dat Luminex® gebaseerde multiplex 
serologie zeer reproduceerbaar is met een hoge gevoeligheid en specificiteit voor de 
detectie van onconeurale antistoffen. Conventionele immunoblotting voor de diagnose 
van onconeurale antistoffen in de setting van een routine laboratorium kan worden 
vervangen door deze nieuwe, robuuste technologie.
162
In hoofdstuk 5 richten we ons op de tot dan toe alleen goed beschreven, maar nog 
steeds niet ‘gekarakteriseerde’ anti-Tr antistof. De associatie tussen Hodgkin lymfoom 
en paraneoplastische cerebellaire degeneratie (PCD) is al lang bekend en werd gevolgd 
door de identificatie van antistoffen tegen cerebellaire Purkinje cellen in verschillende 
sera. Naar de eerste patiënt werden deze antistoffen later anti-Tr genoemd. De antistoffen 
geven bij immuunhistochemie een specifieke kleuring in het cerebellum met gestippelde 
immunoreactiviteit in de dendritische boom en soma van de Purkinje-cellen, maar niet in 
de axonen.  Dit karakteristieke patroon wordt gebruikt om anti-Tr te diagnosticeren, maar 
vereist omslachtige bevestiging door blokkeren van het epitoop met een controle serum. 
Ondanks vele pogingen tot identificatie, was het anti-Tr doelwit antigeen nog onbekend.  Wij 
gebruikten vier verschillende anti-Tr positieve sera voor immunopreciptiatie met extract van 
rattenhersenen als substraat. Massaspectrometrische analyse van de immunoprecipitaten 
leidde tot de identificatie van ‘Delta/Notch-like epidermal growth factor-related Receptor’ 
(DNER) als Tr antigeen. Vervolgens testten we  12 anti-Tr positieve sera en 246 negatieve 
controles op DNER getransfecteerde HeLa-cellen. Alle 12 anti-Tr sera testten positief, 
evenals een van 246 controle sera. Dat laatste serum bleek afkomstig van een patiënt 
mét Hodgkin lymfoom, maar zonder ataxie. Dit sample toonde op immunohistochemie 
ook het kenmerkende anti-Tr kleuringspatroon. Western blotting met gebruikmaking van 
gezuiverd DNER als substraat kon de meeste positieve samples opsporen, maar niet alle 
anti-Tr sera (11 van 12). Met behulp van deletie constructen konden we vaststellen dat 
het belangrijkste epitoop zich in het extracellulaire domein bevond. Zowel knockdown 
van endogene DNER in hippocampale neuronen en N-glycosylatie mutaties leidde tot 
verdwijnen van de anti-Tr kleuring, wat aangeeft dat glycosylering van DNER vereist is 
om te kunnen worden herkend door anti-Tr-antistoffen. Zo identificeerden we DNER als 
het antigeen dat herkend wordt door anti-Tr sera. Anti-Tr antistoffen kunnen nu snel en 
betrouwbaar gedetecteerd worden in een cell-based assay. 
In 2007 werd een nieuwe anti-neuronale autoantistof beschreven, reagerend met de 
N-methyl-d-aspartaat receptor (NMDAR). Het bijbehorende klinische syndroom was zeer 
karakteristiek met prominente psychiatrische symptomen en amnesie gevolgd door 
epileptische aanvallen, dyskinesieën, autonome dysfunctie en verminderd bewustzijn 
waarvoor vaak beademing nodig was. Veel van de patiënten waren jonge vrouwen met 
een onderliggend teratoma. In hoofdstuk 6 beschrijven we in detail de psychiatrische 
presentatie bij de eerste Nederlandse patiënten met NMDAR encefalitis, om vroege 
diagnose en behandeling van deze behandelbare aandoening te bevorderen. Serum 
en liquor (CSF) van patiënten met verdenking anti-NMDAR encefalitis werden getest op 
HEK293 cellen die met de NR1 subunit van de NMDAR zijn getransfecteerd. Monsters 
van 15 patiënten (13 vrouwen, 2 mannen, gemiddelde leeftijd 24 jaar, bereik 5-56 jaar) 
testten positief op anti-NMDAR antistoffen. In 3 van onze patiënten (20%) waren de anti-
NMDAR antistoffen alleen detecteerbaar in CSF. Klinische informatie werd opgevraagd bij 
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de verwijzende psychiaters en neurologen en geïnventariseerd. Twaalf van de 15 patiënten 
(80%) presenteerden met prominente psychiatrische symptomen en 8 werden aanvankelijk 
primair psychiatrisch geduid. De belangrijkste initiële psychiatrische symptomen waren 
angst bij zeven (47%), gedragsverandering (vaak bizarre) bij zes (40%) en agitatie bij vijf 
(33%) patiënten. Alle patiënten ontwikkelden psychiatrische symptomen in de eerste 6 
weken van de ziekte. Dertien patiënten ontvingen psychofarmaca: antipsychotica in 12 en 
benzodiazepines in 11. Behandelend artsen beschouwden de psychotrope medicatie niet 
effectief bij 11 patiënten, wat leidde tot veel medicatie veranderingen. Alle patiënten waren 
op het dieptepunt in een zeer slechte conditie. Echter, acht patiënten (53%) herstelden 
(nagenoeg) volledig. Het herstel lijkt beter bij patiënten die vroeg immunotherapie 
ontvingen of bij wie in een vroeg stadium een onderliggende tumor verwijderd werd. 
Daarom moet autoimmuun-encefalitis en het testen op anti-NMDAR testen in serum en 
CSF worden overwogen bij patiënten, die zich presenteren met atypische psychiatrische 
verschijnselen. 
Paraneoplastische en autoimmuun encefalitis presenteren vaak met subacute en snel 
progressieve neurologische symptomen. Vooral de snel progressieve cognitieve stoornissen 
hebben een uitgebreide differentiaal diagnose die ook de sporadische ziekte van 
Creutzfeldt-Jakob (sCJD) bevat. We ontdekten 22 patiënten die vanwege snel progressieve 
dementie, gediagnosticeerd waren als mogelijk of waarschijnlijk sCJD, maar die bij obductie 
in het Nederlandse Surveillance Centrum voor Prionziekten (DSCPD) retrospectief bleken 
te hebben geleden aan mogelijk behandelbare autoimmuun encefalitis. Hoofdstuk 
7 heeft tot doel de klinische kenmerken en de aanwezigheid in CSF van antineuronale 
antistoffen bij deze patiënten te beschrijven. Binnen een cohort van 384 obducties van 
vermoedelijke CJD uitgevoerd over een periode van 14 jaar (1998-2011) diagnosticeerde 
de neuropatholoog bij 22 gevallen autoimmuun-encefalitis op basis van pathologische 
en immunohistochemische bevindingen. Wij vonden antineuronale antistoffen in post-
mortem afgenomen CSF van 6 patiënten (29%), gericht tegen HuD, NMDAR, GABABR1/2, 
Caspr2 en een onbekend synaptisch antigeen in twee casus. Neuropathologisch onderzoek 
toonde inflammatoire infiltraten die voornamelijk perivasculair voorkwamen, hoofdzakelijk 
bestaand uit T-cellen. De meest voorkomende locaties waren basale ganglia en thalamus 
(90%), temporale kwabben en de hippocampus (81%).
Uit opgevraagde klinische gegevens bleken de meest voorkomende symptomen dementie 
(90%), gestoord looppatroon (86%), cerebellaire stoornissen (67%) en neuropsychiatrische 
symptomen (67%). Immunopathologische en klinische bevindingen verschilden niet 
tussen de auto-antistof negatieve patiënten en patiënten met anti-neuronale antistoffen. 
Deze studie bevestigt dat het belangrijk is om immuun-gemedieerde aandoeningen te 
overwegen in de differentiële diagnose van snel progressieve neurologische gebreken. 
Detectie van specifieke antineuronal antistoffen in serum en/of CSF kan de diagnose van 
auto-immune encefalitis stellen en leiden tot gepaste behandeling.
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(g)AchR acetylcholine receptor; g, ganglionic;
AMPAR alpha-amino-3-hydroxy-5-methyl-4-osixazolepropionic acid receptor
AN autonomic neuropathy
ANNA anti-neuronal nuclear antibody
APC antigen presenting cells
BE brainstem encephalitis
BSA bovine serum albumin
Caspr2 contactin-associated protein-like 2
CDR complementarity determining regions
CDR2 cerebellar degeneration-Related Protein 2, 62kD (Yo-antigen)
CJD Creutzfeldt-Jakob disease
CRMP-5 collapsin response mediator protein 5 (CV2 antigen)
CSF cerebrospinal fluid
CT computed tomography
CTX cyclophosphamide
CV coefficient of variation
DAPI 4’,6-diamidino-2-fenylindole
DNER delta/notch-like epidermal growth factor-related receptor
DPPX dipeptidyl-peptidase-like protein-6
DSCPD Dutch surveillance centre for prion diseases
EDC 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide HCL
ELISA enzyme-linked immuno sorbent assay
EM encephalomyelitis
Fab fragment antigen binding
Fc fragment crystallisable
GABAAR gamma-aminobutyric acid A receptor
GABABR gamma-aminobutyric acid B receptor
GAD glutamic acid decarboxylase
hCG human chorionic gonadotropin
Hu antigen called after the first patient’s initials
Hu-Ab Hu-antibody
HuC neuronspecific RNA binding protein
HuD neuronspecific RNA binding protein
ICU intensive care unit
IEF isoelectric focusing
Ig immunoglobulin
IgG immunoglobulin G
IIF indirect immunofluorescence
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ivIg intravenous immunoglobulins
LC liquid chromatography
LC /ESI-MS liquid chromatography coupled to electrospray ionization mass  
spectrometry
LC-MS liquid chromatography-mass Spectrometry
LGI1 leucine-rich glioma inactivated 1
LE limbic encephalitis
LEMS Lambert-Eaton myasthenic syndrome
LP lumbar puncture
m/z Ratio of mass to number of charges (regardless of sign).
Ma antigen called after the first patient’s initials
Maldi-FT MS Matrix-assisted Laser Desorption/Ionization-Fourier Transform Mass
Maldi-TOF MS Matrix-assisted Laser Desorption/Ionization-Time-of-Flight Mass 
Spectrometry
MES 2-(N-morpholino)ethanesulfonic acid sodium salt
MFI median fluorescent intensity
mGluR metabotropic glutamate receptor.
MP methylprednisolone
MRI magnetic resonance imaging
MRM multiple reaction monitoring
mRS modified Rankin scale
MS mass spectrometry
MS/MS tandem mass spectrometry
NMDAR N-methyl-D-aspartate receptor
NOVA1 Neuro-oncological ventral antigen 1 (Ri antigen)
NSCLC non-small cell lung cancer
PBS phosphate buffered saline
PCA Purkinje cell cytoplasmatic autoantibodies
PCD paraneoplastic cerebellar degeneration
PCR polymerase chain reaction
PE plasma exchange
PEM paraneoplastic encephalomyelitis
PET positron emission tomography
PFA paraformaldehyde
PLE paraneoplastic limbic encephalitis
PMN polymorphonuclear cells
PNS paraneoplastic neurological syndromes
Ri antigen called after the first patient’s initials
RT radiotherapy
SCLC small cell lung cancer
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SDS-PAGE  sodium dodecyl sulfate polyacrylamide gel electrophoresis
SMN   sensory motor neuropathy
SOX1  Sex determining region Y-box 1
SPS   stiff-person syndrome
SPECT   single-photon emission computed tomography
SRM   selective reaction monitoring
SSN   subacute sensory neuronopathy
Ta   antigen called after the first patient’s initials
TBS  Tris (tris(hydroxymethyl)aminomethaan) buffered saline
Tr   antigen called after the first patient’s initials
VGCC   voltage-gated calcium channel
VGKC   voltage gated potassium channel
Yo   antigen called after the first patient’s initials
ZIC4  zinc-finger protein of the cerebellum
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dAnKwOORd
Eindelijk is het dan zover!  Na lange tijd zwoegen ligt het boekje voor u, waar al vaak 
naar geïnformeerd, op aan gedrongen of verwachtingsvol over gezwegen werd.
Ik ben blij dat al deze verwachtingen nu waargemaakt worden.
Een aantal mensen wil ik bedanken voor hun aandeel in het resultaat:
Bij een onderzoek naar zeldzame neurologische ziekten zijn veel patiënten of hun 
ziektegeschiedenissen betrokken. Vaak ongemerkt leveren zij of hun families een 
belangrijke bijdrage aan verdere ontwikkeling van kennis in de geneeskunde. Belangrijke 
link is daarbij ook hun behandelend huisarts, medisch specialist/neuroloog of zelfs 
oplettende verpleegkundige. Een dankwoord kan niet passeren zonder hen daarin te 
noemen en te erkennen.
Daarnaast gaat mijn dank naar mijn promotor, Prof.dr. P.A.E. Sillevis Smitt. Beste Peter, 
ik weet nog goed hoe je mij op woensdag 24 oktober 2007 tijdens mijn oncologie stage 
die ik vanuit de opleiding tot neuroloog in Tilburg liep, in de Daniel Den Hoed aansprak 
met de vraag of ik geïnteresseerd was in het doen van translationeel onderzoek. 
Een dag later had ik een projectbeschrijving per mail, waarin een nieuwe wereld van 
massaspectrometrie voor me open ging. Tijdens mijn stage, de periode op “je” PNS-
lab in het Josephine Nefkens Instituut, maar ook tijdens mijn afrondende AIOS-jaren 
en zelfs tijdens mijn werk als neuroloog in Ede hadden we intensief contact over dat 
translationele gedeelte, maar ook over de vele klinische zijsporen die we zijn ingeslagen. 
Enkele daarvan hebben tot relevante resultaten geleid, zoals in dit proefschrift 
beschreven.  Ik waardeer je wetenschappelijke maar ook persoonlijke betrokkenheid 
en je bereidwilligheid om telkens in je overvolle agenda een plek te vinden voor overleg.
In dat verband wil ik niet zeker voorbij gaan aan de hulp van je secretaresses Arjenne 
Romeijn (jammer dat je uiteindelijk moest stoppen met je werk) en Marja Klüver!
Mijn copromotor Dr. T. Luider, beste Theo. Uiteindelijk was jij een van de stuwers achter 
het oorspronkelijke MassPac project en de eigenaar van het lab, de “technische baas” 
over alles wat met massaspectrometrie te maken had. Dank voor je steunende rol in 
deze.
Esther Hulsenboom en Eric Brouwer: Jullie waren toch wel de constante factor op de 
werkvloer; dank voor jullie hulp bij het aanleren van alle technische vaardigheden. We 
hebben een leerzame maar ook gezellige periode gehad. Ik kan me voorstellen dat 
het soms wel vreemd was om zo’n clinicus in hart en nieren als ik was, alle technische 
foefjes te leren. Ik heb er veel aan gehad; het was een ervaring om nooit te vergeten!
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Ook de voorgangers: Janet de Beukelaar, Marieke de Graaf en Arjen de Jongste: fijn om 
een clubje van “gelijkgerichten” te hebben. In het belang van het onderwerp fijn om te 
zien dat dit gegroeid is met Maarten Titulaer en de opvolger uit Tilburg: Marienke de 
Bruijn. De koppeling tussen kliniek en laboratorium blijft essentieel.
De sfeer op het lab was warm. Met de hele club waaronder Pim French, Linda Bralten, 
Mathilde Kouwenhoven, Lonneke Gravendeel, Nanne Kloosterhof, Jenneke Kloezeman 
en vele anderen hadden we een warme wetenschappelijk stimulerende omgeving. 
Geweldig was het dat er onder de lunch of tijdens een “ DE-momentje” ook over veel 
maatschappelijke issues werd gediscussieerd!
Wellicht iets minder intensief, maar niet minder inspirerend waren de contacten met 
de proteomics groep. Met Ingrid Broodman en Dominique optimaliseerden we veel 
technieken om de IgG’s te zuiveren en tot nog specifiekere resultaten te komen, met de 
steun van Lennard Dekker en Lona Zeneyedpour als het op de echte massaspectrometrie 
samples aankwam.  
Erg veel steun op het hybride vlak van antistof-werk en chemie heb ik gehad van Martijn 
Van Duijn. Beste Martijn, dank voor je heerlijk analytische blik, je scherpe vindingrijkheid 
in veel zaken; dat deed me goed!
Esther de Graaff, wat geweldig dat ik de kans had om met je samen te werken! De overleg 
momenten bij Casper Hoogenraad waren erg enthousiasmerend. 
En dan was er natuurlijk het achterland: de opleidingskliniek in Tilburg. Na het eerder 
genoemde mailtje over het doen van translationeel onderzoek volgde snel overleg met 
dr. C. Tijssen, op dat moment opleider in Tilburg. Beste Cees, wat ik zo aan je waardeer, 
is je niet aflatende steunende en bemoedigende interesse in het beloop. Dank voor 
het feit dat je me gevormd hebt tot de neuroloog die ik nu ben.  Ik ben ook blij dat je 
bij de ultieme ceremoniele afsluiting van het traject een rol speelt! Natuurlijk mogen 
de andere supervisoren niet vergeten worden. Paul de Kort, als latere opleider, Edo 
Arnoldus, Geert Brekelmans, Leo Visser, Gerwin Roks, Peter Nijssen, Ben Jansen, Hub 
van der Leeuw, Thies van Asseldonk, Jordie van Tuijl, Mariël Wohlgemut… Dank voor 
jullie steun!
Ook de AIOS groep. Ik maakte een gekke move door een periode “uit de opleiding te 
stappen” door de lab-tijd in Rotterdam en dat leverde wellicht een vreemde plek in de 
latere groep op. We hielden en houden contact! Jörgen Rovers en Martijn Smidt, ik ben 
blij dat we samen een constructief “Tilburgs trio” vormen in Ede.
Inmiddels hebben we Tilburg verruild voor de mooie Gelderse Vallei. Aan alle 
vakgroepsleden neurologie: Cees en Paul Jansen, Marcel Smits, Sven Matthijs, naast 
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natuurlijk  de eerder genoemde Jörgen en Martijn, dank voor jullie steun in het drukke 
laatste traject. We hopen op een patiëntgerichte en voorspoedige toekomst samen!
Mark Snitselaar, wat is het leuk om oude Utrechtse studiegenoten weer binnen de eigen 
vakgroep terug te zien. Zo zie je nog maar eens dat “hardware” (het brein) en “software” 
(psyche/gedrag) toch meer verweven zijn dan de historisch gegroeide dichotomie doet 
vermoeden. Fijn dat je ook mijn paranimf wilt zijn.  
Arian Paul, ik herinner me nog goed ons eerste treffen in Gent, Belgie. Wat hebben 
we daar een leuke tijd gehad! De gezamenlijke maaltijden met Pieter van Roekel en 
Michiel van Schaik en de gezellige avonden bij familie Bor zijn om nooit te vergeten. Fijn 
dat we – ondanks dat we vanuit Gent gescheiden internationale wegen gingen – toch 
altijd contact hebben gehouden en dat je me vandaag aan de andere zijde als paranimf 
bijstaat. Die studie geneeskunde in Gent is een goede basis geweest!
Geen mens kan zonder familie. Lieve pa en ma! Dank voor jullie steun en interesse. Ik 
hoop dat het met dit boekje duidelijker is geworden waar ik me al die tijd mee bezig 
hield. Ook alle broers en zussen: dank dat jullie meeleefden. Zus Jacoline: dank voor de 
hulp in het vormgeven van dit boekje.
Ook uit de schoonfamilie ontving ik veel steun. Janine: je kent het wereldje van binnenuit 
en begrijpt als geen ander hoeveel zweet en zwoegen er met een promotietraject gemoeid 
is.  Zwager Marinus, ik ben trots dat één van de door jouw gemaakte ‘skeletklokken’ het 
verbindende thema is in de vormgeving van mijn proefschrift.
Erg bijzonder is de band met Rijk, Jeannette, Labrinus en Anne-Marie. De start van dit 
onderzoek viel samen met het vaststellen van een ernstige ziekte bij Jan-Willem. Helaas 
werd hij niet meer beter. Maar de gedachte aan Jan-Willem blijft levend! Het intensieve 
contact uit die tijd is gebleven. Het onderzoek en Jan-Willems ziekte zijn daarom ook 
gevoelsmatig aan elkaar verbonden. 
Jos Hodde, de zwemcoach. Het is waarschijnlijk een grote verrassing voor je dat ik je 
noem. Het wekelijkse zwemmen met de zwagers Martin en Rijk werd een belangrijk 
mentaal rustpunt temidden van vaak drukke dagen. Ik heb geleerd dat promoveren wel 
iets weg heeft van snorkelen: je moet diep gaan, maar zorgen dat je altijd voldoende 
adem overhoudt om je mondstuk leeg te blazen en weer te gaan voor die volgende duik!
Als laatste maar allerbelangrijkste mijn enorme dank aan jou, Janneke. Je bent een 
lieve en fantastische vrouw, en je was een enorme steun voor me als het soms wat 
moeizaam ging.  Lieve Hugo en Anne-Ruth! Zelfs tijdens de vele vroege ochtenduren 
kwamen jullie papa regelmatig stilletjes gezelschap houden. De dagen dat papa zich 
opsluit in de studeerkamer worden minder; we gaan veel nieuwe avonturen beleven!
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